

Exhibit 416

Specific Causation Expert Report for David Fancher

Matthew John Weiss, MD, MBA, FACS

Deputy Physician-in-Chief, Northwell Health Cancer Institute

Director of Surgical Oncology, Northwell Health

Professor of Surgery and Oncology, Donald and Barbara Zucker School of Medicine

Professor, Feinstein Institute for Medical Research

Adjunct Professor, Cold Spring Harbor Laboratory

Executive Vice Chair of the Surgery Service Line, Northwell Health

450 Lakeville Rd

New Hyde Park, NY 11042

Signed by:

Matthew J. Weiss

C4E3045E716C48A...

Matthew John Weiss, MD

Table of Contents

I.	Scope of Report	1
II.	Qualifications	1
III.	Records Reviewed	3
IV.	Methodology	3
V.	TCE, PCE, VC and Benzene	4
VI.	Water Contamination at Camp Lejeune	5
VII.	Levels of the Chemicals that are Hazardous to Humans and Cause Kidney Cancer	7
VIII.	Mr. Fancher's Exposure	9
IX.	Differential Diagnosis for Etiology	11
X.	Response to Defendant's Supplemental Answers to Interrogatories	12
XI.	Mr. Fancher's Injuries	13
XII.	Conclusion	13

February 5, 2025

Re: David Fancher

DOB: 11/23/1958

I. Scope of Report

I was asked to review the scientific and medical evidence concerning the potential causal relationship between Mr. David Fancher's carcinogenic exposure to the contaminated water at Camp Lejeune, which included TCE, PCE, 1,2-dichloroethylene (DCE), benzene and vinyl chloride (VC), and his resultant diagnosis of kidney cancer. I have reviewed the scientific literature regarding Trichloroethylene methods of exposure and mechanism of carcinogenesis. I also reviewed the scientific literature regarding the carcinogenic potential of PCE, Benzene and Vinyl Chloride. For concentrations of the toxins in the water, I reviewed the Agency for Toxic Substances and Disease Registry (ATSDR) reports and the reports from Plaintiff's expert Morris Maslia. Finally, I reviewed Mr. Fancher's medical history with a focus on the development of his kidney cancer and special focus on potential causative agents, both environmental and genetic. All of my opinions in this report are expressed to a reasonable degree of scientific and medical certainty.

II. Qualifications

I obtained my medical degree from Jefferson Medical College and trained in general surgery at Johns Hopkins Hospital. I was selected for AOA which is a medical honor society that represents the top 5% of graduating medical students based on objective performance. I performed research in immunology at the Massachusetts General Hospital for two years and trained in complex general surgical oncology and hepatopancreatobiliary surgery at Memorial Sloan Kettering Cancer Center. I previously practiced surgical oncology at the Johns Hopkins Hospital where I was promoted to an Associate Professor of Surgery and subsequently took a position leading surgical oncology for the largest health system in the state of New York, Northwell Health. As the Deputy Physician-in-Chief of the Northwell Health Cancer Institute I am responsible for all cancer-related programs across 21 hospitals, where we treat over 20,000 cancer patients annually. In this role, we are responsible for preventative strategies and identifying high risk individuals both genetically and due to environmental exposures. I also personally have over 20 years of experience diagnosing and treating patients with cancer.

I currently have the following appointments: Deputy Physician-in-Chief of the Northwell Health Cancer Institute, Director of Surgical Oncology for Northwell Health, Professor of Surgery and Oncology at the Donald and Barbara Zucker School of Medicine, Professor at the Feinstein Institute for Medical Research, Adjunct Professor at the Cold Spring Harbor Laboratory and Executive Vice Chair of the Surgery Service Line for Northwell Health. I have a robust research background in cancer, publishing over 350 cancer-related peer-reviewed journal articles as well

as numerous review papers and book chapters. I am also regularly invited to present my research both nationally and internationally. I have received several awards including Pi Mu Epsilon National Mathematics Honor Society, William Potter Medical Student Research Prize, Hobart Amory Hare Honor Society of Thomas Jefferson University, Clinical Surgery Prize of Jefferson Medical College, Ruth L. Kirkstein National Research Service Award, American College of Surgeons Resident Research Scholarship, Thoracic Surgery Foundations for Research and Education Research Award, Novartis International Society for Heart and Lung Transplantation Research Award, Genzyme Advances in Organ Transplantation Conference Scholarship Award, Genzyme Advances in Organ Transplantation Basic Science Award, Massachusetts General Hospital Calderwood Research Prize, Johns Hopkins Hospital Medicine Department Osler Resident Teaching Award, Alpha Omega Alpha Medical Honor Society, The John L. Cameron Best Technical Surgical Resident Award, Baltimore Magazine Top Doctors, Miller Coulson Academy of Clinical Excellence, John L. Cameron Clinical Excellence Award, Department of Surgery Director's Award, Mentor for Kenneth Warren IHPBA Fellowship Awardee, Paul K. Neumann Professor of Pancreatic Surgery, Makuuchi Teaching Award at Johns Hopkins, Northwell Health 6th Annual Clinical Symposium, Cutting Edge Innovations in Robotic Surgery Award, Step-By-Step Foundation Healthcare Hero Award, Senior Surgical Resident Faculty Teaching Award, Northwell Health, American Cancer Society Doctors of Distinction Golf Invitational, Springside Chestnut Hill Academy Roll of Fame Honoree, Senior Surgical Resident Faculty Teaching Award at Northwell Health, Complex General Surgical Oncology Teaching Award at Northwell Health, Lustgarten Foundation's Inaugural Hope Through Compassion Award

I am a reviewer for several medical journals, including Journal of the American College of Surgeons, Annals of Surgery, Annals of Surgical Oncology, Surgery, Journal of Surgical Research, HPB, British Medical Journal, World Journal of Surgery, Journal of Gastrointestinal Surgery, Journal of Surgical Oncology, Pancreatology, British Journal of Surgery.

I am both board certified and serve as an examiner for the American Board of Surgery. I currently hold a medical license to practice medicine in the state of New York. In my surgical oncology practice, I evaluate patients exposed to a variety of toxins on a daily basis that have developed malignancies. In recent years, I have treated hundreds of patients with 9/11 related malignancies.

As a result of my background, I have extensive experience in recognizing carcinogenic exposures and their resultant development of cancers in patients. My opinions are based upon my experiential knowledge of carcinogenesis and review of the existing literature. In order to review this case, I used methods that are scientifically proven to be reliable for performing research and then developed a differential of the etiology of cancer development and then further analyzed the evidence for causation with respect to Mr. Fancher's medical records.

I have attached my curriculum vitae to this report.

III. Records Reviewed

I reviewed and relied on the documents and materials in the attached document entitled materials considered list.

IV. Methodology

In developing my opinions, I first reviewed the existing literature on PubMed regarding Trichloroethylene methods of exposure and mechanism of carcinogenesis. My searches on the PubMed database used terms such as: TCE, PCE, benzene, vinyl chloride, trichloroethylene, tetrachloroethylene, perchloroethylene combined with kidney cancer, renal cell cancer, clear cell kidney/renal cancer. I reviewed the Agency for Toxic Substances and Disease Registry (ATSDR) report on Camp Lejeune and documents provided by plaintiff's counsel.^{1, 2}

I then reviewed the levels of reported contaminants at Camp Lejeune while Mr. Fancher was living and/or working on the base. Finally, I reviewed Mr. Fancher's medical history with a focus on the development of his kidney cancer and special focus on potential causative agents, both environmental and genetic. I developed a differential diagnosis for the potential etiologies of the development of his cancer and specifically looked for other factors that could have potentially played a role in the causation.

In the case of Camp Lejeune exposures, the standard for causation has been defined as "sufficient to conclude that a causal relationship exists" or "sufficient to conclude that a causal relationship is at least as likely as not." *The ATSDR Assessment of the Evidence (2017)* further delineated this standard:

Sufficient evidence for causation: the evidence is sufficient to conclude that a causal relationship exists. This category would be met, for example, if:

- 1. There is sufficient evidence from human studies in which chance and biases (including confounding) can be ruled out with reasonable confidence, **or***
- 2. There is less than sufficient evidence from human studies but sufficient evidence in animal studies and strong evidence that the agent acts through a relevant mechanism in humans.*

Sufficient evidence from human studies can be provided by a meta-analysis and/or by several studies considered to have high utility.

Considerations in assessing the evidence include several of Hill's viewpoints: (1) temporal relationship, (2) consistent positive associations (e.g., risk ratio or odds ratio greater than 1.1), (3) magnitude of the effect estimate (e.g., risk ratio, odds ratio), (4) exposure-response relationship, and (5) biological plausibility (Hill 1965).

Equipoise and above evidence for causation: The evidence is sufficient to conclude that a causal relationship is at least as likely as not, but not sufficient to conclude that a causal relationship exists. This category would be met, for example, if:

- 1. The degree of evidence from human studies is less than sufficient but there is supplementary evidence from animal studies and/or mechanistic studies that supports causality, **or***
- 2. A meta-analysis does not provide convincing evidence (e.g., the summary risk estimate is close to the null value of 1.0, i.e., ≤ 1.1), or if the meta-analysis observes a non-monotonic exposure-response relationship) but there is at least one epidemiological study considered to be of high utility occurring after the meta-analysis has been conducted, in which an association between the exposure and increased risk of the disease of interest has been found and in which chance and biases can be ruled out with reasonable confidence.*
- 3. A meta-analysis has not been conducted, but there is at least one epidemiological study considered to be of high utility in which an association between the exposure and increased risk of the disease of interest has been found and in which chance and biases can be ruled out with reasonable confidence.*

It is my opinion that exposure to contaminated drinking water and specifically TCE at Camp Lejeune is more likely than not the cause of David Fancher's kidney cancer. Mr. Fancher's exposure to TCE alone is enough to have caused his kidney cancer, but his additional exposure to PCE, Benzene, and VC at Camp Lejeune all increased his risk and likely were additive. Based on my review of the toxicology literature and records of water contaminant levels at Camp Lejeune, I believe the water was contaminated with significant levels of benzene, TCE, PCE, and vinyl chloride, which was sufficient to cause Mr. Fancher's kidney cancer. This opinion is also based upon the current literature that exposure to these chemicals is associated with the development of numerous malignancies, including specifically kidney cancer, combined with the estimated levels Mr. Fancher was exposed to during his inhabitancy at Camp Lejeune, and the absence of any other known risk factors for the development of his disease.

V. TCE, PCE, VC and Benzene

I have reviewed the general causation reports of Drs. Hatten and Bird. Each of them states that the four chemicals at issue are causally related to kidney cancer. I agree with those statements and use that analyses in my opinions in this case.

For example, TCE has the most robust literature relating to kidney cancer. Trichloroethylene (TCE) is a volatile organic compound widely used as an industrial solvent and degreaser. TCE has become a common environmental contaminant, often found in groundwater and drinking water supplies. Concerns regarding human TCE exposure have led to extensive research, particularly regarding its potential carcinogenicity. There is now a significant amount of literature and evidence that exposure to TCE increases the risk of kidney cancer.^{1,3,4,5,6,7,8,9}

Exposure to TCE can occur through various routes, including inhalation, ingestion of contaminated water, and dermal contact. Therefore, exposure to TCE via Camp Lejeune water facilities could occur from drinking, cooking, washing, bathing, or any type of ingestion or dermal contact. Anyone living or working on the base would have significant exposure to such contaminated water. TCE is readily absorbed into the bloodstream and distributed throughout the body. It is metabolized primarily in the liver, producing several metabolites, some of which are considered more toxic than the parent compound. These metabolites, including dichloroacetic acid (DCA) and trichloroacetic acid (TCA), are believed to play a significant role in TCE's carcinogenic potential.¹⁰

Initial suspicions about TCE's carcinogenicity arose from occupational studies observing an excess of kidney cancer among workers exposed to high levels of TCE. Although these early studies were based on associations and therefore had limitations due to lack of available information on actual exposure levels, they did clearly demonstrate a significant association between such exposures and the development of kidney cancer. These initial studies as well as several case reports, provided the impetus for further investigations.

The general causation reports of Drs. Hatten and Bird, in addition to discussing the epidemiology, also detail the toxicology and mechanism of injury for these four chemicals. I agree with their analyses and conclusions. I am relying on those opinions, as well as my own opinions on these topics, for this report.

VI. Water Contamination at Camp Lejeune

Historical reconstruction of drinking-water contamination within the service areas of the Hadnot Point water treatment plants at Camp Lejeune show clear evidence of elevated levels of TCE, PCE, Benzene and VC concentrations. Mr. Fancher was present at Camp Lejeune over different time periods from October of 1979 through June of 1981. Mr. Fancher lived for a period of time on base in the Hadnot Point area and worked at Hadnot Point when he was stationed at Camp Lejeune. From November of 1979 to May of 1980, Mr. Fancher lived in an apartment off base. During this time-period, the levels of the chemicals at issue were as follows:

Exposure Dates	Total Days	Total Days	TCE (ug/l-M)	PCE (ug/l-M)	VC (ug/l-M)	BZ (ug/l-M)
10/16/1979-10/31/1979	16	16	71	3	4	4
11/1/1979-11/20/1979	20	4.3	507	23	33	6
12/10/1979-12/31/1979	22	4.7	504	23	33	6
1/1/1980-1/31/1980	31	6.6	264	12	17	7
2/1/1980-2/29/1980	29	6.2	378	17	24	6
3/1/1980-3/31/1980	31	6.6	433	20	28	6
4/1/1980-4/30/1980	30	6.4	273	12	17	8

5/1/1980-5/8/1980	8	1.7	322	15	21	6
12/3/1980-12/31/1980	29	29	541	26	37	6
1/1/1981-1/11/1981	0	0	295	14	19	8
1/12/1981-1/31/1981	20	20	295	14	19	8
2/1/1981-2/28/1981	28	28	387	18	26	7
3/1/1981-3/3/1981	3	3	397	19	27	6
4/4/1981-4/30/1981	27	27	266	12	17	9
5/1/1981-5/31/1981	31	31	322	15	22	7
6/1/1981-6/12/1981	12	12	380	18	26	7
	337	203	5,340	247	351	99

Much of the existing evidence on TCE induced malignancy risk relies on epidemiological research which investigated the association between TCE exposure and kidney cancer. This includes several papers available in the medical literature as well as the ATSDR Assessment of the Evidence for the Drinking Water Contaminants at Camp Lejeune and Specific Cancers and Other Disease.^{1,5,6,7,8,9} The ATSDR Public Health Assessment for Camp Lejeune connects exposure to TCE in contaminated drinking water to an increased risk of kidney cancer.² In this report, they performed historical reconstructions which estimated the TCE levels in the Hadnot Point water systems frequently exceeding comparison values and standards for many years, including the years that Mr. Fancher lived and worked on the base.² It is important to note that in this report, they also used modeling to calculate exposure doses for different groups and found that the estimated cancer risk exceeded the USEPA's target risk range.² ATSDR cited several epidemiological studies showing an association between exposure to TCE and the development of kidney cancer.²

Importantly, Dr. Bove and ATSDR wrote several epidemiologic studies that examined the real-life implications of these chemicals on base at Camp Lejeune. Bove et al., published two such studies in 2014 evaluating personnel exposed to contaminated drinking water specifically at Camp Lejeune.^{5,6} These retrospective cohort studies examined mortality among Marines and Navy personnel stationed at Camp Lejeune (exposed to contaminated drinking water) or Camp Pendleton (unexposed) between 1975-1985, with mortality follow-up through 2008.⁵ Compared to Camp Pendleton, Camp Lejeune personnel experienced elevated mortality hazard ratios for all cancers, kidney cancer, liver cancer, esophageal cancer, cervical cancer, Hodgkin lymphoma, and multiple myeloma.⁵ Within the Camp Lejeune cohort, exposure-response trends for cumulative contaminant exposure were observed for kidney cancers.⁵

The International Agency for Research on Cancer (IARC), part of the World Health Organization, evaluates the carcinogenicity of various agents. Based on all of the available evidence from human and animal studies, IARC has classified TCE as "carcinogenic to humans." Specifically, IARC notes an association between TCE exposure and kidney cancer. In my

opinion, this classification underscores the scientific consensus regarding TCE's carcinogenic potential.³

VII. Levels of the Chemicals that are Hazardous to Humans and Cause Kidney Cancer

I have reviewed the general causation reports of Dr Benjamin Hatten and Dr. Steven Bird. Those reports detail an extensive review of the epidemiologic, toxicologic and mechanistic literature relating to the toxins at issue and kidney cancer. I have reviewed these reports and agree with their opinions regarding the four chemicals at issue and their causal connection to kidney cancer. I also agree with their conclusions as to the levels of the chemicals that are hazardous to humans and that are known to cause kidney cancer.

For example, the reports detail specific levels of the chemicals at issue that are known to be causally related to kidney cancer. Dr. Hatten's report states,

The most relevant evidence for on-base exposures is a monotonic exposure-response relationship with TVOC rather than any individual component exposure (Bove 2014a). Thus, the lowest exposure category to cumulative TVOC with a monotonic dose-response provides evidence of a low level of Camp Lejeune water that is hazardous to human health and a known cause of kidney cancer. This is the "low" exposure group of >1 to 4600 ug/L*month (HR 1.42) in the Bove 2014a study.

Alternatively, a duration-based intensity of exposure is also supported by the Camp Lejeune literature with a monotonic exposure response evident (Bove 2024b). Consequently, the lowest duration category in the monotonic exposure-response finding that demonstrates an elevated measure of association is a level that is hazardous to human health and a known cause of kidney cancer. This is the "low" duration group with 1-5 quarters on base (HR 1.36).

Mr. Fancher's exposure was similar to these levels. In fact, Mr. Fancher's TVOC exposure would be considered to be in the medium exposure group, which had an even higher HR. Dr. Hatten's report goes on to list additional levels that are relevant to this analysis, including exposure categories linked to increased risk ratios for kidney cancer for the chemicals in the water at Camp Lejeune.

Dr. Bird's report similarly details levels that are hazardous to humans and known to cause kidney cancer. For example, his report states,

I have been asked to evaluate the levels of exposure to these chemicals that have been identified in scientific literature to be hazardous to human beings generally and are known to cause kidney cancer as likely as not. Numerous studies provide evidence of specific levels of exposure—some of which are similar in intensity with the contamination observed at Camp Lejeune—that are associated with increased risks for kidney cancer:

1. **Cumulative exposure to 27-44 mg of PCE:** Aschengrau A, Ozonoff D, Paulu C, et al. Cancer risk and tetrachloroethylene-contaminated drinking water in Massachusetts. *Arch Environ Health*. 1993;48(5):284-292.
2. **Exposure to a TCE concentration of > 76 ppb:** Moore LE, Boffetta P, Karami S, et al. Occupational trichloroethylene exposure and renal carcinoma risk: evidence of genetic susceptibility by reductive metabolism gene variants. *Cancer Res*. 2010;70(16):6527-6536.
3. **Cumulative exposure of > 1,580 ppb-years:** Moore et al., 2010.
4. **Sustained exposure to 0-25 ppb of TCE:** Andrew AS, Li M, Shi X, Rees JR, Craver KM, Petali JM. Kidney Cancer Risk Associated with Historic Groundwater Trichloroethylene Contamination. *Int J Environ Res Public Health*. 2022;19(2):618.
5. **Exposure to a TCE concentration of 267 ppb:** Parker GS, Rosen, S. Woburn: Cancer Incidence and Environmental Hazards 1969-1978. Commonwealth of Massachusetts, Department of Public Health, 1981.
6. **Exposure to a PCE concentration of 21 ppb:** Parker and Rosen, 1981.
7. **Cumulative exposure of 1 - 3,100 µg/L-month of TCE:** Bove FJ, Ruckart PZ, Maslia M, Larson TC. Evaluation of mortality among Marines and Navy personnel exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. *Environ Health*. 2014;13:10.
8. **Cumulative exposure of 1 - 155 µg/L-month of PCE:** Bove et al, 2014a.
9. **Cumulative exposure of 1 – 4,600 µg/L-month of exposure to all compounds at Camp Lejeune:** Bove et al, 2014a.
10. **Cumulative exposure of 3,100 – 7,700 µg/L-month of TCE:** Bove et al, 2014a.
11. **Cumulative exposure of 155 - 380 µg/L-month of PCE:** Bove et al, 2014a.
12. **Cumulative exposure of 4,600 – 12,250 µg/L-month of exposure to all compounds at Camp Lejeune:** Bove et al, 2014a.
13. **Cumulative exposure greater than 7,700 µg/L-month of TCE:** Bove et al, 2014a.
14. **Cumulative exposure greater than 380 µg/L-month of PCE:** Bove et al, 2014a.
15. **Cumulative exposure greater than 12,250 µg/L-month of exposure to all compounds at Camp Lejeune:** Bove et al, 2014a.
16. **18 months of residence on base from 1975 to 1985:** Bove et al, 2014a.
17. **Employment on base for 2.5 years:** Bove FJ, Ruckart PZ, Maslia M, Larson TC. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. *Environ Health*. 2014;13:68.
18. **Cumulative exposure to 110 – 11,030 ppb-months of TCE:** Agency for Toxic Substances and Disease Registry (ATSDR). *Morbidity Study of Former Marines, Employees, and Dependents Potentially Exposed to Contaminated Drinking Water at U.S. Marine Corps Base Camp Lejeune*. April 2018.
19. **Cumulative exposure to 36 - 711 ppb-months of PCE:** ATSDR, 2018.
20. **Cumulative exposure greater than 11,030 ppb-months of TCE:** ATSDR, 2018.
21. **Cumulative exposure greater than 711 ppb-months of PCE:** ATSDR, 2018.

22. **1-6 quarters stationed on base as a service member from 1975 to 1985:** Bove FJ. Cancer Incidence among Marines and Navy Personnel and Civilian Workers Exposed to Industrial Solvents in Drinking Water at US Marine Corps Base Camp Lejeune: A Cohort Study. *Environ Health Perspect* 2024b;132;10.
23. **More than 21 quarters spent on base as a civilian worker from 1975 to 1985:** Bove et al, 2024b.

Mr. Fancher's exposure is similar to many of the above listed levels that have been found to be correlated with kidney cancer. This data is used in my analyses of this case and in forming the opinion that Mr. Fancher's kidney cancer is associated with exposure to the toxins at issue.

VIII. Mr. Fancher's Exposure

Mr. Fancher was exposed at Camp Lejeune for 337 days between 10/16/79 and 6/12/81. He was diagnosed with a kidney cancer 16 years later at the age of 39, which is very young for such cancers. The latency period between exposure and the development of cancer is normal. For example, in the New York City area, we are currently treating many cancers that are a result of exposures to toxins on 9/11/01 near the World Trade Centers, the development of these cancer had a similar latency period. Less than 5% of all kidney cancers are diagnosed under the age of 40. Mr. Fancher's cancer was diagnosed in 1997. It was a type of kidney cancer known as clear cell renal carcinoma. He underwent an open right radical nephrectomy through a thoracoabdominal incision on 12/12/1997 and fortunately has never had a recurrence of his disease. Pathology demonstrated a Stage B (capsule involvement) clear cell renal cell carcinoma. According to the records, his surgery was complicated by a surgical site infection. It is important to note that most kidney cancers are diagnosed after the sixth decade of life and according to the records Mr. Fancher was a non-smoker and had no other known risk factors for kidney cancer, including no family history, no hypertension, and no other known carcinogen exposures, so his case is very unusual. Importantly, the percentage of kidney cancers that occur in non-smokers who are under the age of 40, like Mr. Fancher, is far less than 5%. Mr. Fancher had an elevated BMI following his RCC diagnosis. His BMI prior to his diagnosis was much lower and in the normal or only slightly elevated range.

According to ATSDR, a marine in training at Camp Lejeune consumes an estimated 6 liters of water per day for three days per week and 3 liters per day the rest of the week.¹

"Under warm weather conditions, a marine may consume between 1 and 2 quarts of water per hour and shower twice a day."⁵ According to ATSDR/Bove, it is likely that during training, the water supplied in the field came from the Hadnot Point water system with both measured and estimated levels of TCE and PCE substantially higher than their MCLs.^{1,7,8}

Mr. Fancher testified in a deposition to many aspects of his life at Camp Lejeune that evidence the substantial nature of his exposure. For example, he testified that he would shower on base, even when he was living in an apartment across the street from Camp Lejeune. He testified he

would shower at least once per day, his showers would be approximately thirty minutes long and he would sometimes shower more than once a day. This evidences significant inhalation and dermal exposure. Mr. Fancher testified that he would eat his meals on base at the dining hall. Even when he was living off base he would eat meals on base (for example, approximately three times a week for dinner) and he would sleep on base several nights a week when he had an apartment off base. He drank mostly water supplied by the base at meals and when he was training. This evidences a substantial ingestion exposure.

There are other examples of deposition testimony and other evidence that indicates the substantial nature of his exposure.

In sum, Mr. Fancher's exposure was substantial based on: (1) the amount of exposure for Mr. Fancher in terms of the levels of the chemicals in the water and how often Mr. Fancher was consuming, inhaling and coming into contact with the water, (2) the duration he was exposed to the chemicals over 337 days, (3) the intensity of the exposure as shown by the ATSDR water modeling data and other data and (4) the fact that he was exposed to and effected by the chemicals so frequently throughout his day to day life at Camp Lejeune.

I formed my opinion that Mr. Fancher had substantial exposure solely based upon Mr. Fancher's deposition, the elevated levels of concentrations in the water and additional documents from Mr. Fancher's file. I also reviewed Plaintiff's expert Kelly Reynolds' exposure charts. These charts support my opinions that Mr. Fancher's exposure was substantial and causally related to his kidney cancer. The charts provide a dose of ingestion exposure for Mr. Fancher as follows:

Chart 1: 1L		Chart 2: ATSDR		Chart 3 Deposition/FM
	Cumulative ug/l-M	Cumulative consumption (total ug= days*concentration per L)	Cumulative consumption (total ug= days*concentration per ATSDR exposure assumptions)	Cumulative consumption (total ug= days*concentration per deposition/FM exposure assumptions)
TCE	5,340	92,052	422,266	577,666
PCE	247	4,263	19,535	26,742
VC	351	6,068	27,803	38,065
BZ	99	1,771	8,083	11,095

Levels of TCE in this magnitude clearly represent a substantial exposure. Additionally, Mr. Fancher was exposed through inhalation and dermal exposure as well. Kelly Reynolds' charts only attempted to calculate ingestion. The charts, by definition, underestimate the true exposure for Mr. Fancher as a whole. Ingestion of hundreds of thousands of ppb of TCE is substantial and known to cause kidney cancer, whether through ingestion, inhalation or dermal exposure. If you have exposure to these amounts through all three routes of exposure, it becomes exponentially worse for the patient, as was likely the case for Mr. Fancher.

I use these charts to add weight to the differential diagnosis analyses below.

IX. Differential Diagnosis for Etiology

In examining Mr. Fancher's case, it is important to first develop an exhaustive differential about potential causes of his kidney cancer. In general, risks for the development of cancer can be divided into environmental exposures, carcinogenic chemicals and genetic predispositions. Well established and accepted environmental risk factors for the development of renal cell carcinoma include smoking and cadmium. Other known risk factors for the development of renal cell carcinoma are family history of kidney cancer, long-term dialysis or chronic renal insufficiency, and genetic disorders (Von-Hippel-Lindau disease, acquired cystic kidney disease, tuberous sclerosis, hereditary papillary renal carcinoma, hereditary leiomyomatosis and renal cell carcinoma, Birt-Hogg-Dube syndrome, hereditary paraganglioma-pheochromocytoma syndrome, Cowden syndrome, BAP1 tumor predisposition syndrome, sickle cell trait disease).

According to Mr. Fancher's medical records, he was a never smoker at the time of his diagnosis which eliminates personal tobacco use as a potential carcinogenic exposure. In Mrs. Fancher's deposition, she also confirms that Mr. Fancher never smoked. Mr. Fancher also has no known or documented exposure to other chemicals such as cadmium. He had normal renal function and was not on dialysis eliminating chronic renal failure as a cause. He also never reported any relatives with a history of developing kidney cancers. The only family history of cancer according to the records and depositions was a grandfather with lung or throat cancer and brother with throat cancer, neither of which have been linked to genetic syndromes predisposing to kidney cancers. Although he did not undergo genetic testing, the absence of any family members with kidney cancers or other associated malignancies to predisposition syndromes, as well as his lack of developing another renal cancer in his remaining kidney, make it very unlikely that he was at increased genetic risk of developing such a malignancy. Based on Mr. Fancher's own medical history as well as his reported family medical history, it is highly unlikely Mr. Fancher had a genetic predisposition to develop a kidney cancer. His history would not warrant genetic testing under the current standard of care due to the extreme low likelihood of revealing a genetic defect. Mr. Fancher had an elevated BMI at times following his kidney cancer diagnosis, but his

BMI prior to and around the time of his diagnosis was much lower and in the normal or only slightly elevated range. Therefore, this is a very low risk factor if any at all.

However, exposure to certain chemicals such as TCE is considered a significant risk factor for developing renal cell carcinoma as previously described and, in my opinion, this represents his only known and identifiable risk factor. Mr. Fancher was also exposed to PCE, Benzene and VC, which are known carcinogens and also associated with the development of kidney cancer. This exposure likely and probably would have been additive or synergistic when combined with his TCE exposure. His only identifiable exposure to carcinogenic agents from the records occurred at Camp Lejeune. He lived on the base and was exposed while working on the base to contaminated water between 10/16/1979 and 6/12/1981. During these periods, he had an estimated exposure of 5,340 microgram/liter months of TCE, 247 microgram/liter months of PCE, 351 microgram/liter months of vinyl chloride and 99 microgram/liter months of benzene. This exposure level far exceeds those levels which are considered safe for human exposure and would be carcinogenic and known to cause kidney cancer. After exposure to carcinogenic chemicals, there is well established latency period before the actual development of cancer and 16 years is well within the normal range.

X. Response to Defendant's Supplemental Answers to Interrogatories

I have reviewed Defendant's supplemental responses to Interrogatories sent by the Plaintiffs. In those responses, Defendant makes certain contentions about the cause of Mr. Fancher's kidney cancer, other than the water at Camp Lejeune. These contentions are wrong for the following reasons:

"There may be alternative causes or contributing factors for the Plaintiff's alleged illnesses and conditions. The plaintiff has a family history of throat cancer. See Tr. 18:23-24; 23:5-9 (noting grandfather and brother who had throat cancer). Plaintiff may have been occupationally exposed to asbestos and other carcinogens. But see Tr. 74:9-75:4. (describing employment with Volusia County School District)."

Response: As previously stated, the only known risk factors for the development of a kidney cancer are either genetic or environmental exposures. Mr. Fancher does not have any risk factors for kidney cancer described in the differential above except for exposure to TCE, PCE, Benzene and VC. There is no genetic syndrome or family predisposition to throat cancer that would effect the development of kidney cancers. Mr. Fancher's grandfather and brother may have developed throat cancer from carcinogenic exposures such as smoking, but Mr. Fancher does not have known exposure to either of these agents. Mr. Fancher was not, according to his testimony, exposed to asbestos. He testified in his deposition that the school he taught at had a company abate the asbestos in their buildings before Mr. Fancher arrived there to teach.

“The Plaintiff’s exposure to water at Camp Lejeune may not have been significant enough to cause the alleged illness or injury, and the length of time (latency period) between any exposure to the water at Camp Lejeune and the onset of the Plaintiff’s illness or injury may indicate an alternative cause or that the cause of the Plaintiff’s illness or injury is idiopathic.”

Response: As per above, Mr. Fancher did have significant and sufficient exposure to water at Camp Lejeune to cause his kidney cancer. A significant latency period for the development cancers after toxin exposure is extremely common in medicine, frequently 15-20 years, which fits exactly with Mr. Fancher’s timeline.

XI. Mr. Fancher’s Injuries

I will talk about the harms suffered by Mr. Fancher as a result of his kidney cancer. For example, Mr. Fancher has a substantial bulge on the right side of his abdomen following the surgery to remove his kidney in 1997. To a reasonable degree of medical certainty, the bulge in his abdomen is as a direct result of the surgery to remove his kidney. Additionally:

1. The harms and injuries and damages suffered by Mr. Fancher that are described in this report are permanent.
2. The treatment and care Mr. Fancher has received and is now receiving is fair, reasonable and medically necessary.
3. The Plaintiff is expected to live a normal life expectancy.
4. The medical billing relating to Mr. Fancher’s kidney cancer diagnosis, the surgery to remove his kidney and the follow up treatment related to his kidney cancer was reasonable and medically necessary.

XII. Conclusion

In summary, there is significant and sufficient evidence that TCE exposure is carcinogenic and specifically increases the risk of developing kidney cancer. The other chemicals in the water, PCE, VC and Benzene, are also causally related to kidney cancer and more likely than not acted additively or synergistically with the TCE to cause Mr. Fancher’s kidney cancer. The water at Camp Lejeune was contaminated with TCE, PCE, VC and Benzene leading to high levels of exposure during Mr. Fancher’s time on the base. Mr. Fancher had no other known risk factors for developing renal cell carcinoma and he was much younger than the age that 95% of such cancers are usually diagnosed. In my opinion, the TCE in conjunction with the PCE, VC and Benzene exposure caused the development of Mr. Fancher’s kidney tumor and is more likely than any other potential cause.

CITATIONS

¹ Agency for Toxic Substances and Disease Registry. Assessment of the Evidence for the Drinking Water Contaminants at Camp Lejeune and Specific Cancers and Other Diseases. January 13, 2017.

² Agency for Toxic Substances and Disease Registry. Public Health Assessment for Camp Lejeune Drinking Water US Marine Corps Base Camp Lejeune, North Carolina. January 20, 2017.

³ IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. TRICHLOROETHYLENE, TETRACHLOROETHYLENE, AND SOME OTHER CHLORINATED AGENTS. *Monogr Eval Carcinog Risks Hum.* 2014;106:1-512.

⁴ National Toxicology Program. Report on Carcinogens: Monograph on Trichloroethylene. *RoC Monograph 05.* 2015.

⁵ Bove FJ, Ruckart PZ, et al. Evaluation of mortality among marines and navy personnel exposed to contaminated drinking water at USMC base Camp Lejeune: a retrospective cohort study. *Environmental Health.* 2014. <http://www.ehjournal.net/content/13/1/10>.

⁶ Bove FJ, Ruckart PZ, et al. Mortality study of civilian employees exposed to contaminated drinking water at USMC Base Camp Lejeune: a retrospective cohort study. *Environmental Health.* 2014. <http://www.ehjournal.net/content/13/1/68>.

⁷ Bove FJ, Greek A, Cancer Incidence among Marines and Navy Personnel and Civilian Workers Exposed to Industrial Solvents in Drinking Water at US Marine Corps Base Camp Lejeune: A Cohort Study. *Environmental Health Perspectives.* 2024. 132(1). <https://doi.org/10.1289/EHP14966>.

⁸ Bove FJ, Greek A, Evaluation of mortality among Marines, Navy personnel, and civilian workers exposed to contaminated drinking water at USMC base Camp Lejeune: a cohort study. *Environmental Health.* 2024(23):61. <https://doi.org/10.1186/s12940-024-01099-7>.

⁹ Karami S, Lan Q, Rothman N, et al. Occupational trichloroethylene exposure and kidney cancer risk: A meta-analysis. *Occup Environ Med.* 2012;69(12):858-867. doi:10.1136/oemed-2012-100932.

¹⁰ Lash LH, Chiu WA, et al. Trichlorethylene Biotransformation and its Role in Mutagenicity, Carcinogenicity and Target Organ Toxicity. *Mutat. Res. Rev. Mutat. Res.* 2014;762:22-36. doi:10.1016/j.mrrev.2014.04.003.

MATTHEW WEISS'S CV

CURRICULUM VITAE

Matthew J. Weiss, M.D., MBA

August 15, 2024

Date of this version

DEMOGRAPHIC AND PERSONAL INFORMATION

Current Appointments

February 2019-present	Deputy Physician-in-Chief, Northwell Health Cancer Institute Director of Surgical Oncology, Northwell Health Cancer Institute Professor of Surgery and Oncology, Donald and Barbara Zucker School of Medicine at Hofstra/Northwell
September 2021-present	Professor in the Institute of Cancer Research at the Feinstein Institutes for Medical Research
August 2022-present	Adjunct Professor at the Cold Spring Harbor Laboratory
August 2022-present	Affiliate Member, Cold Spring Harbor Cancer Center
September 2022-present	Executive Vice Chair of Surgery, Northwell Health
September 2022-present	Vice President of Clinical Surgical Services, Northwell Health
September 2022-present	System Chief of Surgical Oncology, Northwell Health
October 2022-present	Eli B. and Mollie B. Cohen Family Professor of Surgical Oncology

Personal Data

Northwell Health Cancer Institute
1111 Marcus Avenue
Lake Success, NY 11042
Office: 516-321-2239
Cell: 443-465-1734
E-mail: mweiss8@northwell.edu

Education and Training

1998	BA	College of the Holy Cross	Mathematics
2003	MD	Jefferson Medical College	Medicine
2003	Internship	Johns Hopkins University	Surgery
2004	Residency	Johns Hopkins University	Surgery
2005-2007	Research Fellowship	Massachusetts General Hospital	Immunology
2007-2010	Residency	Johns Hopkins University	Surgery
2010-2012	Fellowship	Memorial Sloan-Kettering Cancer Center	Surgical Oncology
2011-2012	Fellowship	Memorial Sloan-Kettering Cancer Center	HPB Surgery
2020	MBA	Carey Business School of Johns Hopkins	Health Care

Management

Professional Experience

1997-1998	Research Technician I	Thomas Jefferson University
1998-1999	Research Technician III	Children's Hospital of Philadelphia
1999-2003	Medical Student Research	Children's Hospital of Philadelphia
2010-2012	Instructor of Surgery	Memorial Sloan-Kettering Cancer Center
2010-2012	Instructor of Surgery	Weil Medical College of Cornell University
2012-2017	Assistant Professor of Surgery	Johns Hopkins University
2013-2017	Assistant Professor of Oncology	Johns Hopkins University
2013-2019	Surgical Director Pancreas MultiID Clinic	Johns Hopkins University
2013-2019	Surgical Director Liver MultiID Clinic	Johns Hopkins University
2016-2019	Program Director CGSO Fellowship	Johns Hopkins University
2017-2019	Associate Professor of Surgery	Johns Hopkins University

2017-2019	Associate Professor of Oncology	Johns Hopkins University
2018-2019	Chief, Hepatobiliary Surgery	Johns Hopkins University
2018-2019	Paul K. Neumann Professor of Surgery	Johns Hopkins University
2019-present	Affiliate Member	Cold Spring Harbor Laboratory
2019-present	Professor of Surgery	Zucker School of Medicine at Hofstra/Northwell
2019-present	Professor of Oncology	Zucker School of Medicine at Hofstra/Northwell
2021-present	Associate Program Director CGSO Fellowship	Zucker School of Medicine at Hofstra/Northwell
2022-present	Professor	Feinstein Institutes for Medical Research
2022-present	Adjunct Professor	Cold Spring Harbor Laboratory
2022-present	Affiliate Member	Cold Spring Harbor Laboratory Cancer Center
2022-present	Executive Vice Chair of Surgery	Northwell Health
2022-present	Vice President of Clinical Surgical Services	Northwell Health
2022-present	System Chief of Surgical Oncology	Northwell Health

PUBLICATIONS

Original Research [OR]

1. Guo C, White PS, **Weiss MJ**, Hogarty MD, Thompson PM, Stram DO, Gerbing R, Matthay KK, Seeger RC, Brodeur GM Maris JM: Allelic deletion at 11q23 is common in MYCN single copy neuroblastomas. *Oncogene* 1999; 18(35):4948-4957.
2. Maris JM, **Weiss MJ**, Guo C, Gerbing RB, Stram DO, White PS, Hogarty MD, Sulman EP, Thompson PM, Lukens JN, Maris JM: Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. *J Clin Oncol* 2000; 18(9):1888-1899.
3. Hogarty MD, Liu X, Guo C, Thompson PM, **Weiss MJ**, White PS, Sulman EP, Brodeur GM, Maris JM: Identification of a 1-megabase consensus region of deletion at 1p36.3 in primary neuroblastomas. *Med Pediatr Oncol* 2000; 35(6):512-515.
4. **Weiss MJ**, Guo C, Shusterman S, Hii G, Mirensky TL, White PS, Hogarty MD, Rebbeck TR, Teare D, Urbanek M, Brodeur GM, Maris JM: Localization of a hereditary neuroblastoma predisposition gene to 16p12-p13. *Med Pediatr Oncol* 2000; 35(6):526-530.
5. Maris JM, **Weiss MJ**, Mosse Y, Hii G, Guo C, White PS, Hogarty MD, Mirensky T, Brodeur GM, Rebbeck TR, Urbanek M, Shusterman S: Evidence for a hereditary neuroblastoma predisposition locus at chromosome 16p12-13. *Cancer Res* 2002; 62(22):6651-6658.
6. Sahara H, Shoji T, Ng CY, **Weiss MJ**, Muniappan A, Guenther DA, Houser SL, Pujara AC, Sayre JK, Wain JC, Madsen JC, Allan JS: The role of indirect recognition of MHC class I and II allopeptides in a fully mismatched miniature swine model of lung transplantation. *Transplant Proc* 2006; 38(10):3256-3258.
7. Sahara H, **Weiss MJ**, Ng CY, Houser SL, Pujara AC, Sayre JK, Wain JC, Sachs DH, Madsen JC, Allan JS: Thymectomy does not abrogate long-term acceptance of MHC class I-disparate lung allografts in miniature Swine. *Transplant Proc* 2006; 38(10):3253-3255.
8. Meltzer AJ, **Weiss MJ**, Veillette GR, Sahara H, Ng CY, Cochrane ME, Houser SL, Sachs DH, Rosengard BR, Madsen JC, Allan JS: Repetitive gastric aspiration leads to augmented indirect allorecognition after lung transplantation in miniature swine. *Transplantation* 2009; 86(12):1824-1829.
9. **Weiss MJ**, Guenther DA, Mezrich JD, Sahara H, Ng CY, Meltzer AJ, Sayre JK, Cochrane ME, Pujara AC, Houser SL, Allen JS, Madsen JC: The indirect alloresponse impairs the induction but not maintenance of tolerance to MHC class I-disparate allografts. *Am J Transplant* 2009; 9(1):105-113.
10. **Weiss MJ**, Reddy S, Cameron JL, Hruban RH, Fishman EK, Pawlik TM, Schulick RD, Edil BH, Wolfgang CL: Is it safe to observe asymptomatic branch duct or mixed-type intraductal papillary mucinous neoplasms (IPMN) less than 3CM and without a solid component?: the pathological

- findings of 16 patients who underwent pancreatectomy for this condition. *Journal of Surgical Research* 2009; 151(2):297-297.
11. Veillette GR, Sahara H, Meltzer AJ, **Weiss MJ**, Iwamoto Y, Kim KM, Rosengard BR, Allan JS, Houser SL, Sachs DH, Benichou G, Madsen JC: Autoimmune sensitization to cardiac myosin leads to acute rejection of cardiac allografts in miniature swine. *Transplantation* 2011; 91(11):1187-1191.
 12. Grishkan IV, Beaty C, **Weiss M**, Wolfgang C, Khashab MA, Giday SA, Eckhauser FE: Double Hamoudi: A case report. *Int J Surg Case Rep* 2012; 3(2):70-73.
 13. **Weiss MJ**, Ito H, Araujo RL, Zabor EC, Gonen M, D'Angelica MI, Allen PJ, DeMatteo RP, Fong Y, Blumgart LH, Jarnagin WR: Hepatic pedicle clamping during hepatic resection for colorectal liver metastases: no impact on survival or hepatic recurrence. *Annals of surgical oncology* 2013; 20(1):285-294. PMID: 22868921. First author.
 14. Law JK, Singh VK, Khashab MA, Hruban RH, Canto MI, Shin EJ, Saxena P, **Weiss MJ**, Pawlik TM, Wolfgang CL, Lennon AM: Endoscopic ultrasound (EUS)-guided fiducial placement allows localization of small neuroendocrine tumors during parenchymal-sparing pancreatic surgery. *Surg Endosc* 2013; 27(10):3921-3926. PMID: 23636530. Co-author.
 15. Hyder O, Dodson RM, Mayo SC, Schneider EB, **Weiss MJ**, Herman JM, Wolfgang CL, Pawlik TM: Post-treatment surveillance of patients with colorectal cancer with surgically treated liver metastases. *Surgery* 2013; 154(2):256-265. PMID: 23889953. Co-author.
 16. Hyder O, Dodson RM, Nathan H, Schneider EB, **Weiss MJ**, Cameron JL, Choti MA, Makary MA, Hirose K, Wolfgang CL, Herman JM, Pawlik TM: Influence of patient, physician, and hospital factors on 30-day readmission following pancreatoduodenectomy in the United States. *JAMA Surg* 2013; 148(12):1095-1102. PMID: 24108580. Co-author.
 17. Hyder O, Dodson RM, **Weiss M**, Cosgrove DP, Herman JM, Geschwind JF, Kamel IR, Pawlik TM: Trends and patterns of utilization in post-treatment surveillance imaging among patients treated for hepatocellular carcinoma. *Journal of Gastrointestinal Surgery* 2013; 17(10):1774-1783. PMID: 23943387. Co-author.
 18. Nathan H, **Weiss MJ**, Soff GA, Stempel M, Dematteo RP, Allen PJ, Kingham TP, Fong Y, Jarnagin WR, D'Angelica MI: Pharmacologic prophylaxis, postoperative INR, and risk of venous thromboembolism after hepatectomy. *Journal of Gastrointestinal Surgery* 2014; 18(2):295-302; discussion 302-293. PMID: 24129829. Co-author.
 19. Hyder O, Dodson RM, Sachs T, **Weiss M**, Mayo SC, Choti MA, Wolfgang CL, Herman JM, Pawlik TM: Impact of adjuvant external beam radiotherapy on survival in surgically resected gallbladder adenocarcinoma: a propensity score-matched surveillance, epidemiology, and end results analysis. *Surgery* 2014; 155(1):85-93. PMID: 23876364. Co-author.
 20. Arnaoutakis DJ, Mavros MN, Shen F, Alexandrescu S, Firoozmand A, Popescu I, **Weiss M**, Wolfgang CL, Choti MA, Pawlik TM: Recurrence patterns and prognostic factors in patients with hepatocellular carcinoma in noncirrhotic liver: a multi-institutional analysis. *Annals of Surgical Oncology* 2014; 21(1):147-154. PMID: 23959056. Co-author.
 21. Hatzaras I, Sachs TE, **Weiss M**, Wolfgang CL, Pawlik TM: Pancreaticoduodenectomy after bariatric surgery: challenges and available techniques for reconstruction. *Journal of Gastrointestinal Surgery* 2014; 18(4):869-877.
 22. Lucas DJ, Schexneider KI, **Weiss M**, Wolfgang CL, Frank SM, Hirose K, Ahuja N, Makary M, Cameron JL, Pawlik TM: Trends and risk factors for transfusion in hepatopancreatobiliary surgery. *Journal of Gastrointestinal Surgery* 2014; 18(4):719-728.
 23. Ejaz A, Spolverato G, Kim Y, Lucas DL, Lau B, **Weiss M**, Johnston FM, Kheng M, Hirose K, Wolfgang CL, Haut E, Pawlik TM: Defining incidence and risk factors of venous thromboembolism after hepatectomy. *Journal of Gastrointestinal Surgery* 2014; 18(6):1116-1124. PMID: 24337986. Co-author.
 24. Aslakson RA, Schuster AL, Miller J, **Weiss M**, Volandes AE, Bridges JF: An environmental scan of advance care planning decision AIDS for patients undergoing major surgery: a study protocol. *Patient* 2014; 7(2):207-217.
 25. Spolverato G, Ejaz A, Kim Y, **Weiss M**, Wolfgang CL, Hirose K, Pawlik TM: Readmission incidence and associated factors after a hepatic resection at a major hepato-pancreatico-biliary academic centre. *HPB* 2014; 16(11):972-978. PMID: 24712690. Co-author.

26. Schneider EB, Calkins KL, **Weiss MJ**, Wolfgang CL, Makary MA, Ahuja N, Haider AH, Pawlik TM: Black and hispanic pancreaticoduodenectomy patients are treated by lower volume providers and have longer hospital stays compared with white patients. *Journal of Surgical Research* 2014; 186(2):607-608.
27. Wu W, He J, Cameron JL, Makary M, Soares K, Ahuja N, Rezaee N, Herman J, Zheng L, Laheru D, **Weiss MJ**: The impact of postoperative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. *Annals of Surgical Oncology* 2014; 21(9):2873-2881. PMID: 24770680. Senior author.
28. Ejaz A, Sachs T, He J, Spolverato G, Hirose K, Ahuja N, Wolfgang CL, Makary MA, **Weiss M**, Pawlik TM: A comparison of open and minimally invasive surgery for hepatic and pancreatic resections using the Nationwide Inpatient Sample. *Surgery* 2014; 156(3):538-547.
29. **Weiss MJ**, Kim Y, Ejaz A, Spolverato G, Haut ER, Hirose K, Wolfgang CL, Choti MA, Pawlik TM: Venous thromboembolic prophylaxis after a hepatic resection: patterns of care among liver surgeons. *HPB* 2014; 16(10):892-898. PMID: 24888461. First author.
30. Law JK, Wolfgang CL, **Weiss MJ**, Lennon AM: Concomitant pancreatic adenocarcinoma in a patient with branch-duct intraductal papillary mucinous neoplasm. *World J Gastroenterol* 2014; 20(27):9200-9204. PMID: 25083095. Co-author.
31. Lennon AM, Manos LL, Hruban RH, Ali SZ, Fishman EK, Kamel IR, Raman SP, Zaheer A, Hutfless S, Salamone A, **Weiss MJ**, Wolfgang CL: Role of a multidisciplinary clinic in the management of patients with pancreatic cysts: a single-center cohort study. *Annals of Surgical Oncology* 2014; 21(11):3668-3674. PMID: 24806116. Co-author.
32. Sachs TE, Ejaz A, **Weiss M**, Spolverato G, Ahuja N, Makary MA, Wolfgang CL, Hirose K, Pawlik TM: Assessing the experience in complex hepatopancreatobiliary surgery among graduating chief residents: is the operative experience enough? *Surgery* 2014; 156(2):385-393.
33. Schneider EB, Calkins KL, **Weiss MJ**, Herman JM, Wolfgang CL, Makary MA, Ahuja N, Haider AH, Pawlik TM: Race-based differences in length of stay among patients undergoing pancreatoduodenectomy. *Surgery* 2014; 156(3):528-537. PMID: 24973128. Co-author.
34. Lennon AM, Victor D, Zaheer A, Ostovaneh MR, Jeh J, Law JK, Rezaee N, Molin MD, Ahn YJ, Wu W, Khashab MA, Girotra M, Ahuja N, Makary MA, **Weiss MJ**, Hirose K, Goggins M, Hruban RH, Cameron A, Wolfgang CL, Gurakar A: Liver transplant patients have a risk of progression similar to that of sporadic patients with branch duct intraductal papillary mucinous neoplasms. *Liver Transpl* 2014; 20(12):1462-1467. PMID: 25155689. Co-author.
35. Oduyebo I, Law JK, Zaheer A, **Weiss MJ**, Wolfgang C, Lennon AM: Choledochal or pancreatic cyst? Role of endoscopic ultrasound as an adjunct for diagnosis: a case series. *Surg Endosc* 2015; 29(9):2832-6. PMID: 25492450. Co-author.
36. Rezaee N, Khalifian S, Cameron JL, Pawlik TM, Hruban RH, Fishman EK, Makary MA, Lennon AM, Wolfgang CL, **Weiss MJ**: Smoking is not associated with severe dysplasia or invasive carcinoma in resected intraductal papillary mucinous neoplasms. *Journal of Gastrointestinal Surgery* 2015; 19(4):656-65. PMID: 25477314. Senior author.
37. Tosoian JJ, Hicks CW, Cameron JL, Valero V, 3rd, Eckhauser FE, Hirose K, Makary MA, Pawlik TM, Ahuja N, **Weiss MJ**, Wolfgang CL: Tracking early readmission after pancreatectomy to index and nonindex institutions: a more accurate assessment of readmission. *JAMA Surg* 2015; 150(2):152-158. PMID: 25535811. Co-author.
38. Valero V, 3rd, Amini N, Spolverato G, **Weiss MJ**, Hirose K, Dagher NN, Wolfgang CL, Cameron AA, Philosophe B, Kamel IR, Pawlik TM: Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. *Journal of Gastrointestinal Surgery* 2015; 19(2):272-281. PMID: 25389056. Co-author.
39. Schneider EB, Ejaz A, Spolverato G, Hirose K, Makary MA, Wolfgang CL, Ahuja N, **Weiss M**, Pawlik TM: Hospital volume and patient outcomes in hepato-pancreatico-biliary surgery: is assessing differences in mortality enough?. *Journal of Surgical Research* 2014; 18(12):2105-15. PMID: 25297443. Co-author.
40. Page AJ, Ejaz A, Spolverato G, Zavadsky T, Grant MC, Galante DJ, Wick EC, **Weiss M**, Makary MA, Wu CL, Pawlik TM: Enhanced recovery after surgery protocols for open hepatectomy-physiology, immunomodulation, and implementation. *Journal of Gastrointestinal Surgery* 2015; 19(2):387-399.

41. Al Efshat M, Wolfgang CL, **Weiss MJ**: Stage III pancreatic cancer and the role of irreversible electroporation. *BMJ* 2015; 350:h521. PMID: 25787829. Senior author.
42. Valero V, 3rd, Grimm JC, Kilic A, Lewis RL, Tosoian JJ, He J, Griffin JF, Cameron JL, **Weiss MJ**, Vollmer CM, Jr., Wolfgang CL: A novel risk scoring system reliably predicts readmission after pancreatectomy. *Journal of the American College of Surgeons* 2015; 220(4):701-713. PMID: 25797757. Co-author.
43. Raman SP, Reddy S, **Weiss MJ**, Manos LL, Cameron JL, Zheng L, Herman JM, Hruban RH, Fishman EK, Wolfgang CL: Impact of the time interval between MDCT imaging and surgery on the accuracy of identifying metastatic disease in patients with pancreatic cancer. *American Journal of Roentgenology* 2015; 204(1):W37-42. PMID: 25539271. Co-author.
44. Moningi S, Walker AJ, Hsu CC, Reese JB, Wang JY, Fan KY, Rosati LM, Laheru DA, **Weiss MJ**, Wolfgang CL, Pawlik TM, Herman JM: Correlation of clinical stage and performance status with quality of life in patients seen in a pancreas multidisciplinary clinic. *Journal of Oncol Pract* 2015; 11(2):e216-21. PMID: 25563703. Co-author.
45. Moningi S, Dholakia AS, Raman SP, Blackford A, Cameron JL, Le DT, De Jesus-Acosta AM, Hacker-Prietz A, Rosati LM, Assadi RK, Dipasquale S, Pawlik TM, Zheng L, **Weiss MJ**, Laheru D, Wolfgang CL, Herman JM: The role of stereotactic body radiation therapy for pancreatic cancer: a single-institution experience. *Annals of Surgical Oncology* 2015; 22(7):2352-8. PMID: 25564157. Co-author.
46. Poruk KE, Kim Y, Cameron JL, He J, Eckhauser FE, Rezaee N, Herman J, Laheru D, Zheng L, Fishman EK, Hruban RH, Pawlik TM, Wolfgang CL, **Weiss MJ**: What is the significance of indeterminate pulmonary nodules in patients undergoing resection for pancreatic adenocarcinoma? *Journal of Gastrointestinal Surgery* 2015; 19(5):841-7. PMID: 25595307. Senior author.
47. Kim Y, Amini N, He J, Margonis GA, **Weiss M**, Wolfgang CL, Makary M, Hirose K, Spolverato G, Pawlik TM: National trends in the use of surgery for benign hepatic tumors in the United States. *Surgery* 2015; 157(6):1055-1064. PMID: 25769697. Co-author.
48. Amini N, Spolverato G, Gupta R, Margonis GA, Kim Y, Wagner D, Rezaee N, **Weiss MJ**, Wolfgang CL, Makary MM, Kamel IR, Pawlik TM: Impact total psoas volume on short- and long-term outcomes in patients undergoing curative resection for pancreatic adenocarcinoma: a new tool to assess sarcopenia. *Journal of Gastrointestinal Surgery* 2015; 19(9):1593-1602. PMID: 25925237. Co-author.
49. Ejaz A, Spolverato G, Kim Y, Wolfgang CL, Hirose K, **Weiss M**, Makary MA, Pawlik TM: The impact of resident involvement on surgical outcomes among patients undergoing hepatic and pancreatic resections. *Surgery* 2015; 158(2):323-330.
50. Valero V, 3rd, Saunders TJ, He J, **Weiss MJ**, Cameron JL, Dholakia A, Wild AT, Shin EJ, Khashab MA, O'Brein-Lennon AM, Ali SZ, Laheru D, Hruban RH, Iacobuzio-Donahue CA, Herman JM, Wolfgang CL: Reliable detection of somatic mutations in fine needle aspirates of pancreatic cancer with next-generation sequencing: implications for surgical management. *Annals of Surgery* 2016; 263(1):153-61. PMID: 26020105. Co-author.
51. Springer S, Wang Y, Molin MD, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbyn L, Allen PJ, Klimstra DS, Schattner MA, Schmidt MC, Yip-Schneider M, Cummings OW, Brand RE, Zeh HJ, Singhi AD, Scarpa A, Salvia R, Malleo G, Zamboni G, Falconi M, Jang J, Kim SW, Kwon W, Hong SM, Song KB, Kim SC, Swan N, Murphy J, Geoghegan J, Brugge W, Fernandez-Del Castillo C, Mino-Kenudson M, Schulick R, Edil BH, Adsay V, Paulino J, van Hooft J, Yachida S, Nara S, Hiraoka N, Yamao K, Hijioka S, van der Merwe S, Goggins M, Canto MI, Ahuja N, Hirose K, Makary M, **Weiss MJ**, Cameron J, Pittman M, Eshleman JR, Diaz LA, Papadopoulos N, Kinzler KW, Karchin R, Hruban RH, Vogelstein B, Lennon AM: A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology* 2015; 149(6):1501-10.
52. Rao AD, Chang DT, Parekh A, Rosati LM, Moningi S, Blackford A, Hacker-Prietz A, Wild AT, Zheng L, **Weiss M**, Pawlik TM, Asrari F, Fisher G, Laheru DA, Wolfgang CL, Koong AC, Herman JM: Multiplex proximity ligation assay to identify a biomarker panel for prognosis in unresectable pancreatic cancer patients treated with stereotactic body radiation therapy. *International Journal of Radiation Oncology, Biology, Physics* 2015. PMID: 29157747. Co-author.

53. He J, Amini N, Spolverato G, Hirose K, Makary M, Wolfgang CL, **Weiss MJ**, Pawlik TM: National trends with a laparoscopic liver resection: results from a population-based analysis. *HPB* 2015; 17(10):919-926. PMID: 26234323. Co-author.
54. Springer S, Wang Y, Dal Molin M, Masica DL, Jiao Y, Kinde I, Blackford A, Raman SP, Wolfgang CL, Tomita T, Niknafs N, Douville C, Ptak J, Dobbys J, Allen PJ, Klimstra DS, Schattner MA, **Weiss MJ**, Hruban RH, Vogelstein B, Lennon AM: A combination of molecular markers and clinical features improve the classification of pancreatic cysts. *Gastroenterology* 2015; 149(6):1501-1510.
55. Javed AA, Bagante F, Hruban RH, **Weiss MJ**, Makary MA, Hirose K, Cameron JL, Wolfgang CL, Fishman EK: Postoperative omental infarct after distal pancreatectomy: appearance, etiology management, and review of literature. *Journal of Gastrointestinal Surgery* 2015; 19(11):2028-2037. PMID: 26302877. Co-author.
56. Aslakson RA, Schuster AL, Reardon J, Lynch T, Suarez-Cuervo C, Miller JA, Moldovan R, Johnston F, Anton B, **Weiss M**, Bridges JF: Promoting perioperative advance care planning: a systematic review of advance care planning decision aids. *Journal of Comparative Effectiveness Research* 2015; 4(6):615-50. PMID: 26346494. Co-author.
57. Lu F, Poruk KE, **Weiss MJ**: Surgery for oligometastasis of pancreatic cancer. *Chinese Journal of Cancer Research* 2015; 27(4):358-367. PMID: 26361405. Senior author.
58. Wangjam T, Zhang Z, Zhou XC, Lyer L, Faisal F, Soares KC, Fishman E, Hruban RH, Herman JM, Laheru D, **Weiss M**, Li M, DeJesus-Acosta A, Wolfgang CL, Zheng L: Resected pancreatic ductal adenocarcinomas with recurrence limited in lung have a significantly better prognosis than those with other recurrence patterns. *Oncotarget* 2015; 6(34):36903-36910. PMID: 26372811. Co-author.
59. Hicks CW, Tosoian JJ, Craig-Schapiro R, Valero V, 3rd, Cameron JL, Eckhauser FE, Hirose K, Makary MA, Pawlik TM, Ahuja N, **Weiss MJ**, Wolfgang CL: Early hospital readmission for gastrointestinal-related complications predicts long-term mortality after pancreatectomy. *American Journal of Surgery* 2015; 210(4):636-642. PMID: 26384793. Co-author.
60. Wild AT, Herman JM, Dholakia AS, Moningi S, Lu Y, Rosati LM, Hacker-Prietz A, Assadi RK, Saeed AM, Pawlik TM, Jaffee EM, Laheru DA, Tran PT, **Weiss MJ**, Wolfgang CL, Ford E, Grossman SA, Ye X, Ellsworth SG: Lymphocyte-Sparing effect of stereotactic body radiation therapy in patients with unresectable pancreatic cancer. *International Journal of Radiation Oncology, Biology, Physics* 2016; 94(3): 571-579. PMID: 26867885. Co-author.
61. Rezaee N, Barbon C, Zaki A, He J, Salman B, Hruban RH, Cameron JL, Herman JM, Ahuja N, Lennon AM, **Weiss MJ**, Wood LD, Wolfgang CL: Intraductal papillary mucinous neoplasm (IPMN) with high-grade dysplasia is a risk factor for the subsequent development of pancreatic ductal adenocarcinoma. *HPB* 2016; 18(3):236-46. PMID: 27017163. Co-author.
62. Choti MA, Thomas M, Wong SL, Eaddy M, Pawlik TM, Hirose K, **Weiss MJ**, Kish J, Green MR: Surgical resection preferences and perceptions among medical oncologists treating liver metastases from colorectal cancer. *Annals of Surgical Oncology* 2016; 23(2):375-81. PMID: 26561404. Co-author.
63. Gani F, Kim Y, **Weiss MJ**, Makary MA, Wolfgang CL, Hirose K, Cameron JL, Wasey JO, Frank SM, Pawlik TM: Effect of surgeon and anesthesiologist volume on surgical outcomes. *The Journal of Surgical Research* 2016; 200(2):427-34. PMID: 26342836. Co-author.
64. Poruk KE, Valero V 3rd, Saunders T, Blackford AL, Griffin JF, Poling J, Hruban RH, Anders RA, Herman J, Zheng L, Rasheed ZA, Laheru DA, Ahuja N, **Weiss MJ**, Cameron JL, Goggins M, Iacobuzio-Donahue CA, Wood LD, Wolfgang CL: Circulating tumor cell phenotype predicts recurrence and survival in pancreatic adenocarcinoma. *Ann Surg* 2016; 264(6) 1073-1081. PMID: 26756760. Co-author.
65. Yachida S, Wood LD, Suzuki M, Takai E, Totoki Y, Kato M, Luchini C, Arai Y, Nakamura H, Hama N, Elzawahry A, Hosoda F, Shiota T, Morimoto N, Hori K, Funazaki J, Tanaka H, Morizane C, Okusaka T, Nara S, Shimada K, Hiraoka N, Taniguchi H, Higuchi R, Oshima M, Okano K, Hirono S, Mizuma M, Arihiro K, Yamamoto M, Unno M, Yamaue H, **Weiss MJ**, Wolfgang CL, Furukawa T, Nakagama H, Vogelstein B, Kiyono T, Hruban RH, Shibata T: Genomic sequencing identifies ELF3 as a driver of ampullary carcinoma. *Cancer Cell* 2016; 29(2)229-40. PMID: 26806338. Co-author.
66. Hicks CW, Burkhart RA, **Weiss MJ**, Wolfgang CL, Cameron AM, Pawlik TM. Management of type-9 hepatic arterial anatomy at the time of pancreaticoduodenectomy: Considerations for

- preservation and reconstruction of a completely replaced common hepatic artery. *J Gastrointest Surg* 2016; 20(7):1400-4. PMID: 27138326. Co-author.
67. Wu W, Dodson R, Makary MA, **Weiss MJ**, Hirose K, Cameron JL, Ahuja N, Pawlik TM, Wolfgang CL, He J. A contemporary evaluation of the cause of death and long-term quality of life after total pancreatectomy. *World J Surgery* 2016; 40(10) 2513-8. PMID: 27177647. Co-author.
 68. Allen PJ, Kuk D, Castillo CF, Basturk O, Wolfgang CL, Cameron JL, Lillemoe KD, Ferrone CR, Morales-Oyarvide V, He J, **Weiss MJ**, Hruban RH, Gonen M, Klimstra DS, Mino-Kenudson M. Multi-institutional validation study of American Joint Commission on Cancer (8th Edition) changes for T and N staging in patients with pancreatic adenocarcinoma. *Ann Surgery* 2016; 265(1) 185-191. PMID: 27163957. Co-author.
 69. Aslakson RA, **Weiss MJ**: Opportunities for novel, innovative, and transformative partnerships with patients and their families. *JAMA Surgery* 2016 (Epub ahead of print) (Manuscript preparation)
 70. Peters NA, Javed AA, Cameron JL, Makary MA, Hirose K, Pawlik TM, He J, Wolfgang CL, **Weiss MJ**. Modified Appleby procedure for pancreatic adenocarcinoma: Does improved neoadjuvant therapy warrant such an aggressive approach? *Ann Surg Onc* 2016; 23(11) 3757-64. PMID: 27328946. Senior author.
 71. Hata T, Dal Molin M, Suenaga M, Yu J, Pittman M, **Weiss MJ**, Canto M, Wolfgang CL, Lennon AM, Hruban RH, Goggins MG. Cyst fluid telomerase activity predicts the histological grade of cystic neoplasms of the pancreas. *Clin Cancer Res* 2016; 22(20) 5141-5151. PMID: 27230749. Co-author.
 72. Masica DL, Dal Molin M, Wolfgang CL, Tomita T, Ostovaneh MR, Blackford A, Moran RA, Law JK, Barkley T, Goggins M, Canto M, Pittman M, Eshelman JR, Ali SZ, Fishman EK, Kamel IR, Raman SP, Zaheer A, Ahuja N, Makary MA, **Weiss MJ**, Hirose K, Cameron JL, Rezaee N, He J, Joon AY, Wu W, Wang Y, Springer S, Diaz LL, Papadopoulos N, Hruban RH, Kinzler KW, Vogelstein B, Karchin R, Lennon AM. A novel approach for selecting combination clinical markers of pathology applied to a large retrospective cohort of surgically resected pancreatic cysts. *J Am Med Inform Assoc* 2016; 24(1) 145-152. PMID: 27330075. Co-author.
 73. Pea A, Yu J, Rezaee N, Luchini C, He J, Dal Molin M, Griffin JF, Fedor H, Fesharakizadeh S, Salvia R, **Weiss MJ**, Bassi C, Cameron JL, Zheng L, Scarpa A, Hruban RH, Lennon AM, Goggins M, Wolfgang CL, Wood LD. Targeted DNA sequencing reveals patterns of local progression in the pancreatic remnant following resection of intraductal papillary mucinous neoplasm (IPMN) of the pancreas. *Ann Surg* 2016 (Epub ahead of print). PMID: 27433916. Co-author.
 74. Martin RC 2nd, Durham AN, Besselink MG, Iannitti D, **Weiss MJ**, Wolfgang CL, Huang KW. Irreversible electroporation in locally advanced pancreatic cancer: A call for standardization of energy delivery. *J Surg Oncol* 2016 114(7):865-871. PMID: 27546233. Co-author.
 75. Wright GP, Poruk KE, Zenati MS, Steve J, Bahary N, Hogg ME, Zuriekat AH, Wolfgang CL, Zeh III HJ, **Weiss MJ**. Primary tumor resection following favorable response to systemic chemotherapy in stage IV pancreatic adenocarcinoma with synchronous metastases: A bi-institutional analysis. *J Gastrointest Surg* 2016; 20(11)1830-1835. PMID: 27604886. Senior Author.
 76. Lee SR, Gemenetis G, Cooper M, Javed A, Cameron JL, Wolfgang CL, Eckhauser FE, He J, **Weiss MJ**. Long-term outcomes of 98 surgically resected metastatic tumors in the pancreas. *Annals of Surg Onc* 2016 (Epub ahead of print). PMID: 27770346. Senior author.
 77. Peters NA, Javed AA, He J, Wolfgang CL, **Weiss MJ**. Socioeconomic factors are associated with patterns of surgical therapy utilization and survival differences of early stage hepatocellular carcinoma. *J Surg Res* 2016;210:253-260. Senior author.
 78. Poruk KE, Lin JA, Cooper MA, He J, Makary MA, Hirose K, Cameron JL, Pawlik TM, Wolfgang CL, Eckhauser FE, **Weiss MJ**. A novel, validated risk score to predict surgical site infection after pancreaticoduodenectomy. *HPB* 2016; 18(11) 893-899. PMID: 27624516. Senior author.
 79. Luo G, Javed A, Strosberg JR, Jin K, Chang Y, Liu J, Soares K, **Weiss MJ**, Zheng L, Wolfgang CL, Cives M, Wong J, Sun J, Shao C, Wang W, Tan H, Li J, Ni Q, Chen M, He J, Chen J, Yu X. Modified staging classification for pancreatic neuroendocrine tumors on the basis of the American joint committee on cancer and European neuroendocrine tumor society systems. *J Clin Oncol* 2016; 35(3) 274-280. PMID: 27646952. Co-author.
 80. Spolverato G, Bagante F, **Weiss M**, He J, Wolfgang CL, Johnston F, Makary MA, Yang W, Frank SM, Pawlik TM. Impact of Delta hemoglobin on provider transfusion practices and post-operative

- morbidity among patients undergoing liver and pancreatic surgery. *J Gastrointest Surg* 2016; 20(12):2010-2020. (Epub ahead of print).
81. Sasaki K, Andreatos N, Margonis GA, He J, **Weiss M**, Johnston F, Wolfgang C, Antonious E, Pikoulis E, Pawlik TM. The prognostic implications of primary colorectal tumor location on recurrence and overall survival in patients undergoing resection for colorectal liver metastasis. *J Surg Oncol* 2016. (Epub ahead of print). PMID: 27792291. Co-author.
 82. Gemenetzi G, Bagante F, Griffin JF, Rezaee N, Javed AA, Manos LL, Lennon AM, Wood LD, Hruban RH, Zheng L, Zaheer A, Fishman EK, Ahuja N, Cameron JL, **Weiss MJ**, He J, Wolfgang CL. Neutrophil-to-lymphocyte ratio is a predictive marker for invasive malignancy in intraductal papillary mucinous neoplasms of the pancreas. *Ann Surg* 2016 (Epub ahead of print). PMID: 27631774. Co-author.
 83. Zaky AM, Wolfgang CL, **Weiss MJ**, Javed AA, Fishman EK, Zaheer A. Tumor-vessel relationships in pancreatic ductal adenocarcinoma at multidetector CT: Different classification systems and their influence on treatment planning. *Radiographics* 2016; 37(1) 93-112. PMID: 27885893. Co-author.
 84. Lu F, Soares KC, He J, Javed A, Cameron JL, Rezaee N, Pawlik TM, Wolfgang CL, **Weiss MJ**. Neoadjuvant therapy prior to surgical resection for previously explored pancreatic cancer patients is associated with improved survival. *HBSN* 2017;6(3):144-53. PMID: 28652997. Senior author.
 85. Aslam E, Pawlik TM, Reames B, Shishir KM, Poultsides GA, Bauer TW, Fields RC, **Weiss MJ**, Marques H, Aldrighetti LA. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis: A multi-institutional analysis. *J Clin Oncol* 2017; 35(4):277-277.
 86. Poruk KE, Blackford AL, **Weiss MJ**, Cameron JL, He J, Goggins MG, Rasheed Z, Wolfgang CL, Wood LD. Circulating tumor cells expressing markers of tumor initiation cells predict poor survival and cancer recurrence in patients with pancreatic ductal adenocarcinoma. *Clin Cancer Res* 2016. (Epub ahead of print). PMID: 27789528. Co-author.
 87. Attiyeh MA, Fernández-Del Castillo C, Al Efshat M, Eaton AA, Gönen M, Batts R, Pergolini I, Rezaee N, Lillemoe KD, Ferrone CR, Mino-Kenudson M, **Weiss MJ**, Cameron JL, Hruban RH, D'Angelica MI, DeMatteo RP, Kingham TP, Jarnagin WR, Wolfgang CL, Allen PJ. Development and Validation of a Multi-Institutional Preoperative Nomogram for Predicting Grade of Dysplasia in Intraductal Papillary Mucinous Neoplasms (IPMNs) of the Pancreas: A Report from The Pancreatic Surgery Consortium. *Ann Surg* 2016. (Epub ahead of print). PMID: 28079542. Co-author.
 88. Groot VP, Rezaee N, Wu W, Cameron JL, Fishman EK, Hruban RH, **Weiss MJ**, Zheng L, Wolfgang CL, He J. Patterns, timing, and predictors of recurrence following pancreatectomy for pancreatic ductal adenocarcinoma. *Ann Surg* 2017. PMID: 28338509. Co-author.
 89. Spolverato G, Bagante F, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti L, Maithal SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Pawlik TM. Comparative performances of the 7th and the 8th editions of the American Joint Committee on Cancer staging systems for intrahepatic cholangiocarcinoma. *J Surg Oncol* 2017. (Epub ahead of print). PMID: 28194791. Co-author.
 90. Sasaki K, Margonis GA, Andreatos N, Wilson A, **Weiss M**, Wolfgang C, Sergentanis TN, Polychronidis G, He J, Pawlik TM. Prognostic impact of margin status in liver resections for colorectal metastases after bevacizumab. *Br J Surg* 2017. (Epub ahead of print). PMID: 28266705. Co-author.
 91. Hata T, Dal Molin M, Hong SM, Tamura K, Suenaga M, Yu J, Sedogawa H, **Weiss MJ**, Wolfgang CL, Lennon AM, Hruban RH, Goggins MG. Predicting the grade of dysplasia of pancreatic cystic neoplasms using cyst fluid DNA methylation markers. *Clin Cancer Res* 2017. PMID: 28148542. Co-author.
 92. Luchini C, Robertson SA, Hong SM, Felsenstein M, Anders RA, Pea A, Nottegar A, Veronese N, He J, **Weiss MJ**, Capelli P, Scarpa A, Argani P, Kapur P, Wood LD. PBRM1 loss is a late event during the development of cholangiocarcinoma. *Histopathology* 2017. PMID: 28394406. Co-author.
 93. Griffin JF, Page AJ, Samaha GJ, Christopher A, Bhajjee F, Pezhohu MK, Peters NA, Hruban RH, He J, Makary MA, Lennon AM, Cameron JL, Wolfgang CL, **Weiss MJ**. Patients with a resected pancreatic mucinous cystic neoplasm have a better prognosis than patients with an intraductal papillary mucinous neoplasm: A large single institution series. *Pancreatology* 2017. (Epub ahead of print). PMID: 28416122. Senior author.

94. Bagante F, Spolverato G, **Weiss MJ**, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Assessment of the lymph node status in patients undergoing liver resection for intrahepatic cholangiocarcinoma: the new eighth edition AJCC staging system. *J Gastrointest Surg* 2017. (Epub ahead of print). PMID: 28424987. Co-author.
95. Dal Molin M, Blackford AL, Siddiqui A, Brant A, Cho C, Rezaee N, Yu J, He J, **Weiss M**, Hruban RH, Wolfgang C, Goggins M. Duodenal involvement is an independent prognostic factor for patients with surgically resected pancreatic ductal adenocarcinoma. *Ann Surg Oncol* 2017. (Epub ahead of print). PMID: 28439733. Co-author.
96. Bagante F, Spolverato G, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Impact of morphological status on long-term outcome among patients undergoing liver surgery for intrahepatic cholangiocarcinoma. *Ann Surg Oncol* 2017. (Epub ahead of print). PMID: 28466403. Co-author.
97. Spolverato G, Bagante F, Aldrighetti L, Poultides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, **Weiss M**, Pawlik TM. Management and outcomes of patients with recurrent neuroendocrine liver metastasis after curative surgery: An international multi-institutional analysis. *J Surg Oncol* 2017. (Epub ahead of print). PMID: 28513896. Co-author.
98. Aslakson RA, Isenberg SR, Crossnohere NL, Conca-Cheng AM, Yang T, **Weiss M**, Volandes AE, Bridges JFP, Roter DL. Utilising advance care planning videos to empower perioperative cancer patients and families: a study protocol of a randomized controlled trial. *BMJ Open* 2017;7(5):e016257. PMID: 28592584. Co-author.
99. Pea A, Yu J, Marchionni L, Luchini C, Noe M, Rezaee N, Bassi C, **Weiss M**, He J, Scarpa A, Wood L, Wolfgang CL. Comparative genomic analysis on well-differentiated pancreatic neuroendocrine tumors with small size (<3cm) reveals genetic alterations associated with distant metastases. *Pancreatolgy*. 2017. 17(3):S5-S6. 10.1016/j.pan.2017.05.017.
100. Sasaki K, Margonis GA, Maitani K, Andreatos N, Wang J, Pikoulis E, He J, Wolfgang CL, **Weiss M**, Pawlik TM. The Prognostic Impact of Determining Resection Margin Status for Multiple Colorectal Metastases According to the Margin of the Largest Lesion. *Ann Surg Oncol* 2017;24(9):2438-2446. PMID: 28695393. Co-author.
101. Burkhart RA, Javed AA, Ronnenkleiv-Kelly S, Wright BS, Poruk KE, Eckhauser FE, Makary MA, Cameron JL, Wolfgang CL, **Weiss MJ**. The use of negative pressure wound therapy to prevent post-operative surgical site infections following pancreaticoduodenectomy. *HPB* 2017. (Epub ahead of print). PMID: 28602643. Senior author.
102. Margonis GA, Buettner S, Andreatos N, Sasaki K, Pour MZ, Deshwar A, Wang J, Ghasebeh A, Damaskos C, Rezaee N, Pawlik TM, Wolfgang CL, Kamel IR, **Weiss MJ**. Preoperative Bevacizumab and volumetric recovery after resection of colorectal liver metastases. *J Surg Oncol* 2017. (Epub ahead of print). PMID: 28743167. Senior author.
103. Shrestha B, Sun Y, Faisal F, Kim V, Blair A, Herman JM, Narang A, Dholakia AS, Rosati L, Hacker-Prietz A, Chen L, Laheru DA, De Jesus-Acosta A, Le DT, Donehower R, Azad N, Diaz LA, Murphy A, Lee V, Fishman EK, Hruban RH, Liang T, Cameron JL, Makary M, **Weiss MJ**, Ahuja N, He J, Wolfgang CL, Huang CY, Zheng L. Long-term survival benefit of upfront chemotherapy in patients with newly diagnosed borderline resectable pancreatic cancer. *Cancer Med* 2017. (Epub ahead of print). PMID: 28639410. Co-author.
104. Epstein JD, Kozak G, Fong ZV, He J, Javed AA, Joneja U, Jiang W, Ferrone CR, Lillemoe KD, Cameron JL, **Weiss MJ**, Lavu H, Yeo CJ, Fernandez-Del Castillo C, Wolfgang CL, Winter JM. Microscopic lymphovascular invasion is an independent predictor of survival in resected pancreatic ductal adenocarcinoma. *J Surg Oncol* 2017. (Epub ahead of print). PMID: 28628722. Co-author.
105. Ejaz A, Reames BN, Maithel S, Poultides GA, Bauer TW, Fields RC, **Weiss M**, Marques HP, Aldrighetti L, Pawlik TM. The impact of extrahepatic disease among patients undergoing liver-directed therapy for neuroendocrine liver metastasis. *J Surg Oncol* 2017. (Epub ahead of print). PMID: 28650564. Co-author.
106. Margonis GA, Sasaki K, Andreatos N, Pour MZ, Shao N, Ghasebeh MA, Buettner S, Antoniou E, Wolfgang CL, **Weiss M**, Kamel IR, Pawlik TM. Increased kinetic growth rate during late phase liver

- regeneration impacts the risk of tumor recurrence after colorectal liver metastases resection. HPB 2017. (Epub ahead of print). PMID: 28602644. Co-author.
107. Sasaki K, Margonis GA, Andreatos N, Zhang XF, Buettner S, Wang J, Deshwar A, He J, Wolfgang CL, **Weiss M**, Pawlik TM. The prognostic utility of the “Tumor Burden Score” based on preoperative radiographic features of colorectal liver metastases. J Surg Oncol 2017. (Epub ahead of print). PMID: 28543544. Co-author.
 108. Yongfei H, Javed AA, Burkhart R, Peters NA, Hasanain A, **Weiss MJ**, Wolfgang CL, He J. Geographical variation and trends in outcomes of laparoscopic spleen-preserving distal pancreatectomy with or without splenic vessel preservation: A meta-analysis. Int J Surg 2017. (Epub ahead of print). PMID: 28735894. Co-author.
 109. Al Efshat MA, Attiyeh MF, Eaton AA, Gönen M, Prosser D, Lokshin AE, Castillo CF, Lillemoe KD, Ferrone CR, Pergolini I, Mino-Kenudson M, Rezaee N, Dal Molin M, **Weiss MJ**, Cameron JL, Hruban RH, D'Angelica MI, Kingham TP, DeMatteo RP, Jarnagin WR, Wolfgang CL, Allen PJ. Multi-institutional validation study of pancreatic cyst fluid protein analysis for prediction of high-risk intraductal papillary mucinous neoplasms of the pancreas. Ann Surg. 2018 Aug; 268(2): 340–347. PMID: 28700444. Co-author.
 110. Reames BN, Bagante F, Ejaz A, Spolverato G, Ruzzenente A, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Pawlik TM. Impact of adjuvant chemotherapy on survival in patients with intrahepatic cholangiocarcinoma: A multi-institutional analysis. HPB 2017. (Epub ahead of print). PMID: 28728891. Co-author.
 111. Margonis GA, Andreatos N, Pawlik TM, **Weiss MJ**. Consideration of KRAS Mutational Status May Enhance the Prognostic Impact of Indeterminate Extrahepatic Disease in the Lungs, as Identified by 18FDG-PET Scan, in Patients With Colorectal Liver Metastases. Ann Surg 2017. (Epub ahead of print). PMID: 28448388. Senior author.
 112. Buettner S, Galjart B, van Vugt JLA, Bagante F, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Margonis GA, **Weiss M**, Bauer TW, Shen F, Poultides GA, Marsh JW, IJzermans JNM, Groot Koerkamp B, Pawlik TM. Performance of prognostic scores and staging systems in predicting long-term survival outcomes after surgery for intrahepatic cholangiocarcinoma. J Surg Oncol 2017. (Epub ahead of print). PMID: 28703880. Co-author.
 113. Zhang XF, Beal EW, Chakedis J, Lv Y, Bagante F, Aldrighetti L, Poultides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, **Weiss M**, Pawlik TM. Early recurrence of neuroendocrine liver metastasis after curative hepatectomy: Risk factors, prognosis, and treatment. J Gastrointest Surg 2017. (Epub ahead of print). PMID: 28730354. Co-author.
 114. Margonis GA, Buettner S, Andreatos N, Sasaki K, IJzermans JNM, van Vugt JLA, Pawlik TM, Choti MA, Cameron JL, He J, Wolfgang CL, **Weiss MJ**. Anatomical resections improve disease-free survival in patients with KRAS-mutated colorectal liver metastases. Ann Surg 2017. Oct;266(4):641-649. doi: 10.1097/SLA.0000000000002367. PMID: 28657938. Senior author.
 115. Shindo K, Yu J, Suenaga M, Fesharakizadeh S, Cho C, Macgregor-Das A, Siddiqui A, Witmer PD, Tamura K, Song TJ, Navarro Almario JA, Brant A, Borges M, Ford M, Barkley T, He J, **Weiss MJ**, Wolfgang CL, Roberts NJ, Hruban RH, Klein AP, Goggins M. Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma. J Clin Oncol 2017. PMID: 28767289. Co-author.
 116. Zhang XF, Bagante F, Chakedis J, Moris D, Beal EW, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Perioperative and Long-Term Outcome for Intrahepatic Cholangiocarcinoma: Impact of Major Versus Minor Hepatectomy. J Gastrointest Surg 2017. (Epub ahead of print). PMID: 28744741. Co-author.
 117. Spolverato G, Bagante F, Aldrighetti L, Poultides G, Bauer TW, Field RC, Marques HP, **Weiss M**, Maithel SK, Pawlik TM. Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. J Gastrointest Surgery 2017. (Epub ahead of print). PMID: 28744737. Co-author.
 118. Aslakson RA, Schuster ALR, Lynch TJ, **Weiss MJ**, Gregg L, Miller J, Isenberg SR, Crossnohere NL, Conca-Cheng AM, Volandes AE, Smith TJ, Bridges JFP. Developing the Storyline for an Advance

- Care Planning Video for Surgery Patients: Patient-Centered Outcomes Research Engagement from Stakeholder Summit to State Fair. *J Palliat Med* 2017. (Epub ahead of print). PMID: 28817359. Co-author.
119. Zhang XF, Chakedis J, Bagante F, Beal EW, Lv Y, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Implications of Intrahepatic Cholangiocarcinoma Etiology on Recurrence and Prognosis after Curative-Intent Resection: a Multi-Institutional Study. *World J Surg* 2017. (Epub ahead of print). PMID: 28879598. Co-author.
 120. Bagante F, Spolverato G, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Defining Long-Term Survivors Following Resection of Intrahepatic Cholangiocarcinoma. *J Gastrointest Surg* 2017. (Epub ahead of print). PMID: 28840497. Co-author.
 121. Javed AA, Bleich K, Bagante F, He J, **Weiss MJ**, Wolfgang CL, Fishman EK. Pancreaticoduodenectomy with venous resection and reconstruction: current surgical techniques and associated postoperative imaging findings. *Abdom Radiol* 2017. (Epub ahead of print). PMID: 28828527. Co-author.
 122. Hua Y, Javed AA, Burkhart RA, Makary MA, **Weiss MJ**, Wolfgang CL, He J. Preoperative risk factors for conversion and learning curve of minimally invasive distal pancreatectomy. *Surgery* 2017. (Epub ahead of print). PMID: 28866314. Co-author.
 123. Buettner S, Ethun CG, Poultides G, Tran T, Idrees K, Isom CA, **Weiss M**, Fields RC, Krasnick B, Weber SM, Salem A, Martin RCG, Scoggins CR, Shen P, Mogal HD, Schmidt C, Beal E, Hatzaras I, Shenoy R, Koerkamp BG, Maithel SK, Pawlik TM. Surgical Site Infection Is Associated with Tumor Recurrence in Patients with Extrahepatic Biliary Malignancies. *J Gastrointest Surg* 2017;21(11):1813-1820. PMID: 28913712. Co-author.
 124. Burkhart RA, **Weiss MJ**. Surgical site infections following pancreaticoduodenectomy. *HPB* 2017. (Epub ahead of print). PMID: 28935454. Senior author.
 125. Zhang XF, Beal EW, **Weiss M**, Aldrighetti L, Poultides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Timing of disease occurrence and hepatic resection on long-term outcome of patients with neuroendocrine liver metastasis. *J Surg Oncol* 2017. (Epub ahead of print). PMID: 28940257. Co-author.
 126. Ejaz A, Reames BN, Maithel S, Poultides GA, Bauer TW, Fields RC, **Weiss MJ**, Marques HP, Aldrighetti L, Pawlik TM. Cytoreductive debulking surgery among patients with neuroendocrine liver metastasis: a multi-institutional analysis. *HPB* 2017. (Epub ahead of print). PMID: 28964630. Co-author.
 127. Margonis GA, Sergeantanis TN, Ntanasis-Stathopoulos I, Andreatos N, Tzanninis G, Sasaki K, Psaltopoulou T, Wang J, Buettner S, Papalois AE, He J, Wolfgang CL, Pawlik TM, **Weiss MJ**. Impact of surgical margin width on recurrence and overall survival following R0 hepatic resection of colorectal metastases: as systemic review and meta-analysis. *Ann Surg*. 2018 Jun;267(6):1047-1055. doi: 10.1097/SLA.0000000000002552. PMID: 29189379. Senior author.
 128. Blair AB, Burkhart RA, Griffin JF, Miller JA, **Weiss MJ**, Cameron JL, Wolfgang CL, He J. Long-term survival after resection of sarcomatoid carcinoma of the pancreas: an updated experience. *J Surg Res* 2017;219:238-243. PMID: 29078888. Co-author.
 129. Ryan JF, Groot VP, Rosati LM, Hacker-Prietz A, Narang AK, McNutt TR, Jackson JF, Le DT, Jaffee EM, Zheng L, Laheru DA, He J, Pawlik TM, **Weiss MJ**, Wolfgang CL, Herman JM. Stereotactic Body Radiation Therapy for Isolated Local Recurrence After Surgical Resection of Pancreatic Ductal Adenocarcinoma Appears to be Safe and Effective. *Ann Surg Oncol* 2017; (Epub ahead of print). PMID: 29063299. Co-author.
 130. Morales-Oyarvide V, Mino-Kenudson M, Ferrone CR, Warshaw AL, Lillemoe KD, Sahani DV, Pergolini I, Attiyeh MA, Al Efshat M, Rezaee N, Hruban RH, He J, **Weiss MJ**, Allen PJ, Wolfgang CL, Fernández-Del Castillo C. Intraductal Papillary Mucinous Neoplasm of the Pancreas in Young Patients: Tumor Biology, Clinical Features, and Survival Outcomes. *J Gastrointest Surg* 2017; (Epub ahead of print). PMID: 29047068. Co-author.
 131. Damaskos C, Garmpis N, Garmpi A, Nonni A, Sakellariou S, Margonis GA, Spartalis E, Schizas D, Andreatos N, Magkouti E, Grivas A, Kontzoglou K, **Weiss MJ**, Antoniou EA. Angiomyolipoma of

- the Liver: A Rare Benign Tumor Treated with a Laparoscopic Approach for the First Time. *In Vivo* 2017; 31(6):1169-1173. PMID: 29102941. Co-author.
132. Dogeas E, Chong CCN, **Weiss MJ**, Ahuja N, Choti MA. Can echogenic appearance of neuroendocrine liver metastases on intraoperative ultrasonography predict tumor biology and prognosis? *HPB* 2017; (Epub ahead of print). PMID: 29103839. Co-author.
 133. Javed AA, **Weiss MJ**, Wolfgang CL, John L. Cameron, MD: Overview of his career. *Ann Surg* 2017. (Epub ahead of print). PMID: 29112005. Co-author.
 134. Chen SY, Stem M, Cerullo M, Gearhart SL, Safar B, Fang SH, **Weiss MJ**, He J, Efron JE. The Effect of Frailty Index on Early Outcomes after Combined Colorectal and Liver Resections. *J Gastrointest Surg* 2017. (Epub ahead of print). PMID: 29209981. Co-author.
 135. Antoniou EA, Kairi E, Margonis GA, Andreatos N, Sasaki K, Damaskos C, Garmpis N, Samaha M, Argyra E, Polymeneas G, **Weiss MJ**, Pawlik TM, Voros D, Kouraklis G. Effect of Increased Intra-abdominal Pressure on Liver Histology and Hemodynamics: An Experimental Study. *In vivo* 2018; 21(1):85-91. PMID: 29275303. Co-author.
 136. Zhang XF, Beal EW, Merath K, Ethun CG, Salem A, Weber SM, Tran T, Poultides G, Son AY, Hatzaras I, Jin L, Fields RC, **Weiss M**, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM. Oncologic effects of preoperative biliary drainage in resectable hilar cholangiocarcinoma: Percutaneous biliary drainage has no adverse effects on survival. *J Surg Oncol* 2017. (Epub ahead of print). PMID: 29205351. Co-author.
 137. Chianchiano P, Pezhohu MK, Kim A, Luchini C, Cameron A, **Weiss MJ**, He J, Voltaggio L, Oshima K, Anders RA, Wood LD. Distinction of Intrahepatic Metastasis from Multicentric Carcinogenesis in Multifocal Hepatocellular Carcinoma Using Molecular Alterations. *Hum Pathol* 2017. (Epub ahead of print). PMID: 29180252. Co-author.
 138. Zhang XF, Beal EW, Bagante F, Chakedis J, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Pawlik TM. Early versus late recurrence of intrahepatic cholangiocarcinoma after resection with curative intent. *Br J Surg* 2017. (Epub ahead of print). PMID: 29193010. Co-author.
 139. Rosati LM, Kummerlowe MN, Poling J, Hacker-Prietz A, Narang AK, Shin EJ, Le DT, Fishman EK, Hruban RH, Yang SC, **Weiss MJ**, Herman JM. A rare case of esophageal metastasis from pancreatic ductal adenocarcinoma: a case report and literature review. *Oncotarget* 2017; 8(59):100942-100950. PMID: 29246032. Co-author.
 140. Javed AA, **Weiss MJ**, John L. Cameron: A Historical Perspective. *Ann Surg* 2017. (Epub ahead of print). PMID: 29189382. Senior author.
 141. Antoniou EA, Kairi E, Margonis GA, Andreatos N, Sasaki K, Damaskos C, Garmpis N, Samaha M, Argyra E, Polymeneas G, **Weiss MJ**, Pawlik TM, Voros D, Kouraklis G. Preoperative Risk Score and Prediction of Long-Term Outcomes after Hepatectomy for Intrahepatic Cholangiocarcinoma. *J Am Coll Surg* 2017. PMID: 29274841. Co-author.
 142. Blair AB, Groot VP, Gemenetis G, Wei J, Cameron JL, **Weiss MJ**, Goggins M, Wolfgang CL, Yu J, He J. BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Adenocarcinoma. *J Am Coll Surg*. 2018. (Epub ahead of print). PMID: 29309945. Co-author.
 143. Antoniou E, Andreatos N, Margonis GA, Papalois A, Wang J, Damaskos C, Garmpis N, Buettner S, Deshwar A, Pappas V, **Weiss MJ**, Pawlik TM, Pikoulis E. Systemic treatment and primary tumor location in patients with metastatic colorectal cancer. *J Buon* 2017;22(6):1447-1456. PMID: 29332337. Co-author.
 144. He J, Blair AB, Groot VP, Javed AA, Burkhart RA, Gemenetis G, Hruban RH, Waters KM, Poling J, Zheng L, Laheru D, Herman JM, Makary MA, **Weiss MJ**, Cameron JL, Wolfgang CL. Is a Pathological Complete Response Following Neoadjuvant Chemoradiation Associated With Prolonged Survival in Patients With Pancreatic Cancer? *Ann Surg*. 2018 Jul; 268(1): 1–8. PMID: 29334562. Co-author.
 145. Zhang XF, Bagante F, Chen Q, Beal EW, Lv Y, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Pawlik TM. Perioperative and long-term outcome of intrahepatic cholangiocarcinoma involving the hepatic hilus after curative-intent resection: comparison with peripheral intrahepatic cholangiocarcinoma and hilar cholangiocarcinoma. *Surgery* 2018. (Epub ahead of print). PMID: 29398035. Co-author.

146. Blair AB, Rosati LM, Rezaee N, Gemenetzi G, Zheng L, Hruban RH, Cameron JL, **Weiss MJ**, Wolfgang CL, Herman JM, He J. Postoperative complications after resection of borderline resectable and locally advanced pancreatic cancer: The impact of neoadjuvant chemotherapy with conventional radiation or stereotactic body radiation therapy. *Surgery* 2018. (Epub ahead of print). PMID: 29395234. Co-author.
147. Reames BN, Gage MM, Ejaz A, Blair AB, Fishman EK, Cameron JL, **Weiss MJ**, Wolfgang CL, He J. Pancreaticoduodenectomy and Superior Mesenteric Vein Resection Without Reconstruction for Locally Advanced Pancreatic Cancer. *J Gastrointest Surg.* 2018. (Epub ahead of print). PMID: 29363015. Co-author.
148. Bagante F, Merath K, Squires MH, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. The Limitations of Standard Clinicopathologic Features to Accurately Risk-Stratify Prognosis after Resection of Intrahepatic Cholangiocarcinoma. *J Gastrointest Surg.* 2018. (Epub ahead of print). PMID: 29352440. Co-author.
149. Gage MM, Reames BN, Ejaz A, Sham J, Fishman EK, **Weiss MJ**, Wolfgang CL, He J. Pancreaticoduodenectomy with en bloc vein resection for locally advanced pancreatic cancer: a case series without venous reconstruction. *Chin Clin Oncol.* 2018 Feb;7(1):7. doi: 10.21037/cco.2018.01.01. PMID: 29486566. Co-author.
150. Fan CJ, Hung-Lun C, **Weiss MJ**, He J, Wolfgang CL, Cameron CL, Cameron JL, Pawlik TM, Makary MA. Minimally invasive versus open surgery in the Medicare population: a comparison of post-operative and economic outcomes. *Surgical Endoscopy* 2018. (Epub ahead of print). PMID: 29484556. Co-author.
151. Felsenstein M, Noë M, Masica DL, Hosoda W, Chianchiano P, Fischer CG, Lionheart G, Brosens LAA, Pea A, Yu J, Gemenetzi G, Groot VP, Makary MA, He J, **Weiss MJ**, Cameron JL, Wolfgang CL, Hruban RH, Roberts NJ, Karchin R, Goggins MG, Wood LD. IPMNs with co-occurring invasive cancers: neighbours but not always relatives. *Gut* 2018. (Epub ahead of print). PMID: 29530477. Co-author.
152. Groot VP, Thakker SS, Gemenetzi G, Noë M, Javed AA, Burkhart RA, Noveiry BB, Cameron JL, **Weiss MJ**, VandenBussche CJ, Fishman EK, Hruban RH, Wolfgang CL, Lennon AM, He J. Lessons learned from 29 lymphoepithelial cysts of the pancreas: institutional experience and review of the literature. *HPB(Oxford)* 2018. (Epub ahead of print). PMID: 29530477. Co-author.
153. Deshwar A, Margonis GA, Andreatos N, Wang J, Buettner, Wagner D, Sasaki K, Beer A, Loes IM, Pikoulis E, Damaskos C, Garmpis G, Lonning PE, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, **Weiss MJ**. Double KRAS and BRAF mutations in surgically treated colorectal cancer liver metastases: An international, multi-institutional case series. *Anticancer Res.* 2018 May;38(5):2891-2895. PMID: 29715113. Senior author.
154. Margonis GA, Buettner S, Andreatos, Kim Y, Wagner D, Sasaki K, Beer A, Schwarz C, Loes IM, Smolle M, Kamphues C, He J, Pawlik TM, Kaczirek K, Poultsides G, Lonning PE, Cameron JL, Burkhart RA, Gerger A, Aucejo FN, Kreis ME, Wolfgang CL, **Weiss MJ**. Association of BRAF Mutations With Survival and Recurrence in Surgically Treated Patients With Metastatic Colorectal Liver Cancer. *JAMA Surgery* 2018 Jul 18;153(7):e180996. doi: 10.1001/jamasurg.2018.0996. PMID: 29799910. Senior Author.
155. Margonis G, Sasaki K, Gholami S, Kim Y, Andreatos A, Rezaee N, Deshwar A, Buttner S, Allen P, Kingham T, Pawlik TM, He J, Cameron JL, Jarnagin W, Wolfgang CL, D'Angelica M, **Weiss MJ**. Genetic And Morphological Evaluation (GAME) score for patients with colorectal liver metastases. *Br J Surg.* 2018 Aug;105(9):1210-1220. doi: 10.1002/bjs.10838. PMID: 29691844. Senior author.
156. Wang J, Margonis GA, Amini N, Andreatos N, Yuan C, Damaskos C, Antoniou E, Garmpis N, Buettner S, Barbon C, Deshwar A, He J, Burkhart R, Pawlik TM, Wolfgang CL, **Weiss MJ**. The prognostic value of varying definitions of positive resection margin in patients with colorectal cancer liver metastases. *J Gastrointest Surg.* 2018 Aug;22(8):1350-1357. doi: 10.1007/s11605-018-3748-3. PMID: 29633114. Senior author.
157. Barbon C, Margonis GA, Andreatos N, Rezaee N, Sasaki K, Buettner S, Damaskos C, Pawlik TM, He J, Wolfgang CL, **Weiss MJ**. Colorectal liver metastases: does the future of precision medicine lie in genetic testing? *JOGS* 2018. (Epub ahead of print). PMID: 29644557. Senior author.

158. Groot VP, Gemenetzis G, Blair AB, Rivero-Soto RJ, Yu J, Javed AA, Burkhart RA, Rinkes IHMB, Molenaar IQ, Cameron JL, **Weiss MJ**, Wolfgang CL, He J. Defining and Predicting Early Recurrence in 957 Patients With Resected Pancreatic Ductal Adenocarcinoma. *Ann Surg*. 2018(Epub ahead of print). PMID: 31082915. Co-author.
159. Gemenetzis G, Groot VP, Blair AB, Laheru DA, Zheng L, Narang AK, Fishman EK, Hruban RH, Yu J, Burkhart RA, Cameron JL, **Weiss MJ**, Wolfgang CL, He J. Survival in Locally Advanced Pancreatic Cancer After Neoadjuvant Therapy and Surgical Resection. *Ann Surg*. 2018. (Epub ahead of print). PMID: 29596120. Co-author.
160. Partelli S, Javed AA, Andreasi V, He J, Muffatti F, **Weiss MJ**, Sessa F, La Rosa S, Doglioni C, Zamboni G, Wolfgang CL, Falconi M. The number of positive nodes accurately predicts recurrence after pancreaticoduodenectomy for nonfunctioning neuroendocrine neoplasms. *Eur J Surg Oncol*. 2018. (Epub ahead of print). PMID: 29610023. Co-author.
161. Sasaki K, Margonis GA, Andreatos N, Chen Q, Barbon C, Bagante F, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Endo I, Aucejo FN, Pawlik TM. Serum tumor markers enhance the predictive power of the AJCC and LCSGJ staging systems in resectable intrahepatic cholangiocarcinoma. *HPB (Oxford)*. 2018. (Epub ahead of print). PMID: 29887261. Co-author.
162. Buettner S, Spolverato G, Kimbrough CW, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, **Weiss M**, Bauer TW, Shen F, Poultsides GA, Marsh JW, IJzermans JNM, Koerkamp BG, Pawlik TM. The impact of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio among patients with intrahepatic cholangiocarcinoma. *Surgery*. 2018. (Epub ahead of print). PMID: 29903509. Co-author.
163. Noë M, Rezaee N, Asrani K, Skaro M, Groot VP, Wu PH, Olson MT, Hong SM, Kim SJ, **Weiss MJ**, Wolfgang CL, Makary MA, He J, Cameron JL, Wirtz D, Roberts NJ, Offerhaus GJA, Brosens LAA, Wood LD, Hruban RH. Immunolabeling of Cleared Human Pancreata Provides Insights into Three-dimensional Pancreatic Anatomy and Pathology. *Am J Pathol*. 2018 Jul; 188(7): 1530–1535. PMID: 29684363. Co-author.
164. Deshwar AB, Sugar E, Torto D, De Jesus-Acosta A, **Weiss MJ**, Wolfgang CL, Le D, He J, Burkhart R, Zheng L, Laheru D, Yarchoan M. Diagnostic intervals and pancreatic ductal adenocarcinoma (PDAC) resectability: a single-center retrospective analysis. *Ann Pancreat Cancer*. 2018;38(5):2891-2895. PMID: 29683142. Co-author.
165. Zhang XF, Chakedis J, Bagante F, Chen Q, Beal EW, Lv Y, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Pawlik TM. Trends in use of lymphadenectomy in surgery with curative intent for intrahepatic cholangiocarcinoma. *Br J Surg*. 2018 Jun;105(7):857-866. PMID: 29656380. Co-author.
166. Tamura K, Yu J, Hata T, Suenaga M, Shindo K, Abe T, MacGregor-Das A, Borges M, Wolfgang CL, **Weiss MJ**, He J, Canto MI, Petersen GM, Gallinger S, Syngal S, Brand RE, Rustgi A, Olson SH, Stoffel E, Cote ML, Zogopoulos G, Potash JB, Goes FS, McCombie RW, Zandi PP, Pirooznia M, Kramer M, Parla J, Eshleman JR, Roberts NJ, Hruban RH, Klein AP, Goggins M. Mutations in the pancreatic secretory enzymes *CPAI* and *CPBI* are associated with pancreatic cancer. *Proc Natl Acad Sci U S A*. 2018. PMID: 29669919. Co-author.
167. Canto MI, Almario JA, Schulick RD, Yeo CJ, Klein A, Blackford A, Shin EJ, Sanyal A, Yenokyan G, Lennon AM, Kamel IR, Fishman EK, Wolfgang C, **Weiss M**, Hruban RH, Goggins M. Risk of Neoplastic Progression in Individuals at High Risk for Pancreatic Cancer Undergoing Long-term Surveillance. *Gastroenterology*. 2018 (Epub ahead of print). PMID: 29803839. Co-author.
168. Groot VP, Gemenetzis G, Blair AB, Ding D, Javed AA, Burkhart RA, Yu J, Borel Rinkes IH, Molenaar IQ, Cameron JL, Fishman EK, Hruban RH, **Weiss MJ**, Wolfgang CL, He J. Implications of the Pattern of Disease Recurrence on Survival Following Pancreatectomy for Pancreatic Ductal Adenocarcinoma. *Ann Surg Oncol*. 2018. (Epub ahead of print). PMID: 29948425. Co-author.
169. Akgül Ö, Bagante F, Olsen G, Cloyd JM, **Weiss M**, Merath K, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Pawlik TM. Preoperative prognostic nutritional index predicts survival of patients with intrahepatic cholangiocarcinoma after curative resection. *J Surg Oncol*. 2018. (Epub ahead of print). PMID: 30084163. Co-author.

170. Sham JG, Ejaz A, Gage MM, Bagante F, Reames BN, Maithel S, Poultides GA, Bauer TW, Fields RC, **Weiss MJ**, Marques HP, Aldrighetti L, Pawlik TM, He J. The Impact of Extent of Liver Resection Among Patients with Neuroendocrine Liver Metastasis: an International Multi-institutional Study. *J Gastrointest Surg*. 2018. (Epub ahead of print). PMID: 29980977. Co-author.
171. Klompmaker S, Boggi U, Hackert T, Salvia R, **Weiss M**, Yamaue H, Zeh HJ, Besselink MG. Distal Pancreatectomy with Celiac Axis Resection (DP-CAR) for Pancreatic Cancer. How I do It. *J Gastrointest Surg*. 2018. (Epub ahead of print). PMID: 30105677. Co-author.
172. Gemenetzi G, Groot VP, Yu J, Ding D, Teinor JA, Javed AA, Wood LD, Burkhart RA, Cameron JL, Makary MA, **Weiss MJ**, He J, Wolfgang CL. Circulating Tumor Cells Dynamics in Pancreatic Adenocarcinoma Correlate With Disease Status: Results of the Prospective CLUSTER Study. *Ann Surg*. 2018;268(3):408-420. PMID: 30080739. Co-author.
173. Poruk KE, Griffin J, Makary MA, He J, Cameron JL, **Weiss MJ**, Wood LD, Goggins M, Wolfgang CL. Blood Type as a Predictor of High-Grade Dysplasia and Associated Malignancy in Patients with Intraductal Papillary Mucinous Neoplasms. *J Gastrointest Surg*. 2018. (Epub ahead of print). PMID: 30187322. Co-author.
174. Hutchings D, Waters KM, **Weiss MJ**, Wolfgang CL, Makary MA, He J, Cameron JL, Wood LD, Hruban RH. Cancerization of the Pancreatic Ducts: Demonstration of a Common and Under-recognized Process Using Immunolabeling of Paired Duct Lesions and Invasive Pancreatic Ductal Adenocarcinoma for p53 and Smad4 Expression. *Am J Surg Pathol*. 2018. (Epub ahead of print). PMID: 30212393. Co-author.
175. Javed AA, Wright MJ, Siddique A, Blair AB, Ding D, Burkhart RA, Makary M, Cameron JL, Narang A, Herman J, Zheng L, Laheru D, **Weiss MJ**, Wolfgang C, He J. Outcome of Patients with Borderline Resectable Pancreatic Cancer in the Contemporary Era of Neoadjuvant Chemotherapy. *J Gastrointest Surg*. 2018. PMID: 30242644. Co-author.
176. Xiang JX, Zhang XF, **Weiss M**, Aldrighetti L, Poultides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Early recurrence of well-differentiated (G1) neuroendocrine liver metastasis after curative-intent surgery: Risk factors and outcome. *J Surg Oncol*. 2018. (Epub ahead of print). PMID: 30261105. Co-author.
177. Margonis GA, Buettner S, Andreatos N, Wagner D, Sasaki K, Galjart B, Kamphues C, Pawlik TM, Poultides G, Kaczirek K, Lønning PE, Verhoef C, Kreis ME, Wolfgang CL, **Weiss MJ**. The prognosis of colorectal cancer liver metastases associated with inflammatory bowel disease: An exploratory analysis. *J Surg Oncol*. 2018 Dec;118(7):1074-1080. doi: 10.1002/jso.25251. PMID: 30261094. Senior author.
178. Javed AA, Teinor J, Wright M, Ding D, Burkhart RA, Hundt J, Cameron JL, Makary MA, He J, Eckhauser FE, Wolfgang CL, **Weiss MJ**. Negative Pressure Wound Therapy for Surgical-site Infections: A Randomized Trial. *Ann Surg*. 2019 Jun;269(6):1034-1040. doi: 10.1097/SLA.0000000000003056. PMID: 31082899. Senior author.
179. Pea A, Yu J, Marchionni L, Noe M, Luchini C, Pulvirenti A, de Wilde RF, Brosens LA, Rezaee N, Javed A, Gobbo S, Regi P, Salvia R, Bassi C, He J, **Weiss MJ**, Cameron JL, Offerhaus GJA, Hruban RH, Lawlor RT, Scarpa A, Heaphy CM, Wood LD, Wolfgang CL. Genetic Analysis of Small Well-differentiated Pancreatic Neuroendocrine Tumors Identifies Subgroups With Differing Risks of Liver Metastases. *Ann Surg*. 2018. (Epub ahead of print). PMID: 30339629. Co-author.
180. Cheng Z, Rosati LM, Chen L, Mian OY, Cao Y, Villafania M, Nakatsugawa M, Moore JA, Robertson SP, Jackson J, Hacker-Prietz A, He J, Wolfgang CL, **Weiss MJ**, Herman JM, Narang AK, McNutt TR. Improving prediction of surgical resectability over current staging guidelines in patients with pancreatic cancer who receive stereotactic body radiation therapy. *Adv Radiat Oncol*. 2018. Oct-Dec; 3(4): 601–610. PMID: 30370361. Co-author.
181. Gemenetzi G, Groot VP, Blair AB, Ding D, Thakker SS, Fishman EK, Cameron JL, Makary MA, **Weiss MJ**, Wolfgang CL, He J. Incidence and risk factors for abdominal occult metastatic disease in patients with pancreatic adenocarcinoma. *J Surg Oncol*. 2018. (Epub ahead of print). PMID: 30380143. Co-author.
182. Hu LS, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Pawlik TM. Impact of microvascular invasion on clinical outcomes after curative-intent resection for intrahepatic cholangiocarcinoma. *J Surg Oncol*. 2018. (Epub ahead of print). PMID: 30466151. Co-author.

183. Masuda T, Margonis GA, Andreatos N, Wang J, Warner S, Mirza MB, Angelou A, Damaskos C, Garmpis N, Sasaki K, He J, Imai K, Yamashita YI, Wolfgang CL, Baba H, **Weiss MJ**. Combined Hepatic Resection and Radio-frequency Ablation for Patients with Colorectal Cancer Liver Metastasis: A Viable Option for Patients with a Large Number of Tumors. *Anticancer Res*. 2018. (Epub ahead of print). PMID: 30396957. Senior author.
184. Kuboki Y, Fischer CG, Beleva Guthrie V, Huang W, Yu J, Chianchiano P, Hosoda W, Zhang H, Zheng L, Shao X, Thompson ED, Waters K, Poling J, He J, **Weiss MJ**, Wolfgang CL, Goggins MG, Hruban RH, Roberts NJ, Karchin R, Wood LD. Single-cell sequencing defines genetic heterogeneity in pancreatic cancer precursor lesions. *J Pathol*. 2018. (Epub ahead of print). PMID: 30430578. Co-author.
185. Luchini C, Pea A, Yu J, He J, Salvia R, Riva G, **Weiss MJ**, Bassi C, Cameron JL, Hruban RH, Goggins M, Wolfgang CL, Scarpa A, Wood LD, Lawlor RT. Pancreatic cancer arising in the remnant pancreas is not always a relapse of the preceding primary. *Mod Pathol*. 2018. (Epub ahead of print). PMID: 30467323. Co-author.
186. Oshi M, Margonis GA, Sawada Y, Andreatos N, He J, Kumamoto T, Morioka D, Wolfgang CL, Tanaka K, **Weiss MJ**, Endo I. Higher Tumor Burden Neutralizes Negative Margin Status in Hepatectomy for Colorectal Cancer Liver Metastasis. *Ann Surg Oncol*. 2018. (Epub ahead of print). PMID: 30483976. Co-author.
187. McVey JC, Sasaki K, Margonis GA, Nowacki AS, Firl DJ, He J, Berber E, Wolfgang C, Miller CC, **Weiss M**, Aucejo FN. The impact of resection margin on overall survival for patients with colon cancer liver metastasis varied according to the primary cancer location. *HPB* 2018. (Epub ahead of print). PMID: 30501989. Co-author.
188. Klompmaker S, Peters NA, van Hilst J, Bassi C, Boggi U, Busch OR, Niesen W, Van Gulik TM, Javed AA, Kleeff J, Kawai M, Lesurtel M, Lombardo C, Moser AJ, Okada KI, Popescu I, Prasad R, Salvia R, Sauvanet A, Stureson C, **Weiss MJ**, Zeh HJ, Zureikat AH, Yamaue H, Wolfgang CL, Hogg ME, Besselink MG. Outcomes and Risk Score for Distal Pancreatectomy with Celiac Axis Resection (DP-CAR): An International Multicenter Analysis. *Ann Surg Oncol*. 2019. (Epub ahead of print). PMID: 30610560. Co-author.
189. Del Chiaro M, Beckman R, Atee Z, Orsini N, Rezaee N, Manos L, Valente R, Yuan C, Ding D, Margonis GA, Yin L, Cameron JL, Makary MA, Burkhart RA, **Weiss MJ**, He J, Arnelo U, Yu J, Wolfgang CL. Main Duct Dilatation Is the Best Predictor of High-grade Dysplasia or Invasion in Intraductal Papillary Mucinous Neoplasms of the Pancreas. *Ann Surg*. 2019. (Epub ahead of print). PMID: 30672797. Co-author.
190. Li L, Knutsdottir H, Hui K, **Weiss MJ**, He J, Philosophe B, Cameron AM, Wolfgang CL, Pawlik TM, Ghiaur G, Ewald AJ, Mezey E, Bader JS, Selaru FM. Human primary liver cancer organoids reveal intratumor and interpatient drug response heterogeneity. *JCI Insight*. 2019. (Epub ahead of print). PMID: 30674722. Co-author.
191. Holland MM, Bhutiani N, Kruse EJ, **Weiss MJ**, Christein JD, White RR, Huang KW, Martin RC 2nd. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. *HPB (Oxford)*. 2019. (Epub ahead of print). PMID: 30737097. Co-author.
192. Kaczmarski K, Wang P, Gilmore R, Overton HN, Euhus DM, Jacobs LK, Habibi M, Camp M, **Weiss MJ**, Makary MA. Surgeon Re-Excision Rates after Breast-Conserving Surgery: A Measure of Low-Value Care. *J Am Coll Surg*. 2019. (Epub ahead of print). PMID: 30703538. Co-author.
193. Groot VP, Blair AB, Gemenetis G, Ding D, Burkhart RA, van Oosten AF, Molenaar IQ, Cameron JL, **Weiss MJ**, Yang SC, Wolfgang CL, He J. Isolated pulmonary recurrence after resection of pancreatic cancer: the effect of patient factors and treatment modalities on survival. *HPB (Oxford)*. 2019. (Epub ahead of print). PMID: 30777697. Co-author.
194. Ruzzenente A, Bagante F, Ratti F, Beal EW, Alexandrescu S, Merath K, Makris EA, Poultsides GA, Margonis GA, **Weiss MJ**, Popescu I, Aldrighetti L, Guglielmi A, Pawlik TM. Response to preoperative chemotherapy: impact of change in total burden score and mutational tumor status on prognosis of patients undergoing resection for colorectal liver metastases. *HPB (Oxford)*. 2019. (Epub ahead of print). PMID: 30792047. Co-author.
195. Merath K, Mehta R, Hyer JM, Bagante F, Sahara K, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, **Weiss MJ**, Bauer TW, Shen F, Poultsides GA, Soubrane O, Martel G,

- Koerkamp BG, Guglielmi A, Itaru E, Ejaz A, Pawlik TM. Impact of body mass index on tumor recurrence among patients undergoing curative-intent resection of intrahepatic cholangiocarcinoma- a multi-institutional international analysis. *Eur J Surg Oncol*. 2019. (Epub ahead of print). PMID: 30871884. Co-author.
196. Javed AA, Wright MJ, Hasanain A, Chang K, Burkhart RA, Hruban RH, Thompson E, Fishman EK, Cameron JL, He J, Wolfgang CL, **Weiss MJ**. Pancreatic Nerve Sheath Tumors: a Single Institutional Series and Systematic Review of the Literature. *J Gastrointest Surg*. 2019. (Epub ahead of print). PMID: 30941687. Senior Author.
 197. Buettner S, Ten Cate DWG, Bagante F, Alexandrescu S, Marques HP, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Margonis GA, **Weiss M**, Bauer TW, Shen F, Poultides GA, Marsh JW, IJzermans JNM, Pawlik TM, Koerkamp BG. Survival after Resection of Multiple Tumor Foci of Intrahepatic Cholangiocarcinoma. *J Gastrointest Surg*. 2019. (Epub ahead of print). PMID: 30887301. Co-author.
 198. Aslakson RA, Isenberg SR, Crossnohere NL, Conca-Cheng AM, Moore M, Bhamidipati A, Mora S, Miller J, Singh S, Swoboda SM, Pawlik TM, **Weiss M**, Volandes A, Smith TJ, Bridges JFP, Roter DL. Integrating Advance Care Planning Videos into Surgical Oncologic Care: A Randomized Clinical Trial. *J Palliat Med*. 2019. (Epub ahead of print). PMID: 30964385. Co-author.
 199. Zhang XF, Lv Y, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Pawlik TM. Should Utilization of Lymphadenectomy Vary According to Morphologic Subtype of Intrahepatic Cholangiocarcinoma? *Ann Surg Oncol*. 2019. (Epub ahead of print). PMID: 30927194. Co-author.
 200. Groot VP, Blair AB, Gemenetzis G, Ding D, Burkhart RA, Yu J, Borel Rinkes IHM, Molenaar IQ, Cameron JL, **Weiss MJ**, Wolfgang CL, He J. Recurrence after neoadjuvant therapy and resection of borderline resectable and locally advanced pancreatic cancer. *Eur J Surg Oncol*. 2019. (Epub ahead of print). PMID: 31023560. Co-author.
 201. Merath K, Chen Q, Bagante F, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, **Weiss MJ**, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Cloyd JM, Pawlik TM. A Multi-Institutional International Analysis of Textbook Outcomes Among Patients Undergoing Curative-Intent Resection of Intrahepatic Cholangiocarcinoma. *AMA Surg*. 2019. (Epub ahead of print). PMID: 31017645. Co-author.
 202. Wach MM, Ayabe RI, Ruff SM, D'Angelica M, Dineen SP, Grubbs EG, Shibata D, Shirley L, **Weiss MJ**, Davis JL, Hernandez JM. A Survey of the Complex General Surgical Oncology Fellowship Programs Regarding Applicant Selection and Rank. *Ann Surg Oncol*. 2019. PMID: 31011903. Co-author.
 203. Hu LS, Zhang XF, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Pawlik TM. Recurrence Patterns and Timing Courses Following Curative-Intent Resection for Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol*. 2019. (Epub ahead of print). PMID: 31020501. Co-author.
 204. Canto MI, Kerdsirichairat T, Yeo CJ, Hruban RH, Shin EJ, Almario JA, Blackford A, Ford M, Klein AP, Javed AA, Lennon AM, Zaheer A, Kamel IR, Fishman EK, Burkhart R, He J, Makary M, **Weiss MJ**, Schulick RD, Goggins MG, Wolfgang CL. Surgical Outcomes After Pancreatic Resection of Screening-Detected Lesions in Individuals at High Risk for Developing Pancreatic Cancer. *J Gastrointest Surg*. 2019. (Epub ahead of print). PMID: 31197699. Co-author.
 205. Hutchings D, Jiang Z, Skaro M, **Weiss MJ**, Wolfgang CL, Makary MA, He J, Cameron JL, Zheng L, Klimstra DS, Brand RE, Singhi AD, Goggins M, Klein AP, Roberts NJ, Hruban RH. Histomorphology of pancreatic cancer in patients with inherited ATM serine/threonine kinase pathogenic variants. *Mod Pathol*. 2019. (Epub ahead of print). PMID: 31285527. Co-author.
 206. Pulvirenti A, Pea A, Rezaee N, Gasparini C, Malleo G, **Weiss MJ**, Cameron JL, Wolfgang CL, He J, Salvia R. Perioperative outcomes and long-term quality of life after total pancreatectomy. *Br J Surg*. 2019 (Epub ahead of print). PMID: 31282569. Co-author.
 207. Wright MJ, Overton HN, Teinor JA, Ding D, Burkhart RA, Cameron JL, He J, Wolfgang CL, **Weiss MJ**, Javed AA. Disparities in the Use of Chemotherapy in Patients with Resected Pancreatic Ductal Adenocarcinoma. *J Gastrointest Surg*. 2019. (Epub ahead of print). PMID: 31270718. Co-author.

208. Margonis GA, Buettner S, Andreatos N, Wagner D, Sasaki K, Barbon C, Beer A, Kamphues C, Løes IM, He J, Pawlik TM, Kaczirek K, Poultides G, Lønning PE, Cameron JL, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, **Weiss MJ**. Prognostic Factors Change Over Time After Hepatectomy for Colorectal Liver Metastases: A Multi-institutional, International Analysis of 1099 Patients. *Ann Surg*. 2019. PMID: 31082912. Senior author.
209. Reames BN, Blair AB, Krell RW, Groot VP, Gemenetzi G, Padussis JC, Thayer SP, Falconi M, Wolfgang CL, **Weiss MJ**, Are C, He J. Management of Locally Advanced Pancreatic Cancer: Results of an International Survey of Current Practice. *Ann Surg*. 2019. (Epub ahead of print). PMID: 31449138. Co-author.
210. Margonis GA, Amini N, Buettner S, Kim Y, Wang J, Andreatos N, Wagner D, Sasaki K, Beer A, Kamphues C, Morioka D, Løes IM, Imai K, He J, Pawlik TM, Kaczirek K, Poultides G, Lønning PE, Burkhart R, Endo I, Baba H, Mischinger HJ, Aucejo FN, Kreis ME, Wolfgang CL, **Weiss MJ**. The Prognostic Impact of Primary Tumor Site Differs According to the KRAS Mutational Status: A Study By the International Genetic Consortium for Colorectal Liver Metastasis. *Ann Surg*. 2019 Aug 5. (Epub ahead of print). PMID: 31389831. Senior author.
211. Springer S, Masica DL, Dal Molin M, Douville C, Thoburn CJ, Afsari B, Li L, Cohen JD, Thompson E, Allen PJ, Klimstra DS, Schattner MA, Schmidt CM, Yip-Schneider M, Simpson RE, Fernandez-Del Castillo C, Mino-Kenudson M, Brugge W, Brand RE, Singhi AD, Scarpa A, Lawlor R, Salvia R, Zamboni G, Hong SM, Hwang DW, Jang JY, Kwon W, Swan N, Geoghegan J, Falconi M, Crippa S, Doglioni C, Paulino J, Schulick RD, Edil BH, Park W, Yachida S, Hijioka S, van Hooft J, He J, **Weiss MJ**, Burkhart R, Makary M, Canto MI, Goggins MG, Ptak J, Dobbryn L, Schaefer J, Sillman N, Popoli M, Klein AP, Tomasetti C, Karchin R, Papadopoulos N, Kinzler KW, Vogelstein B, Wolfgang CL, Hruban RH, Lennon AM. A multimodality test to guide the management of patients with a pancreatic cyst. *Sci Transl Med*. 2019. PMID: 31316009. Co-author.
212. Pulvirenti A, Javed AA, Landoni L, Jamieson NB, Chou JF, Miotto M, He J, Gonen M, Pea A, Tang LH, Nessi C, Cingarlini S, D'Angelica MI, Gill AJ, Kingham TP, Scarpa A, **Weiss MJ**, Balachandran VP, Samra JS, Cameron JL, Jarnagin WR, Salvia R, Wolfgang CL, Allen PJ, Bassi C. Multi-institutional Development and External Validation of a Nomogram to Predict Recurrence After Curative Resection of Pancreatic Neuroendocrine Tumors. *Ann Surg*. 2019 Sep 24. PMID: 31567347. Co-author.
213. Sahara K, Merath K, Tsilimigras DI, Hyer JM, Guglielmi A, Aldrighetti L, **Weiss M**, Fields RC, Poultides GA, Maithel SK, Endo I, Pawlik TM, Other Members Of The U S Neuroendocrine Tumor Study Group. Conditional disease-free survival after curative-intent liver resection for neuroendocrine liver metastasis. *J Surg Oncol*. 2019 Sep 24. (Epub ahead of print). PMID: 31550406. Co-author.
214. Holland, MM, Bhutiani N, Kruse EJ, **Weiss, MJ**, Christein, JD, White RR, Huang KW, Martin II RCG. A prospective, multi-institution assessment of irreversible electroporation for treatment of locally advanced pancreatic adenocarcinoma: initial outcomes from the AHPBA pancreatic registry. *HPB* 2019, 21, 1024–1031. PMID: 30777697. Co-author.
215. He S, Ding D, Wright MJ, Groshek L, Javed AA, Ka-Wan Chu K, Burkhart RA, Cameron JL, **Weiss MJ**, Wolfgang CL, He J. The impact of high body mass index on patients undergoing robotic pancreatectomy: A propensity matched analysis. *Surgery*. 2019 Dec 11. (Epub ahead of print). PMID: 31837833. Co-author.
216. Pulvirenti A, Margonis GA, Morales-Oyarvide V, McIntyre CA, Lawrence SA, Goldman DA, Gonen M, **Weiss MJ**, Ferrone CR, He J, Brennan MF, Cameron JL, Lillemoe KD, Kingham TP, Balachandran V, Qadan M, D'Angelica MI, Jarnagin WR, Wolfgang CL, Castillo CF, Allen PJ. Intraductal Papillary Mucinous Neoplasms: Have IAP Consensus Guidelines Changed our Approach?: Results from a Multi-institutional Study. *Surg*. 2019 Dec 5. (Epub ahead of print) PMID: 31804389. Co-author.
217. Sahara K, Tsilimigras DI, Maithel SK, Abbott DE, Poultides GA, Hatzaras I, Fields RC, **Weiss M**, Scoggins C, Isom CA, Idrees K, Shen P, Endo I, Pawlik TM; and the US Extrahepatic Biliary Malignancy Consortium. Survival benefit of lymphadenectomy for gallbladder cancer based on the therapeutic index: An analysis of the US extrahepatic biliary malignancy consortium. *J Surg Oncol*. 2020 Jan 6. (Epub ahead of print). PMID: 31907941. Co-author.
218. Hu LS, Zhang XF, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW,

- Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Lv Y, Pawlik TM. Redefining Conditional Overall and Disease-Free Survival After Curative Resection for Intrahepatic Cholangiocarcinoma: A Multi-institutional, International Study of 1221 patients. *J Gastrointest Surg*. 2019 Dec. (Epub ahead of print). PMID: 31823320. Co-author.
219. Zhang XF, Xue F, Dong DH, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Lv Y, Pawlik TM. Number and Station of Lymph Node Metastasis After Curative-intent Resection of Intrahepatic Cholangiocarcinoma Impact Prognosis. *Ann Surg*. 2020 Jan 14. (Epub ahead of print). PMID: 31972643. Co-author.
 220. Crippa S, Cirocchi R, **Weiss MJ**, Partelli S, Reni M, Wolfgang CL, Hackert T, Falconi M. A systematic review of surgical resection of liver-only synchronous metastases from pancreatic cancer in the era of multiagent chemotherapy. *Updates Surg*. 2020 Jan. (Epub ahead of print). PMID: 31997233. Co-author.
 221. Ding D, Javed AA, Yuan C, Wright MJ, Javed ZN, Teinor JA, Ye IC, Burkhart RA, Cameron JL, **Weiss MJ**, Wolfgang CL, He J. Role of Lymph Node Resection and Histopathological Evaluation in Accurate Staging of Nonfunctional Pancreatic Neuroendocrine Tumors: How Many Are Enough? *J Gastrointest Surg*. 2020 Feb 5. PMID: 32026333. Co-author.
 222. Blair AB, Yin LD, Pu N, Yu J, Groot VP, Rozich NS, Javed AA, Zheng L, Cameron JL, Burkhart RA, **Weiss MJ**, Wolfgang CL, He J. Recurrence in Patients Achieving Pathological Complete Response After Neoadjuvant Treatment for Advanced Pancreatic Cancer. *Ann Surg*. 2019. (Epub ahead of print). PMID: 32304375. Co-author.
 223. Tsilimigras DI, Moris D, Mehta R, Paredes AZ, Sahara K, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Endo I, Pawlik TM. The systemic immune-inflammation index predicts prognosis in intrahepatic cholangiocarcinoma: an international multi-institutional analysis. *HPB (Oxford)*. 2020 Apr 4. (Epub ahead of print). PMID: 32265108. Co-author.
 224. Moro A, Mehta R, Sahara K, Tsilimigras DI, Paredes AZ, Farooq A, Hyer JM, Endo I, Shen F, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Soubrane O, Koerkamp BG, Sasaki K, Pawlik TM. The Impact of Preoperative CA19-9 and CEA on Outcomes of Patients with Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol*. 2020 Mar 20. (Epub ahead of print). PMID: 32198569. Co-author.
 225. Rao AD, Shin EJ, Meyer J, Thompson EL, Fu W, Hu C, Fishman EK, **Weiss M**, Wolfgang C, Burkhart R, He J, Kerdsirichairat T, Herman JM, Ding K, Narang A. Evaluation of a novel absorbable radiopaque hydrogel in patients undergoing image-guided radiotherapy (IGRT) for borderline resectable and locally advanced pancreatic adenocarcinoma. *Pract Radiat Oncol*. 2020 Mar 6. (epub ahead of print). PMID: 32151732. Co-author.
 226. Sham JG, Guo S, Ding D, Shao Z, Wright M, Jing W, Yin LD, Zhang Y, Gage MM, Zhou Y, Javed A, Burkhart RA, Zhou X, **Weiss MJ**, He T, Li G, Cameron JL, Hu X, Wolfgang CL, Jin G, He J. Radical antegrade modular pancreatosplenectomy versus standard distal pancreatosplenectomy for pancreatic cancer, a dual-institutional analysis. *Chin Clin Oncol*. 2020 Jun. Epub ahead of print. PMID: 32576018. Co-author.
 227. Buettner S, Braat AJAT, Margonis GA, Brown DB, Taylor KB, Borgmann AJ, Kappadath SC, Mahvash A, IJzermans JNM, **Weiss MJ**, Lamarca A, Bell JK, Valle JW, Hagendoorn J, Koerkamp BG, Sze DY, Lam MGEH. Yttrium-90 Radioembolization in Intrahepatic Cholangiocarcinoma: A Multicenter Retrospective Analysis. *J Vasc Interv Radiol*. 2020 Jul. PMID: 32473757. Co-author.
 228. Kolarich AR, Solomon AJ, **Weiss MJ**, Philosophie B, Weiss CR, Hong K. Risk Factors for Complications Requiring Interventional Radiological Treatment After Hepatectomy. *J Gastrointest Surg*. 2020 May 27. Epub ahead of print. PMID: 32462493. Co-author.
 229. Warner-Cohen J, Polokowski AR, Pinto D, Zavatsky T, Beyer K, Saif MW, **Weiss MJ**. Increasing access to multidisciplinary care in pancreatic cancer. *Psychooncology*. 2020 Jul 20. doi: 10.1002/pon.5493. Epub ahead of print. PMID: 32691486. Senior Author.
 230. Tsilimigras DI, Sahara K, Paredes AZ, Moro A, Mehta R, Moris D, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano

- C, Shen F, Soubrane O, Koerkamp BG, Endo I, Pawlik TM. Predicting Lymph Node Metastasis in Intrahepatic Cholangiocarcinoma. *J Gastrointest Surg*. 2020 Jul 14. Epub ahead of print. PMID: 32757124. Co-author.
231. Cohen JD, Javed AA, Thoburn C, Wong F, Tie J, Gibbs P, Schmidt CM, Yip-Schneider MT, Allen PJ, Schattner M, Brand RE, Singhi AD, Petersen GM, Hong SM, Kim SC, Falconi M, Doglioni C, **Weiss MJ**, Ahuja N, He J, Makary MA, Maitra A, Hanash SM, Dal Molin M, Wang Y, Li L, Ptak J, Dobbyn L, Schaefer J, Silliman N, Popoli M, Goggins MG, Hruban RH, Wolfgang CL, Klein AP, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Lennon AM. Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers. *Proc Natl Acad Sci U S A*. 2017 Sep 19;114(38):10202-10207. doi: 10.1073/pnas.1704961114. Epub 2017 Sep 5. PMID: 28874546. Co-author.
 232. Janssen QP, Buettner S, Suker M, Beumer BR, Addeo P, Bachellier P, Bahary N, Bekaii-Saab T, Bali MA, Besselink MG, Boone BA, Chau I, Clarke S, Dillhoff M, El-Rayes BF, Frakes JM, Grose D, Hosein PJ, Jamieson NB, Javed AA, Khan K, Kim KP, Kim SC, Kim SS, Ko AH, Lacy J, Margonis GA, McCarter MD, McKay CJ, Mellon EA, Moorcraft SY, Okada KI, Paniccia A, Parikh PJ, Peters NA, Rabl H, Samra J, Tinchon C, van Tienhoven G, van Veldhuisen E, Wang-Gillam A, **Weiss MJ**, Wilmink JW, Yamaue H, Homs MYV, van Eijck CHJ, Katz MHG, Groot Koerkamp B. Neoadjuvant FOLFIRINOX in Patients With Borderline Resectable Pancreatic Cancer: A Systematic Review and Patient-Level Meta-Analysis. *J Natl Cancer Inst*. 2019 Aug 1;111(8):782-794. doi: 10.1093/jnci/djz073. PMID: 31086963. Co-author.
 233. Amini N, Rezaee N, Habib, J, Blair A, Beckman R, Manos L, Cameron J, Hruban R, **Weiss M**, Fishman E, Zaheer A, Lafaro K, Burkhart R, Lennon A, Burns W, He J, Wolfgang C. Minimal main pancreatic duct dilatation in small branch duct intraductal papillary mucinous neoplasms associated with high-grade dysplasia or invasive carcinoma. September 2020 HPB. DOI: 10.1016/j.hpb.2020.08.004. PMID: 32912834. Co-author.
 234. Kota S, Tsilimigras D, Kikuchi Y, Ethun C, Maithel S, Abbott D, Poultides G, Hatzaras I, Fields R, **Weiss M**, Scoggins C, Isom C, Idrees K, Shen P, Yabushita Y, Matsuyama R, Endo I, Pawlik T. Defining and Predicting Early Recurrence after Resection for Gallbladder Cancer. September 2020. *Annals of Surgical Oncology*. DOI: 10.1245/s10434-020-09108-y. PMID: 32892270. Co-author.
 235. Yu J, Gemenetis G, Kinny-Köster B, Habib J, Groot V, Teinor J, Yin L, Pu N, Hasanain A, van Oosten F, Javed A, **Weiss M**, Burkhart R, Burns W, Goggins M, He J, Wolfgang C. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. *Cancer letters*. 493. September 2020. 10.1016/j.canlet.2020.08.043. PMID: 32896616. Co-author.
 236. Pflüger M, Felsenstein M, Schmock R, Wood L, Hruban R, Fujikura K, Rozich N, van Oosten F, **Weiss M**, Burns W, Yu J, Cameron J, Pratschke J, Wolfgang C, He J, Burkhart, R. Gastric cancer following pancreaticoduodenectomy: Experience from a high-volume center and review of existing literature. *Surgery Open Science*. August 2020. PMID: 32954246. Co-author.
 237. Schwarz C, Fitschek F, Primavesi F, Stättner S, Margonis G, **Weiss M**, Stavrou GA, Oldhafer KJ, Kornprat P, Wundsam H, Fischer I, Längle F, Függer R, Hauer A, Klug R, Kieler M, Prager G, Schindl M, Stremitzer S, Kaczirek K. Metachronous hepatic resection for liver only pancreatic metastases. *Surgical Oncology*. 35. 10.1016/j.suronc.2020.08.005. PMID: 32889249. Co-author.
 238. Groot VP, Mosier S, Javed AA, Teinor JA, Gemenetis G, Ding D, Haley LM, Yu J, Burkhart RA, Hasanain A, Debeljak M, Kamiyama H, Narang A, Laheru DA, Zheng L, Lin MT, Gocke CD, Fishman EK, Hruban RH, Goggins MG, Molenaar IQ, Cameron JL, **Weiss MJ**, Velculescu VE, He J, Wolfgang CL, Eshleman JR. Circulating Tumor DNA as a Clinical Test in Resected Pancreatic Cancer. *Clin Cancer Res*. 2019 Aug 15;25(16):4973-4984. doi: 10.1158/1078-0432.CCR-19-0197. Epub 2019 May 29. PMID: 31142500. Co-author.
 239. **Weiss MJ**, Carnevale F, Rochweg B, Oczkowski S, Dhanani S. Ensuring nondiscrimination in pandemic prioritization decisions. *CMAJ*. 2020 Apr 14;192(15):E421. doi: 10.1503/cmaj.75254. PMID: 32392511; PMCID: PMC7162440. First author.
 240. Gupta A, Kawamoto S, Javed A, **Weiss M**, Wolfgang C, He J, Fishman E, Vadvala H. Perioperative CT angiography assessment of locally advanced distal pancreatic carcinoma to evaluate feasibility of the modified Appleby procedure. *European Journal of Radiology*. 131. 109248. 10.1016/j.ejrad.2020.109248. PMID: 32919264. Co-author.

241. Tsilimigras D, Sahara K, Wu L, Moris D, Bagante F, Guglielmi A, Aldrighetti LA, **Weiss M**, Bauer T, Alexandrescu S, Poultides G, Maithel S, Marques H, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp B, Moro A, Pawlik T. Very Early Recurrence After Liver Resection for Intrahepatic Cholangiocarcinoma: Considering Alternative Treatment Approaches. *JAMA Surgery*. 10.1001/jamasurg.2020.1973. PMID: 32639548. Co-author.
242. Blair A, Jurcak N, Javed A, Teinor J, Groot V, Rozich N, Cameron J, **Weiss M**, He J, Wolfgang C, Zheng L, Burkhart R. Nonselective β -adrenergic blockade impacts pancreatic cancer tumor biology, decreases perineural invasion and improves patient survival. *Annals of Pancreatic Cancer*. 3. 8-8. 10.21037/apc-19-45.
243. Tsilimigras D, Hyer J, Paredes A, Diaz A, Moris D, Guglielmi A, Aldrighetti LA, **Weiss M**, Bauer T, Alexandrescu S, Poultides G, Maithel S, Marques H, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp B, Endo I, Pawlik T. A Novel Classification of Intrahepatic Cholangiocarcinoma Phenotypes Using Machine Learning Techniques: An International Multi-Institutional Analysis. *Annals of Surgical Oncology*. 10.1245/s10434-020-08696-z. PMID: 32495285. Co-author.
244. Zheng L, Ding D, Edil BH, Judkin C, Durham JN, Thomas DL, Bever KM, Mo G, Solt S, Hoare J, Bhattacharya R, Zhu Q, Osipov A, Onners BL, Purtell K, Cai H, Parkinson RM, Hacker-Prietz A, Herman J, Le DT, Azad NS, De Jesus-Acosta A, Blair AB, Kim VM, Soares KC, Manos L, Cameron JL, Makary MA, **Weiss MJ**, Schulick RD, He J, Wolfgang CL, Thompson ED, Anders RA, Sugar EA, Jaffee EM, Laheru DA. Vaccine-Induced Intratumoral Lymphoid Aggregates Correlate with Survival Following Treatment with a Neoadjuvant and Adjuvant Vaccine in Patients with Resectable Pancreatic Adenocarcinoma. *Clin Cancer Res*. 2020 Dec 4;clincanres.2974.2020. doi: 10.1158/1078-0432.CCR-20-2974. Epub ahead of print. PMID: 33277370. Co-author.
245. Amini N, Habib JR, Blair A, Rezaee N, Kinney-Köster B, Cameron JL, Hruban RH, **Weiss MJ**, Fishman EK, Lafaro KJ, Zaheer A, Manos L, Burns WR, Burkhart R, He J, Yu J, Wolfgang CL. Invasive and Non-Invasive Progression after Resection of Non-Invasive Intraductal Papillary Mucinous Neoplasms. *Ann Surg*. 2020 Nov 12. doi: 10.1097/SLA.0000000000004488. Epub ahead of print. PMID: 33201121. Co-author.
246. Crippa S, Pergolini I, Javed AA, Honselmann KC, **Weiss MJ**, Di Salvo F, Burkhart R, Zamboni G, Belfiori G, Ferrone CR, Rubini C, Yu J, Gasparini G, Qadan M, He J, Lillemoe KD, Castillo CF, Wolfgang CL, Falconi M. Implications of Perineural Invasion on Disease Recurrence and Survival After Pancreatectomy for Pancreatic Head Ductal Adenocarcinoma. *Ann Surg*. 2020 Oct 19. doi: 10.1097/SLA.0000000000004464. Epub ahead of print. PMID: 33086324. Co-author.
247. Schmocker RK, Wright MJ, Ding D, Beckman MJ, Javed AA, Cameron JL, Lafaro KJ, Burns WR, **Weiss MJ**, He J, Wolfgang CL, Burkhart RA. An Aggressive Approach to Locally Confined Pancreatic Cancer: Defining Surgical and Oncologic Outcomes Unique to Pancreatectomy with Celiac Axis Resection (DP-CAR). *Ann Surg Oncol*. 2020 Oct 13. doi: 10.1245/s10434-020-09201-2. Epub ahead of print. PMID: 33051739. Co-author.
248. Tsilimigras DI, Hyer JM, Paredes AZ, Moris D, Sahara K, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Endo I, Sasaki K, Aucejo F, Zhang XF, Pawlik TM. Tumor Burden Dictates Prognosis Among Patients Undergoing Resection of Intrahepatic Cholangiocarcinoma: A Tool to Guide Post-Resection Adjuvant Chemotherapy? *Ann Surg Oncol*. 2020 Dec 1. doi: 10.1245/s10434-020-09393-7. Epub ahead of print. PMID: 33259043. Co-author.
249. Ho WJ, Sharma G, Zhu Q, Stein-O'Brien G, Durham J, Anders R, Popovic A, Mo G, Kamel I, **Weiss M**, Jaffee E, Fertig EJ, Yarchoan M. Integrated immunological analysis of a successful conversion of locally advanced hepatocellular carcinoma to resectability with neoadjuvant therapy. *J Immunother Cancer*. 2020 Nov;8(2):e000932. doi: 10.1136/jitc-2020-000932. PMID: 33219090. Co-author.
250. Xiang JX, Zhang XF, **Weiss M**, Aldrighetti L, Poultides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Multi-institutional Development and External Validation of a Nomogram Predicting Recurrence After Curative Liver Resection for Neuroendocrine Liver Metastasis. *Ann Surg Oncol*. 2020 Oct;27(10):3717-3726. doi: 10.1245/s10434-020-08620-5. Epub 2020 May 20. PMID: 32436187. Co-author.
251. Tsilimigras DI, Sahara K, Moris D, Mehta R, Paredes AZ, Ratti F, Marques HP, Soubrane O, Lam V, Poultides GA, Popescu I, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, **Weiss M**, Bauer TW, Maithel SK, Pulitano C, Shen F, Koerkamp BG, Endo I, Pawlik TM.

- Assessing Textbook Outcomes Following Liver Surgery for Primary Liver Cancer Over a 12-Year Time Period at Major Hepatobiliary Centers. *Ann Surg Oncol*. 2020 Sep;27(9):3318-3327. doi: 10.1245/s10434-020-08548-w. Epub 2020 May 9. PMID: 32388742. Co-author.
252. Tsilimigras DI, Mehta R, Moris D, Sahara K, Bagante F, Paredes AZ, Moro A, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Endo I, Pawlik TM. A Machine-Based Approach to Preoperatively Identify Patients with the Most and Least Benefit Associated with Resection for Intrahepatic Cholangiocarcinoma: An International Multi-institutional Analysis of 1146 Patients. *Ann Surg Oncol*. 2020 Apr;27(4):1110-1119. doi: 10.1245/s10434-019-08067-3. Epub 2019 Nov 14. PMID: 31728792. Co-author.
 253. Spolverato G, Bagante F, Aldrighetti L, Poultides G, Bauer TW, Fields RC, Marques HP, **Weiss M**, Maithel SK, Pawlik TM. Correction to: Neuroendocrine Liver Metastasis: Prognostic Implications of Primary Tumor Site on Patients Undergoing Curative Intent Liver Surgery. *J Gastrointest Surg*. 2020 Jan;24(1):231. doi: 10.1007/s11605-019-04371-1. Erratum for: *J Gastrointest Surg*. 2017 Dec;21(12):2039-2047. PMID: 31529199. Co-author.
 254. Bagante F, Spolverato G, Merath K, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Endo I, Pawlik TM. Intrahepatic cholangiocarcinoma tumor burden: A classification and regression tree model to define prognostic groups after resection. *Surgery*. 2019 Dec;166(6):983-990. doi: 10.1016/j.surg.2019.06.005. Epub 2019 Jul 17. PMID: 31326191. Co-author.
 255. Sahara K, Tsilimigras DI, Merath K, Bagante F, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Matsuyama R, Endo I, Pawlik TM. Therapeutic Index Associated with Lymphadenectomy Among Patients with Intrahepatic Cholangiocarcinoma: Which Patients Benefit the Most from Nodal Evaluation? *Ann Surg Oncol*. 2019 Sep;26(9):2959-2968. doi: 10.1245/s10434-019-07483-9. Epub 2019 May 31. PMID: 31152272. Co-author.
 256. Moris D, Machairas N, Tsilimigras DI, Prodromidou A, Ejaz A, **Weiss M**, Hasemaki N, Felekouras E, Pawlik TM. Systematic Review of Surgical and Percutaneous Irreversible Electroporation in the Treatment of Locally Advanced Pancreatic Cancer. *Ann Surg Oncol*. 2019 Jun;26(6):1657-1668. doi: 10.1245/s10434-019-07261-7. Epub 2019 Mar 6. PMID: 30843163. Co-author.
 257. Xiang JX, Zhang XF, Beal EW, **Weiss M**, Aldrighetti L, Poultides GA, Bauer TW, Fields RC, Maithel SK, Marques HP, Pawlik TM. Hepatic Resection for Non-functional Neuroendocrine Liver Metastasis: Does the Presence of Unresected Primary Tumor or Extrahepatic Metastatic Disease Matter? *Ann Surg Oncol*. 2018 Dec;25(13):3928-3935. doi: 10.1245/s10434-018-6751-8. Epub 2018 Sep 14. PMID: 30218247. Co-author.
 258. Bagante F, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Guglielmi A, Itaru E, Pawlik TM. Long-term outcomes of patients with intrahepatic growth sub-type of intrahepatic cholangiocarcinoma. *HPB (Oxford)*. 2018 Dec;20(12):1189-1197. doi: 10.1016/j.hpb.2018.05.017. Epub 2018 Jun 27. PMID: 29958811. Co-author.
 259. Zhang XF, Squires MH 3rd, Bagante F, Ethun CG, Salem A, Weber SM, Tran T, Poultides G, Son AY, Hatzaras I, Jin L, Fields RC, **Weiss M**, Scoggins C, Martin RCG, Isom CA, Idrees K, Mogal HD, Shen P, Maithel SK, Schmidt CR, Pawlik TM. The Impact of Intraoperative Re-Resection of a Positive Bile Duct Margin on Clinical Outcomes for Hilar Cholangiocarcinoma. *Ann Surg Oncol*. 2018 May;25(5):1140-1149. doi: 10.1245/s10434-018-6382-0. Epub 2018 Feb 22. PMID: 29470820. Co-author.
 260. Bagante F, Spolverato G, **Weiss M**, Alexandrescu S, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Groot Koerkamp B, Guglielmi A, Itaru E, Ruzzenente A, Pawlik TM. Surgical Management of Intrahepatic Cholangiocarcinoma in Patients with Cirrhosis: Impact of Lymphadenectomy on Peri-Operative Outcomes. *World J Surg*. 2018 Aug; 42(8):2551-2560. doi: 10.1007/s00268-017-4453-1. PMID: 29299649. Co-author.
 261. Kamphues C, Andreatos N, Kruppa J, Buettner S, Wang J, Sasaki K, Wagner D, Morioka D, Fitschek F, Løes IM, Imai K, Sun J, Poultides G, Kaczirek K, Lønning PE, Endo I, Baba H, Kornprat P, Aucejo FN, Wolfgang CL, Kreis ME, **Weiss MJ**, Margonis GA. The optimal cut-off values for tumor size, number of lesions, and CEA levels in patients with surgically treated colorectal cancer liver

- metastases: An international, multi-institutional study. *J Surg Oncol*. 2021 Jan 5. doi: 10.1002/jso.26361. Epub ahead of print. PMID: 33400818. Co-author.
262. Xiang JX, Zhang XF, Weber SM, Poultides G, Fields RC, Hatzaras I, **Weiss M**, Scoggins C, Idrees K, Shen P, Maithel SK, Pawlik TM. Identification of patients who may benefit the most from adjuvant chemotherapy following resection of incidental gallbladder carcinoma. *J Surg Oncol*. 2021 Jan 26. doi: 10.1002/jso.26389. Epub ahead of print. PMID: 33497466. Co-author.
 263. Yu J, Gemenetis G, Kinny-Köster B, Habib JR, Groot VP, Teinor J, Yin L, Pu N, Hasanain A, van Oosten F, Javed AA, **Weiss MJ**, Burkhart RA, Burns WR, Goggins M, He J, Wolfgang CL. Pancreatic circulating tumor cell detection by targeted single-cell next-generation sequencing. *Cancer Lett*. 2020 Nov 28;493:245-253. doi: 10.1016/j.canlet.2020.08.043. Epub 2020 Sep 5. PMID: 32896616. Co-author.
 264. Blair AB, Krell RW, Ejaz A, Groot VP, Gemenetis G, Padussis JC, Falconi M, Wolfgang CL, **Weiss MJ**, Are C, He J, Reames BN. Proclivity to Explore Locally Advanced Pancreas Cancer Is Not Associated with Surgeon Volume. *J Gastrointest Surg*. 2021 May 23. doi: 10.1007/s11605-021-05034-w. Epub ahead of print. PMID: 34027578. Co-author.
 265. Javed AA, Mirza MB, Sham JG, Ali DM, Jones GF 4th, Sanjeevi S, Burkhart RA, Cameron JL, **Weiss MJ**, Wolfgang CL, He J. Postoperative biliary anastomotic strictures after pancreaticoduodenectomy. *HPB (Oxford)*. 2021 Apr 27:S1365-182X(21)00108-8. doi: 10.1016/j.hpb.2021.04.008. Epub ahead of print. PMID: 34016543. Co-author.
 266. Li L, Halpert G, Lerner MG, Hu H, Dimitrion P, **Weiss MJ**, He J, Philosophie B, Burkhart R, Burns WR, Wesson RN, MacGregor Cameron A, Wolfgang CL, Georgiades C, Kawamoto S, Azad NS, Yarchoan M, Meltzer SJ, Oshima K, Ensign LM, Bader JS, Selaru FM. Protein synthesis inhibitor omacetaxine is effective against hepatocellular carcinoma. *JCI Insight*. 2021 Jun 22;6(12):138197. doi: 10.1172/jci.insight.138197. PMID: 34003798. Co-author.
 267. Javed AA, **Weiss MJ**, Ding D, Javed ZN, Faghih M, Rozich NS, Fishman EK, Burns WR, Cameron JL, Weiss MJ, He J, Singh VK, Wolfgang CL, Burkhart RA. Autoimmune Pancreatitis: A Critical Analysis of the Surgical Experience in an Era of Modern Diagnostics. *Pancreas*. 2021 Apr 1;50(4):556-563. PMID: 33939669. Co-author.
 268. Ruff SM, Standring O, Wu G, Levy A, Anantha S, Newman E, Karpeh MS Jr, Nealon W, Deutsch GB, **Weiss MJ**, DePeralta DK. ASO Visual Abstract: Ampullary Neuroendocrine Tumors-Insight into a Rare Histology. *Ann Surg Oncol*. 2021 Jul 15. doi: 10.1245/s10434-021-10416-0. Epub ahead of print. PMID: 34263373. Co-author.
 269. Gemenetis G, Blair AB, Nagai M, Groot VP, Ding D, Javed AA, Burkhart RA, Fishman EK, Hruban RH, **Weiss MJ**, Cameron JL, Narang A, Laheru D, Lafaro K, Herman JM, Zheng L, Burns WR 3rd, Wolfgang CL, He J. Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. *Ann Surg Oncol*. 2021 Aug 27. doi: 10.1245/s10434-021-10663-1. Epub ahead of print. PMID: 34448965. Co-author.
 270. Ruff SM, Standring O, Wu G, Levy A, Anantha S, Newman E, Karpeh MS Jr, Nealon W, Deutsch GB, **Weiss MJ**, DePeralta DK. Ampullary Neuroendocrine Tumors: Insight into a Rare Histology. *Ann Surg Oncol*. 2021 Jul 26. doi: 10.1245/s10434-021-10371-w. Epub ahead of print. PMID: 34312800. Co-author.
 271. Amini N, Andreatos N, Margonis GA, Buettner S, Wang J, Galjart B, Wagner D, Sasaki K, Angelou A, Sun J, Kamphues C, Beer A, Morioka D, Løes IM, Antoniou E, Imai K, Pikoulis E, He J, Kaczirek K, Poultides G, Verhoef C, Lønning PE, Endo I, Baba H, Kornprat P, NAucejo F, Kreis ME, Christopher WL, **Weiss MJ**, Safar B, Burkhart RA. Mutant KRAS as a prognostic biomarker after hepatectomy for rectal cancer metastases: Does the primary disease site matter? *J Hepatobiliary Pancreat Sci*. 2021 Oct 6. doi: 10.1002/jhbp.1054. Epub ahead of print. PMID: 34614304. Co-author.
 272. Blair AB, Beckman RM, Habib JR, Griffin JF, Lafaro K, Burkhart RA, Burns W, **Weiss MJ**, Cameron JL, Wolfgang CL, He J. Should non-invasive diffuse main-duct intraductal papillary mucinous neoplasms be treated with total pancreatectomy? *HPB (Oxford)*. 2021 Sep 23:S1365-182X(21)01633-6. doi: 10.1016/j.hpb.2021.09.013. Epub ahead of print. PMID: 34610896. Co-author.
 273. Demyan L, Wu G, Moumin D, Blumenthaler AN, Deutsch GB, Nealon W, Herman JM, **Weiss MJ**, Burns EA, DePeralta DK. Advance care planning in patients undergoing surgery to resect pancreatic adenocarcinoma: Underlying tension between balancing hope and realism. *Surgery*. 2021 Sep

- 22:S0039-6060(21)00848-5. doi: 10.1016/j.surg.2021.08.033. Epub ahead of print. PMID: 34563351. Co-author.
274. Gemenetzi G, Blair AB, Nagai M, Groot VP, Ding D, Javed AA, Burkhart RA, Fishman EK, Hruban RH, **Weiss MJ**, Cameron JL, Narang A, Laheru D, Lafaro K, Herman JM, Zheng L, Burns WR 3rd, Wolfgang CL, He J. ASO Visual Abstract: Anatomic Criteria Determine Resectability in Locally Advanced Pancreatic Cancer. *Ann Surg Oncol*. 2021 Sep 13. doi: 10.1245/s10434-021-10739-y. Epub ahead of print. PMID: 34515887. Co-author.
 275. Woeste MR, Wilson KD, Kruse EJ, **Weiss MJ**, Christein JD, White RR, Martin RCG 2nd. Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival. *Front Oncol*. 2022 Jan 13;11:817220. doi: 10.3389/fonc.2021.817220. PMID: 35096621. Co-author.
 276. Javed AA, Pulvirenti A, Razi S, Zheng J, Michelakos T, Sekigami Y, Thompson E, Klimstra DS, Deshpande V, Singhi AD, **Weiss MJ**, Wolfgang CL, Cameron JL, Wei AC, Zureikat AH, Ferrone CR, He J; Pancreatic Neuroendocrine Disease Alliance (PANDA). Grading Pancreatic Neuroendocrine Tumors via Endoscopic Ultrasound-guided Fine Needle Aspiration: A Multi-Institutional Study. *Ann Surg*. 2022 Jan 25. doi: 10.1097/SLA.0000000000005390. Epub ahead of print. PMID: 35081574. Co-author.
 277. Hill CS, Rosati LM, Hu C, Fu W, Sehgal S, Hacker-Prietz A, Wolfgang CL, **Weiss MJ**, Burkhart RA, Hruban RH, De Jesus-Acosta A, Le DT, Zheng L, Laheru DA, He J, Narang AK, Herman JM. Neoadjuvant Stereotactic Body Radiotherapy After Upfront Chemotherapy Improves Pathologic Outcomes Compared With Chemotherapy Alone for Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma Without Increasing Perioperative Toxicity. *Ann Surg Oncol*. 2022 Feb 7. doi: 10.1245/s10434-021-11202-8. Epub ahead of print. PMID: 35129721. Co-author.
 278. Wang Z, Moresco P, Yan R, Li J, Gao Y, Biasci D, Yao M, Pearson J, Hechtman JF, Janowitz T, Zaidi RM, **Weiss MJ**, Fearon DT. Carcinomas assemble a filamentous CXCL12-keratin-19 coating that suppresses T cell-mediated immune attack. *Proc Natl Acad Sci U S A*. 2022 Jan 25;119(4):e2119463119. doi: 10.1073/pnas.2119463119. PMID: 35046049; PMCID: PMC8794816. Co-author.
 279. Javed AA, Ding D, Baig E, Wright MJ, Teinor JA, Mansoor D, Thompson E, Hruban RH, Narang A, Burns WR 3rd, Burkhart RA, Lafaro K, **Weiss MJ**, Cameron JL, Wolfgang CL, He J. Accurate Nodal Staging in Pancreatic Cancer in the Era of Neoadjuvant Therapy. *World J Surg*. 2022 Mar;46(3):667-677. doi: 10.1007/s00268-021-06410-y. Epub 2022 Jan 7. PMID: 34994834. Co-author.
 280. Bertsimas D, Margonis GA, Huang Y, Andreatos N, Wiberg H, Ma Y, McIntyre C, Pulvirenti A, Wagner D, van Dam JL, Gavazzi F, Buettner S, Imai K, Stasinis G, He J, Kamphues C, Beyer K, Seeliger H, **Weiss MJ**, Kreis M, Cameron JL, Wei AC, Kornprat P, Baba H, Koerkamp BG, Zerbi A, D'Angelica M, Wolfgang CL. Toward an Optimized Staging System for Pancreatic Ductal Adenocarcinoma: A Clinically Interpretable, Artificial Intelligence-Based Model. *JCO Clin Cancer Inform*. 2021 Dec;5:1220-1231. doi: 10.1200/CCI.21.00001. PMID: 34936469. Co-author.
 281. Margonis GA, Pulvirenti A, Morales-Oyarvide V, Buettner S, Andreatos N, Kamphues C, Beyer K, Wang J, Kreis ME, Cameron JL, **Weiss MJ**, Soares K, Castillo CF, Allen PJ, Wolfgang CL. Performance of the 7th and 8th Editions of the American Joint Committee on Cancer Staging System in Patients with Intraductal Papillary Mucinous Neoplasm - Associated PDAC: A Multi-Institutional Analysis. *Ann Surg*. 2021 Nov 18. doi: 10.1097/SLA.0000000000005313. Epub ahead of print. PMID: 34793353. Co-author.
 282. Volmer L, Koch A, Matovina S, Dannehl D, **Weiss M**, Welker G, Hahn M, Engler T, Wallwiener M, Walter CB, Oberlechner E, Brucker SY, Pantel K, Hartkopf A. Neoadjuvant Chemotherapy of Patients with Early Breast Cancer Is Associated with Increased Detection of Disseminated Tumor Cells in the Bone Marrow. *Cancers (Basel)*. 2022 Jan 27;14(3):635. doi: 10.3390/cancers14030635. PMID: 35158902. Co-author.
 283. Hill C, Sehgal S, Fu W, Hu C, Reddy A, Thompson E, Hacker-Prietz A, Le D, De Jesus-Acosta A, Lee V, Zheng L, Laheru DA, Burns W, **Weiss M**, Wolfgang C, He J, Herman JM, Meyer J, Narang A. High local failure rates despite high margin-negative resection rates in a cohort of borderline resectable and locally advanced pancreatic cancer patients treated with stereotactic body radiation therapy following multi-agent chemotherapy. *Cancer Med*. 2022 Feb 10. doi: 10.1002/cam4.4527. Epub ahead of print. PMID: 35142085. Co-author.

284. Habib JR, Gao S, Young AJ, Ghabi E, Ejaz A, Burns W, Burkhart R, **Weiss M**, Wolfgang CL, Cameron JL, Liddell R, Georgiades C, Hong K, He J, Lafaro KJ. Incidence and Contemporary Management of Delayed Bleeding Following Pancreaticoduodenectomy. *World J Surg.* 2022 Jan 27. doi: 10.1007/s00268-022-06451-x. Epub ahead of print. PMID: 35084554. Co-author.
285. Franssen S, Soares KC, Jolissaint JS, Tsilimigras DI, Buettner S, Alexandrescu S, Marques H, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Margonis GA, **Weiss MJ**, Bauer TW, Shen F, Poultides GA, Marsh JW, Cercek A, Kemeny N, Kingham TP, D'Angelica M, Pawlik TM, Jarnagin WR, Koerkamp BG. Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. *JAMA Surg.* 2022 May 11. doi: 10.1001/jamasurg.2022.1298. Epub ahead of print. PMID: 35544131. Co-author.
286. Hill CS, Rosati L, Wang H, Tsai HL, He J, Hacker-Prietz A, Laheru DA, Zheng L, Sehgal S, Bernard V, Le DT, Pawlik TM, **Weiss MJ**, Narang AK, Herman JM. Multi-Agent Chemotherapy and Stereotactic Body Radiation Therapy in Patients with Unresectable Pancreatic Adenocarcinoma: A Prospective Nonrandomized Controlled Trial. *Pract Radiat Oncol.* 2022 Mar 16:S1879-8500(22)00072-8. doi: 10.1016/j.prro.2022.02.009. Epub ahead of print. PMID: 35306231. Co-author.
287. Tsilimigras DI, Ejaz A, Cloyd J, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Koerkamp BG, Endo I, Pawlik TM. Tumor Necrosis Impacts Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol.* 2022 Mar 17. doi: 10.1245/s10434-022-11462-y. Epub ahead of print. PMID: 35298762. Co-author.
288. Tsilimigras DI, Ejaz A, Cloyd J, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Soubrane O, Groot Koerkamp B, Endo I, Pawlik TM. ASO Visual Abstract: Tumor Necrosis Impacts the Prognosis of Patients Undergoing Resection for T1 Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol.* 2022 Mar 16. doi: 10.1245/s10434-022-11485-5. Epub ahead of print. PMID: 35294655. Co-author.
289. Olthof PB, Buettner S, Andreatos N, Wang J, Løes IM, Wagner D, Sasaki K, Macher-Beer A, Kamphues C, Pozios I, Seeliger H, Morioka D, Imai K, Kaczirek K, Pawlik TM, Poultides G, Burkhart R, Endo I, Baba H, Kornprat P, Aucejo FN, Lønning PE, Beyer K, **Weiss MJ**, Wolfgang CL, Kreis ME, Margonis GA. KRAS alterations in colorectal liver metastases: shifting to exon, codon, and point mutations. *Br J Surg.* 2022 May 20:znac147. doi: 10.1093/bjs/znac147. Epub ahead of print. PMID: 35595182. Co-author.
290. Bertsimas D, Margonis GA, Sujichantararat S, Boerner T, Ma Y, Wang J, Kamphues C, Sasaki K, Tang S, Gagniere J, Dupré A, Løes IM, Wagner D, Stasinou G, Macher-Beer A, Burkhart R, Morioka D, Imai K, Ardiles V, O'Connor JM, Pawlik TM, Poultides G, Seeliger H, Beyer K, Kaczirek K, Kornprat P, Aucejo FN, de Santibañes E, Baba H, Endo I, Lønning PE, Kreis ME, **Weiss MJ**, Wolfgang CL, D'Angelica M. Using Artificial Intelligence to Find the Optimal Margin Width in Hepatectomy for Colorectal Cancer Liver Metastases. *JAMA Surg.* 2022 Jun 1:e221819. doi: 10.1001/jamasurg.2022.1819. Epub ahead of print. PMID: 35648428; PMCID: PMC9161118. Co-author.
291. Franssen S, Soares KC, Jolissaint JS, Tsilimigras DI, Buettner S, Alexandrescu S, Marques H, Lamelas J, Aldrighetti L, Gamblin TC, Maithel SK, Pulitano C, Margonis GA, **Weiss MJ**, Bauer TW, Shen F, Poultides GA, Marsh JW, Cercek A, Kemeny N, Kingham TP, D'Angelica M, Pawlik TM, Jarnagin WR, Koerkamp BG. Comparison of Hepatic Arterial Infusion Pump Chemotherapy vs Resection for Patients With Multifocal Intrahepatic Cholangiocarcinoma. *JAMA Surg.* 2022 Jul 1;157(7):590-596. doi: 10.1001/jamasurg.2022.1298. PMID: 35544131; PMCID: PMC9096688. Co-author.
292. Demyan L, Habowski AN, Plenker D, King DA, Standring OJ, Tsang C, St Surin L, Rishi A, Crawford JM, Boyd J, Pasha SA, Patel H, Galluzzo Z, Metz C, Gregersen PK, Fox S, Valente C, Abadali S, Matadial-Ragoo S, DePeralta DK, Deutsch GB, Herman JM, Talamini MA, Tuveson DA, **Weiss MJ**. Pancreatic Cancer Patient-derived Organoids Can Predict Response to Neoadjuvant Chemotherapy. *Ann Surg.* 2022 Sep 1. Epub 2022 Jun 27. PMID: 35972511.
293. Fong ZV, Teinor J, Yeo TP, Rinaldi D, Greer JB, Lavu H, Qadan M, Johnston FM, Ferrone CR, Chang DC, Yeo CJ, Wolfgang CL, Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C, **Weiss**

- MJ**, Wolff JL, Wu AW. Assessment of Caregivers' Burden When Caring for Patients With Pancreatic and Periampullary Cancer. *J Natl Cancer Inst*. 2022 Nov 14.
294. McNeil LR, Blair AB, Krell RW, Zhang C, Ejaz A, Groot VP, Gemenetzi G, Padussis JC, Falconi M, Wolfgang CL, **Weiss MJ**, Are C, He J, Reames BN. Geographic variation in attitudes regarding management of locally advanced pancreatic cancer. *Surg Open Sci*. 2022 Aug. PMID: 3606207.
 295. Beyer KM, Demyan L, **Weiss MJ**. Private Equity and Its Increasing Role in US Healthcare. *Adv Surg*. 2022 Sep. PMID: 36096579.
 296. Javed AA, Pulvirenti A, Zheng J, Michelakos T, Sekigami Y, Razi S, McIntyre CA, Thompson E, Klimstra DS, Deshpande V, Singhi AD, Weiss MJ, Wolfgang CL, Cameron JL, Wei AC, Zureikat AH, Ferrone CR, He J; Pancreatic Neuroendocrine Disease Alliance (PANDA). A novel tool to predict nodal metastasis in small pancreatic neuroendocrine tumors: A multicenter study. *Surgery*. 2022 Dec. Epub ahead of print. PMID: 36192215.
 297. Margonis GA, Boerner T, Bachet JB, Buettner S, Moretto R, Andreatos N, Sartore-Bianchi A, Wang J, Kamphues C, Gagniere J, Lonardi S, Løes IM, Wagner D, Spallanzani A, Sasaki K, Burkhart R, Pietrantonio F, Pikoulis E, Pawlik TM, Truant S, Orlandi A, Pikouli A, Pella N, Beyer K, Poultides G, Seeliger H, Aucejo FN, Kornprat P, Kaczirek K, Lønning PE, Kreis ME, Wolfgang CL, **Weiss MJ**, Cremolini C, Benoist S, D'Angelica M. Demystifying BRAF Mutation Status in Colorectal Liver Metastases: A Multi-institutional, Collaborative Approach to 6 Open Clinical Questions. *Ann Surg*. December 2022. Epub ahead of print. PMID: 36453261.
 298. Nagai M, Wright MJ, Ding D, Thompson ED, Javed AA, **Weiss, MJ**, Hruban RH, Yu J, Burkhart RA, He J, Cameron JL, Wolfgang CL, Burns WR. Oncologic resection of pancreatic cancer with isolated liver metastasis: Favorable outcomes in select patients. *J Hepatobiliary Pancreat Sci*. 2023 Jan 18. doi: 10.1002/jhbp 1303. Online ahead of print. PMID: 36652559
 299. Fong ZV, Teinor J, Yeo TP, Rinaldi D, Greer JB, Lavu H, Qadan M, Johnston FM, Ferrone CR, Chang DC, Yeo CJ, Wolfgang CL, Warshaw AL, Lillemoe KD, Fernandez-Del Castillo C, Wolff JL, Wu AW, **Weiss MJ**. Profile of the Postoperative Care Provided for Patients With Pancreatic and Periampullary Cancers by Family and Unpaid Caregivers. *JCO Oncol Pract*. 2023 May 16:OP2200736. doi: 10.1200/OP.22.00736. Online ahead of print. PMID: 37192429
 300. Ruff SM, Thompson DA, Lad NL, Anantha S, DePeralta DK, **Weiss, MJ**, Deutsch GB. Surgical debulking is associated with improved survival for patients with neuroendocrine liver metastases of unknown primary. *HPB (Oxford)*. 2023 May 9:S1365-182X(23)00141-7. doi: 10.1016/j.hpb.2023.05.003. Online ahead of print. PMID: 37258312.
 301. Alaimo L, Lima HA, Moazzam Z, Endo Y, Yang J, Ruzzenente A, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Kitago M, Pawlik TM. Development and validation of a machine-learning model to predict early recurrence of intrahepatic cholangiocarcinoma. *Ann Surg Oncol*. 2023 May 20. doi: 10.1245/s10434-023-13636-8. Online ahead of print. PMID: 37210452
 302. Standring O, Benitez Sanchez S, Pasha S, Demyan L, Lad N, Ruff SM, Anantha S, Karpeh M, Newman E, Nealon W, Talamini M, Coppa G, Deutsch G, **Weiss M**, DePeralta DK. Potential Role for Observation in Small Solid Pseudopapillary Neoplasm (SPN). *Ann Surg Oncol*. 2023 Aug; 30(8):5105-5112. doi: 10.1245/s10434-023-13496-2. Epub 2023 26. PMID: 37233954.
 303. Koti S, Demyan L, Deutsch G, **Weiss M**. Surgery for Oligometastatic Pancreatic Cancer: Defining Biologic Resectability. *Ann Surg Oncol* 2024 Jun;31(6):4031-4041. doi: 10.1245/s10434-024-15129-8. Epub 2024 Mar 19.
 304. Tsilimigras DI, Endo Y, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Popescu I, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Pawlik TM. Recurrent Intrahepatic Cholangiocarcinoma: A 10-Point Score to Predict Post-Recurrence Survival and Guide Treatment of Recurrence. *Ann Surg Oncol*. 2024 Mar 23. doi: 10.1245/s10434-024-15210-2. Online ahead of print. PMID: 38520582
 305. Endo Y, Tsilimigras DI, Woldesenbet S, Marques HP, Cauchy F, **Weiss M**, Bauer TW, Poultides GA, Maithel SK, Kitago M, Alexandrescu S, Martel G, Guglielmi A, Pulitano C, Gleisner A, Hugh T, Aldrighetti L, Shen F, Koerkamp BG, Endo I, Pawlik TM. The complication-overall survival (CompOS) risk tool predicts risk of a severe postoperative complications relative to long-term survival among patients with primary liver cancer. *J Gastrointest Surg*. 2024 Feb;28(2):132-140. doi: 10.1016/j.gassur.2023.12.010. Epub 2024 Feb 5. PMID: 38445934

306. Alaimo L, Moazzam Z, Lima HA, Endo Y, Ruzzenente A, Guglielmi A, Ratti F, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Popescu I, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Kitago M, Aucejo F, Sasaki K, Fields RC, Hugh T, Lam V, Pawlik TM. An attempt to establish and apply global benchmarks for liver resection of malignant hepatic tumors. *Surgery*. 2023 Dec;174(6):1384-1392. doi: 10.1016/j.surg.2023.08.024. Epub 2023 Sep 22. PMID: 37741777.
307. Kawashima J, Sahara K, Shen F, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Cauchy F, Koerkamp BG, Matsuyama R, Endo I, Pawlik TM. Predicting risk of recurrence after resection of stage I intrahepatic cholangiocarcinoma. *J Gastrointest Surg*. 2024 Jan;28(1):18-25. doi: 10.1016/j.gassur.2023.10.002.PMID: 38353070
308. Alaimo L, Endo Y, Catalano G, Ruzzenente A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Kitago M, Pawlik TM. Benchmarks in Liver Resection for Intrahepatic Cholangiocarcinoma. *Ann Surg Oncol*. 2024 May;31(5):3043-3052. doi: 10.1245/s10434-023-14880-8. Epub 2024 Jan 12. PMID: 38214817
309. Tsilimigras DI, Han X, Guglielmi A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Chaucy F, Koerkamp BG, Endo I, Sasaki K, Aucejo F, Zhang XF, Zhu H, Pawlik TM. Early onset intrahepatic cholangiocarcinoma: Clinical characteristics, oncological outcomes, and genomic/transcriptomic features. *Ann Surg Oncol*. 2024 May;31(5):3087-3097. doi: 10.1245/s10434-024-15013-5. Epub 2024 Feb 12. PMID: 38347332.
310. Fong ZV, Teinor J, Engineer L, Yeo TP, Rinaldi D, Greer JB, Lavu H, Qadan M, Johnston FM, Ferrone CR, Chang DC, Yeo CJ, Wolfgang CL, Warshaw AL, Lillemoe KD, Castillo CF, **Weiss MJ**, Wu AW, Wolff JL. Caregiver-reported quality of communication in pancreatic and periampullary cancer. *Cancer*. 2024 Jun 1;130(11):2051-2059. doi: 10.1002/cncr.35154. Epub 2023 Dec 26. PMID: 38146683.
311. Wei T, Lu J, Xiao XL, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Lv Y, Zhang XF, Pawlik TM; International Intrahepatic Cholangiocarcinoma and Hepatocellular Carcinoma Study Groups; U.S. Extrahepatic Biliary Malignancy Consortium. Classification of intrahepatic cholangiocarcinoma into perihilar versus peripheral subtype. *Ann Surg Oncol*. 2024 Feb;31(2):1232-1242. doi: 10.1245/s10434-023-14502-3. Epub 2023 Nov 6. PMID: 37930500
312. Amini N, Demyan L, Shah M, Standring O, Gazzara E, Lad N, Deperalta DK, **Weiss M**, Deutsch G. Decreasing utilization of surgical interventions amongst patients with pancreatic neuroendocrine tumor with liver metastases. *Am J Surg*. 2024 Jan;227:77-84. doi: 10.1016/j.amjsurg.2023.09.035. Epub 2023 Sep 27. PMID: 37798150
313. Yasrab M, Thakker S, Wright MJ, Ahmed T, He J, Wolfgang CL, Chu LC, **Weiss MJ**, Kawamoto S, Johnson PT, Fishman EK, Javed AA. Factors associated with radiological misstaging of pancreatic ductal adenocarcinoma: A retrospective observational study. *Curr Probl Diagn Radiol*. 2024 Jul-Aug;53(4):458-463. doi: 10.1067/j.cpradiol.2024.03.001. Epub 2024 Mar 7. PMID: 38522966
314. Khalid A, Amini N, Pasha SA, Demyan L, Newman E, King DA, DePeralta D, Gholami S, Deutsch GB, Melis M, **Weiss MJ**. Impact of postoperative pancreatic fistula on outcomes in pancreatoduodenectomy: a comprehensive analysis of American College of Surgeons National Surgical Quality Improvement Program data. *J Gastrointest Surg*. 2024 May 29:S1091-255X(24)00483-9. doi: 10.1016/j.gassur.2024.05.035. Online ahead of print. PMID: 38821210
315. Fallon J, Standring O, Vithlani N, Demyan L, Shah M, Gazzara E, Hartman S, Pasha S, King DA, Herman JM, **Weiss MJ**, DePeralta D, Deutsch G. Minorities Face Delays to Pancreatic Cancer Treatment Regardless of Diagnosis Setting. *Ann Surg Oncol*. 2024 Aug;31(8):4986-4996. doi: 10.1245/s10434-024-15352-3. Epub 2024 May 24. PMID: 38789617
316. Fallon J, Standring O, Vithlani N, Demyan L, Shah M, Gazzara E, Hartman S, Pasha S, King DA, Herman JM, **Weiss MJ**, DePeralta D, Deutsch G. ASO Author Reflections: Identifying and Understanding How Vulnerable Populations Are Affected by Delays in Pancreatic Cancer Care. *Ann Surg Oncol*. 2024 Aug;31(8):4998-4999. doi: 10.1245/s10434-024-15476-6. Epub 2024 Jun 7. PMID: 3884798

317. Ma ZJ, Xiang JX, **Weiss M**, Popescu I, Marques HP, Aldrighetti L, Maithel SK, Pulitano C, Bauer TW, Shen F, Poultides GA, Soubrane O, Martel G, Koerkamp BG, Itaru E, Lyu Y, Zhang XF, Pawlik TM. Long-term survivors after curative-intent resection for intrahepatic cholangiocarcinoma. *J Surg Oncol*. 2024 Jun 18. doi: 10.1002/jso.27739. Online ahead of print. PMID: 38894619
318. Margonis GA, Wang JJ, Boerner T, Moretto R, Buettner S, Andreatos N, Gagnière J, Wagner D, Løes IM, Bergamo F, Pietrantonio F, Scartozzi M, Spallanzani A, Vincenzi B, Antoniou E, Pikoulis E, Sartore-Bianchi A, Stasinou G, Sasaki K, Pawlik TM, Orlandi A, Pella N, Fitschek F, Kaczirek K, Dupré A, Pozios I, Beyer K, Kornprat P, Aucejo FN, Burkhart R, **Weiss MJ**, Lønning PE, Poultides G, Cremolini C, Kreis ME, D'Angelica M. Hepatectomy versus systemic therapy for liver-limited BRAF V600E-mutated colorectal liver metastases: multicentre retrospective study. *Br J Surg*. 2024 Jul 2;111(7). PMID: 39051667
319. Pasha SA, Khalid A, Arena J, Alizadeh A, Levine J, Demyan L, Deutsch G, **Weiss MJ**, Newman E, Melis M. Celiac artery stenosis and its impact on postoperative outcomes following pancreaticoduodenectomy: An institutional analysis. *J Surg Oncol*. 2024 Aug 4. doi: 10.1002/jso.27796. Online ahead of print. PMID: 39099190
320. Chatzipanagiotou OP, Tsilimigras DI, Catalano G, Ruzzenente A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Kitago M, Pawlik TM. Preoperative platelet count as an independent predictor of long-term outcomes among patients undergoing resection for intrahepatic cholangiocarcinoma. *J Surg Oncol*. 2024 Aug 13. doi: 10.1002/jso.27806. Online ahead of print. PMID: 39138891
321. Pasha SA, Khalid A, Levy T, Demyan L, Hartman S, Newman E, **Weiss MJ**, King DA, Zanos T, Melis M. Machine learning to predict completion of treatment for pancreatic cancer. *J Surg Oncol*. 2024 Aug 19. doi: 10.1002/jso.27812. Online ahead of print. PMID: 39155666
322. Khalid A, Ahmed H, Amini N, Pasha SA, Newman E, King DA, DePeralta D, Gholami S, **Weiss MJ**, Melis M. Outcomes of minimally invasive vs. open pancreatoduodenectomies in pancreatic adenocarcinoma: analysis of ACS-NSQIP data. *Langenbecks Arch Surg*. 2024 Aug 22;409(1):258. doi: 10.1007/s00423-024-03454-1. PMID: 39168872
323. Altaf A, Munir MM, Endo Y, Khan MMM, Rashid Z, Khalil M, Guglielmi A, Aldrighetti L, Bauer TW, Marques HP, Martel G, Lam V, **Weiss MJ**, Fields RC, Poultides G, Maithel SK, Endo I, Pawlik TM. Development of an artificial intelligence-based model to predict early recurrence of neuroendocrine liver metastasis after resection. *J Gastrointest Surg*. 2024 Nov;28(11):1828-1837. doi: 10.1016/j.gassur.2024.08.024. Epub 2024 Aug 26. PMID: 39197678
324. Catalano G, Alaimo L, Endo Y, Chatzipanagiotou OP, Ruzzenente A, Aldrighetti L, **Weiss M**, Bauer TW, Alexandrescu S, Poultides GA, Maithel SK, Marques HP, Martel G, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Kitago M, Pawlik TM. Development and Validation of a Predictive Risk Score for Blood Transfusion in Patients Undergoing Curative-Intent Surgery for Intrahepatic Cholangiocarcinoma. *J Surg Oncol*. 2024 Sep 16. doi: 10.1002/jso.27903. Online ahead of print. PMID: 39285653
325. Khalid A, Pasha SA, Demyan L, Standring O, Newman E, King DA, DePeralta D, Gholami S, **Weiss MJ**, Melis M. Modified 5-Item Frailty Index (mFI-5) may predict postoperative outcomes after pancreatoduodenectomy for pancreatic Cancer. *Langenbecks Arch Surg*. 2024 Sep 21;409(1):286. doi: 10.1007/s00423-024-03483-w. PMID: 39305322
326. Altaf A, Endo Y, Guglielmi A, Aldrighetti L, Bauer TW, Marques HP, Martel G, Alexandrescu S, **Weiss MJ**, Kitago M, Poultides G, Maithel SK, Pulitano C, Shen F, Cauchy F, Koerkamp BG, Endo I, Pawlik TM. Upfront surgery for intrahepatic cholangiocarcinoma: Prediction of futility using artificial intelligence. *Surgery*. 2024 Sep 24:S0039-6060(24)00670-6. doi: 10.1016/j.surg.2024.06.059. Online ahead of print. PMID: 39322483
327. Catalano G, Alaimo L, Chatzipanagiotou OP, Ruzzenente A, Aucejo F, Marques HP, Lam V, Hugh T, Bhimani N, Maithel SK, Kitago M, Endo I, Martel G, Pulitano C, Shen F, Popescu I, Koerkamp BG, Bauer TW, Cauchy F, Poultides GA, **Weiss M**, Gleisner A, Pawlik TM. Prognostic value of the advanced lung cancer inflammation index in intrahepatic cholangiocarcinoma. *Eur J Surg Oncol*. 2024 Oct 18;50(12):108773. doi: 10.1016/j.ejso.2024.108773. Online ahead of print. PMID: 39447453

328. Akabane M, Kawashima J, Woldesenbet S, Macedo AB, Cauchy F, Shen F, Maithel SK, Groot Koerkamp B, Alexandrescu S, Kitago M, **Weiss M**, Martel G, Pulitano C, Aldrighetti L, Poultsides GA, Imaoka Y, Guglielmi A, Bauer TW, Endo I, Gleisner A, Marques HP, Pawlik TM. Improving Recurrence Prediction in Intrahepatic Cholangiocarcinoma: The Synergistic Impact of the FIB-4 Index and Tumor Burden Score on Post-hepatectomy Outcomes. *Ann Surg Oncol*. 2024 Nov 7. doi: 10.1245/s10434-024-16455-7. Online ahead of print. PMID: 39511008
329. Khalid A, Pasha SA, Demyan L, Newman E, King DA, DePeralta D, Gholami S, **Weiss MJ**, Melis M. Ideal outcome post-pancreatoduodenectomy: a comprehensive healthcare system analysis. *Langenbecks Arch Surg*. 2024 Nov 9;409(1):339. doi: 10.1007/s00423-024-03532-4. PMID: 39516424
330. Koti S, Standing O, Vithlani N, Amini N, Deperalta D, Deutsch G, Karpeh M, **Weiss M**, Lad N. Trends and Outcomes of Neoadjuvant Chemotherapy for Clinical Stage T1 Pancreatic Cancer. *J Surg Oncol*. 2024 Nov 14. doi: 10.1002/jso.28003. Online ahead of print. PMID: 39543457
331. Khalid A, Faiz Z, Shah M, Newman E, King DA, DePeralta D, Gholami S, **Weiss MJ**, Melis M. Factors Influencing Immunotherapy Utilization in Stage IV Pancreatic Cancer: Impact of Race and Socioeconomics in the U.S. *J Gastrointest Cancer*. 2024 Nov 27;56(1):25. doi: 10.1007/s12029-024-01119-2. PMID: 39592489

Review Articles [RA]

1. **Weiss MJ**, Ng CY, Madsen JC: Tolerance, xenotransplantation: future therapies. *Surgical Clinics of North America* 2006; 86(5):1277-96, viii.
2. **Weiss MJ**, D'Angelica MI: Patient selection for hepatic resection for metastatic colorectal cancer. *J Gastrointest Oncol* 2012, 3(1):3-10. PMID: 22811864. First author.
3. Dodson RM, **Weiss MJ**, Cosgrove D, Herman JM, Kamel I, Anders R, Geschwind JF, Pawlik TM: Intrahepatic cholangiocarcinoma: management options and emerging therapies. *Journal of the American College of Surgeons* 2013, 217(4):736-750 e734. PMID: 23890842. Co-author.
4. **Weiss MJ**, Wolfgang CL: Irreversible electroporation: a novel pancreatic cancer therapy. *Curr Probl Cancer* 2013, 37(5):262-265. PMID: 24331180. First author.
5. He J, Page AJ, **Weiss M**, Wolfgang CL, Herman JM, Pawlik TM: Management of borderline and locally advanced pancreatic cancer: where do we stand? *World J Gastroenterol* 2014, 20(9):2255-2266. PMID: 24605025. Co-author.
6. Lennon AM, Wolfgang CL, Canto MI, Klein AP, Herman JM, Goggins M, Fishman EK, Kamel I, **Weiss MJ**, Diaz LA, Papadopoulos N, Kinzler KW, Vogelstein B, Hruban RH. The early detection of pancreatic cancer: what will it take to diagnose and treat curable pancreatic neoplasia? *Cancer Res* 2014, 74(13):3381-3389. PMID: 24924775. Co-author.
7. **Weiss MJ**, Cosgrove D, Herman JM, Rastegar N, Kamel I, Pawlik TM: Multimodal treatment strategies for advanced hilar cholangiocarcinoma. *Langenbecks Arch Surg* 2014, 399(6):679-692. PMID: 24962146. First author.
8. Page AJ, **Weiss MJ**, Pawlik TM: Surgical management of noncolorectal cancer liver metastases. *Cancer* 2014, 120(20):3111-3121.
9. Poruk KE, Wolfgang CL, **Weiss MJ**: Solid pseudopapillary neoplasms of the pancreas: A review. *Pancreat Disord Ther* 2014, 4(3):143.
10. He J, Pawlik TM, Makary MA, Wolfgang CL, **Weiss MJ**: Laparoscopic pancreatic surgery. *Minerva Chir* 2014, 69(6):371-378. PMID: 25077736. Senior author.
11. **Weiss MJ**, Wolfgang CL: Irreversible electroporation: a novel therapy for stage III pancreatic cancer. *Adv Surg* 2014, 58:253-8. PMID: 25293620. First author.
12. Poruk KE, **Weiss MJ**: The current state of surgery for pancreatic cancer. *Minerva Gastroenterol Dietol* 2015, 61(2):101-15. PMID: 25651834. Senior author.
13. Poruk KE, Pawlik TM, **Weiss MJ**: Perioperative management of hilar cholangiocarcinoma. *J Gastrointest Surg* 2015, 19(10):1889-99. PMID: 26022776. Senior author. rel
14. **Weiss MJ**, Hogg ME. Robotic surgery: the future is now. *J Vis Surg* 2018. (epub ahead of print).

- PMID: 29552512. First author.
15. Margonis GA, Kreis ME, Wolfgang CL, **Weiss MJ**. Mutation status and surgical selection. *J Surg Oncol*. 2019. (Epub ahead of print). PMID: 30779134. Senior author.
 16. Margonis GA, Kreis ME, Wang JJ, Kamphues C, Wolfgang CL, **Weiss MJ**. Impact and clinical usefulness of genetic data in the surgical management of colorectal cancer liver metastasis. 2019doi: 10.21037/hbsn.2019.10.05. PMID: 33299826. Senior author.
 17. Ding D, Javed AA, Cunningham D, Teinor J, Wright M, Javed ZN, Wilt C, Parish L, Hodgins M, Ryan A, Judkins C, McIntyre K, Klein R, Azad N, Lee V, Donehower R, De Jesus-Acosta A, Murphy A, Le DT, Shin EJ, Lennon AM, Khashab M, Singh V, Klein AP, Roberts NJ, Hacker-Prietz A, Manos L, Walsh C, Groshek L, Brown C, Yuan C, Blair AB, Groot V, Gemenetzis G, Yu J, **Weiss MJ**, Burkhart RA, Burns WR, He J, Cameron JL, Narang A, Zaheer A, Fishman EK, Thompson ED, Anders R, Hruban RH, Jaffee E, Wolfgang CL, Zheng L, Laher D. Challenges of the current precision medicine approach for pancreatic cancer: A single institution experience between 2013 and 2017. *Cancer Letters*, Volume 497, 221-228. (epub ahead of print) PMID: 33127389. Co-author.

Case Reports [CR]

1. El Zein MH, Kumbhari V, Tieu A, Saxena P, Messallam AA, Azola A, Li Z, **Weiss M**, Khashab MA: Duodenal perforation as a consequence of biliary stent migration can occur regardless of stent type or duration. *Endoscopy* 2014; 46 Suppl 1 UCTN: E281-282.
2. Soni A, Dogeas E, Juluri KR, Wolfgang CL, Hruban RH, **Weiss MJ**: The tail of neuroendocrine tumors from lung to pancreas: Two rare case reports. *Int J Surg Case Rep* 2014; 5(8):537-539. PMID: 25016081. Senior author.
3. Nofi CP, Maloney C, Kallis MP, Levy AT, Nealon WH, **Weiss MJ**, DePeralta DK. Rare, long-term complication after pancreatoduodenectomy-a case report of cecal volvulus. *J Surg Case Rep*. 2021 May 28;2021(5):rjab202. doi: 10.1093/jscr/rjab202. PMID: 34084448. Co-author.

Book Chapters, Monographs [BC]

1. **Weiss MJ**, Hasse J and Armenti VT. Drug nutrient interactions in transplantation, In *Handbook of Drug-Nutrient Interactions*, J.I. Boullata and V.T. Armenti, editors. Humana Press, Totawa, NJ, 2004.
2. **Weiss MJ**. Do not talk to families about organ donation. In *Avoiding Common ICU Errors*, Marcucci L, Martinez E, Haut E, Slonim A, Suarez J, editors. Lippincott Williams and Wilkins, Philadelphia, 2006.
3. **Weiss MJ**. Do not use erythromycin as a prokinetic agent in patients on FK506. In *Avoiding Common ICU Errors*, Marcucci L, Martinez E, Haut E, Slonim A, Suarez J, editors. Lippincott Williams and Wilkins, Philadelphia, 2006.
4. **Weiss MJ**. Alert the transplant team emergently if there is an acute decrease in urine output after a kidney transplant. In *Avoiding Common ICU Errors*, Marcucci L, Martinez E, Haut E, Slonim A, Suarez J, editors. Lippincott Williams and Wilkins, Philadelphia, 2006.
5. **Weiss MJ**, NG CY and Madsen JC. Tolerance, Xenotransplantation-Future Therapies. In *Organ Transplantation for the General Surgeon, Surgical Clinics of North America*, Morrissey P, editor. Elsevier Inc., Philadelphia, 2006:86:1277-1296.
6. **Weiss MJ**, Madsen JC, Rosengard BR and Allan JS. Mechanisms of Chronic Rejection in Cardiothoracic Transplantation. *Frontiers in Biomedicine* 2007.
7. **Weiss MJ**. In *The Johns Hopkins Absite Review Manual*. Nazarian SM, Meguid RA, Lipsett PA, editors. Lippincott Williams and Wilkins, Philadelphia, 2008.
8. **Weiss MJ**, Armenti VT, Sifontis N, and Jasse JM. Drug nutrient interactions in transplantation, In *Handbook of Drug-Nutrient Interactions 2nd Edition*, J.I. Boullata and V.T. Armenti, editors. Humana Press, Totawa, NJ, 2010.
9. **Weiss MJ**. Cytokines in liver, biliary and pancreatic disease. In *Jarnagin and Blumgart: Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas 5th edition*, WR Jarnagin and LH Blumgart, editors. Elsevier, Philadelphia, 2012.
10. **Weiss MJ**, Wolfgang CL. Irreversible electroporation: A novel therapy for stage III pancreatic cancer. In *Current Surgical Therapy: 11th edition*, AM Cameron and JL Cameron, editors. Elsevier, Philadelphia, 2014.

11. Poruk KE, **Weiss MJ**. Cystic lesions of the liver and biliary tract. Jarnagin and Pawlik, editors. Elsevier, Philadelphia, 2015
12. Poruk KE, **Weiss MJ**. The management of benign liver lesions. In Cameron and Cameron: Surgical Therapy, 12th edition, AM Cameron and JC Cameron, editors. Elsevier, Philadelphia, 2016.
13. Boas FE, Griffin JF, **Weiss MJ**, Solomon SB. Postoperative complications requiring intervention: diagnosis and management. In Jarnagin and Blumgart: Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas 6th edition, WR Jarnagin and LH Blumgart, editors. Elsevier, Philadelphia, 2016.
14. Burkhart RA, **Weiss MJ**. Pancreatic adenocarcinoma in the neck of the pancreas involving the celiac trunk (Appleby Procedure). In Case based lessons in the management of complex hepato-pancreato-biliary surgery. Pawlik, Weber, Gamblin, editors. Springer, NY, 2017.
15. Overton HN, **Weiss MJ**. Periampullary Carcinoma. Clinical algorithms in surgery: A practical guide. Editors Salvatore ED, Pauli EM. 2018.
16. Javed AA, **Weiss MJ**. Pancreatic Necrosis. Clinical algorithms in surgery: A practical guide. Editors Salvatore ED, Pauli EM. 2018.
17. Sham J, **Weiss MJ**. Intraductal papillary mucinous neoplasms. Clinical algorithms in surgery: A practical guide. Editors Salvatore ED, Pauli EM. 2018.
18. Reames BN, Ejaz A, **Weiss MJ**. Biliary tract tumors. Case-based reviews in surgical oncology. Editors Hochwald, Decker. 2018.
19. **Weiss MJ**. Hepatic segmental resection. Mastery of hepatobiliary surgery. Editors Lillemoe and Jarnagin. Wolters Kluwer. 2019.
20. Javed AA, **Weiss MJ**. Management of liver hemangiomas. In Current Surgical Therapy: 12th edition, AM Cameron and JL Cameron, editors. Elsevier, Philadelphia, 2019.
21. Margonis G, **Weiss MJ**. Staged Hepatectomies. In Colorectal Cancer Liver Metastases: A Comprehensive Guide to Management. Editors Correia and Choti. Springer Nature. 2019.
22. DePeralta, D, **Weiss M**. Total Pancreatectomy. In Jarnagin and Blumgart: Blumgart's Surgery of the Liver, Biliary Tract, and Pancreas 7th edition, 2020. WR Jarnagin and LH Blumgart, editors. Elsevier, Philadelphia. Senior author.
23. Standing O, Weiss MJ. Management of hepatic abscess. Current Surgical Therapy 15th edition. Editors Cameron JL, Cameron AM. Elsevier, Philadelphia, 2024

Books, Special Issues, Textbooks [BK]

1. Robotic Surgery for Pancreatic Disease. JOVS 2018. Editors **Weiss** and Hogg.

Other Publications: Suggested Additional Subcategory Titles:

Proceedings Reports [PR]

Guidelines/Protocols, Consensus Statement, Expert Opinion, Consortium Articles [GL]

Editorials [ED]

1. **Weiss MJ**. The value of cytology in the management of patients with pancreatic cysts. Cancer Cytopathol. 2019. (Epub ahead of print). PMID: 30668886. Senior author.

Methods and Techniques, "How I Do It" articles [MT]

1. Ronnenkleiv-Kelly S, **Weiss MJ**. Robotic central pancreatectomy with pancreaticogastrostomy. Journal of Visualized Surgery 2016. Pancreatic Surgery, editors. He, Sihoe. Senior author.
2. Javed AA, **Weiss MJ**. Robotic central pancreatectomy and pancreaticogastrostomy: Surgical technique and review of the literature. Annals of Pancreatic Cancer 2018.

Research Letters/White Papers/Brief Reports [RL]

Published Curricula [PC], Learner Assessment Tools, Educational Evaluations, Assessment/Evaluation Instruments [PC]

Letters, Correspondence [LT]

1. Meltzer AJ and **Weiss MJ**. The X Generation. Archives of Surgery (2002) 137(9), 1078-1079.

2. Margonis GA, Pawlik TM, **Weiss MJ**. Consideration of KRAS mutational status may enhance the prognostic impact of indeterminate extrahepatic disease in the lungs, as identified by 18FDG-PET scan, in patients with colorectal liver metastases. *Annals of Surgery* 2018. (Epub ahead of print).
3. Margonis GA, Andreatos N, Wolfgang CL, **Weiss MJ**. Reply to: "Precision Surgery" for Colorectal Liver Metastases: is the Time Ripe?". *Ann Surg.* 2018. (Epub ahead of print).
4. Margonis GA, Andreatos N, Wolfgang CL, **Weiss MJ**. Reply to: "Decoding Tumor Biology of Colorectal Liver Metastases with Radiogenomics: A Novel Insight into Surgical Approach Selection". *Ann Surg.* 2018. (Epub ahead of print). PMID: 29864095. Senior author.
5. Oluwafemi OP, **Weiss MJ**, Haut ER. Is venous thromboembolism in Asian patients undergoing gastrectomy different from venous thromboembolism in their western counterparts? Invited commentary. *JAMA Surgery.* 2018. (Epub ahead of print). PMID: 30027274. Co-author.
6. **Weiss MJ**. The Value of Cytology in Management of Patients with Pancreatic Cysts. *Cancer Cytopathology* 2018. (Epub ahead of print).
7. Margonis GA, Andreatos N, Wolfgang CL, **Weiss MJ**. Response to the Comment on "Anatomical Resections Improve Disease-free Survival in Patients With KRAS-mutated Colorectal Liver Metastases." *Ann Surg.* 2019. 269(4):e49-e51. PMID: 30845013. Senior author.

Media Releases or Interviews [MR]

1. Johns Hopkins Medicine News, A Potential Boon for Pancreatic Cancer Patients (IRE), 2014
2. Johns Hopkins Health, Resilience Rewarded (Patient Story), 2015
3. Journal of the National Cancer Institute, Shock therapy for late-stage pancreatic cancer gets a closer look
4. Johns Hopkins Surgery News, The Ins and Outs of the Minimally Invasive Whipple, 2016
5. Carroll County Times, Looking Toward a Brighter Outlook on Pancreatic Cancer
6. New York Daily News, What Alex Trebek's very promising news could mean for other cancer patients
7. CNN News Room, Interview with Brooke Baldwin, Jeopardy's Alex Trebek Says His Cancer Is Near Remission, 2019
8. CNN News Room, Interview with Brooke Baldwin, Trump Vows to Cure Cancer, 2019
8. Northwell Health News, Northwell Opens Pancreatic Cancer Center (Patient Story), 2019
9. Leaders Online, Leaders in Healthcare Surgical Oncology Interview. Volume 42, Number 4, p. 181. 2019.
10. Lustgarten Foundation's Interview with an Expert. Interview on Leading advances in pancreatic cancer surgery. January 2020.
11. Innovate LI, Patient 'Organoids' May Predict Chemotherapy Effects, April 2022
12. U.S. News Webinar, "The Changing Face of Cancer, July 2023

Other Media [OM] (Videos, Websites, Blogs, Social Media, etc.)

1. **Weiss MJ** and Jarnagin WR. The surgical approach to gallbladder cancer. In *ACS Multimedia Atlas of Surgery: Liver Volume*, HJ Asbun, editor. American College of Surgeons, Chicago, 2012.
2. Johns Hopkins Medicine Surgical Oncology Video and webpage, current
3. Irreversible Electroporation Video, current
4. Robotic Whipple Video, current
5. Johns Hopkins Webinar, Pancreatic Surgery Innovations, June 2016.
6. Connoisseur Media -- KJOY 98.3, Island Outlook Radio Talk Show, Pancreatic Cancer. September 2019.
7. Health Story Podcast: Northwell Health Cancer Institute: Patients and Physicians Working Together, Moving Forward. August 2019.
8. Northwell Health Patient Education Video. August 2020.
9. Northwell Health Surgical Safety Video. August 2020.
10. Guest on "Well Said" with Dr. Ira Nash. WRHU radio, 88.7FM. Coronavirus and Surgical Care. April 2020.
11. Live Zoom Event with Lustgarten's Dr. Andy Rakeman, VP, Research and Jason Rice, National Director of Events. Q&A on Pancreatic surgery, research and safety during covid. September 2020.
12. Covid Provider Update Video, October 2020.

13. Guest on “Well Said” with Dr. Ira Nash. WRHU radio, 88.7FM. Pancreatic Cancer Awareness. November 2020.
14. Guest on “20-Minute Health Talk” a thought leadership podcast from Northwell Health. September 2021.

FUNDING

INTRAMURAL Funding

2023-present	Pilot Study of an Implantable Microdevice for In Situ Evaluation of Drug Response in Patients with Pancreatic Cancer. Kelter Award \$100,000 Role: Principal Investigator
2022-present	Microdose Devices for the Personalized Care of Pancreatic Cancer Patients CSHL-Northwell Affiliation Collaborative Preclinical Project Grant \$750,000 Principal Investigator: Dave Tuveson, MD Role: Co-Principal Investigator

EXTRAMURAL Funding

7/1/05-6/30/07	Immature dendritic cells and tolerance induction in miniature swine NIH Ruth L. Kirkstein NRSA T-32 Training Grant \$60,000 Principal Investigator: David H. Sachs, MD Role: Research Fellow/Trainee, 100%
7/1/05-6/30/07	Using mixed chimerism to induce tolerance in porcine lung allograft recipients Novartis International Society for Heart and Lung Transplantation \$80,000 Role: Principal Investigator, 100%
7/1/13-6/30/16	Patient-Centered Outcomes Research Institute Utilizing advance care planning videos to empower perioperative cancer patients and families 5% salary support for 3 years \$1.2 million Principal Investigator: Rebecca Aslakson, MD Role: Co Investigator
4/01/2018-2019	Patient-Centered Outcomes Research Institute A multi-center randomized trial of perioperative palliative care surrounding cancer surgery for patients and their family members (the PERIO-PC trial) Goal: Study the effect of early palliative care intervention for cancer surgery patients. \$2.2 million 5% salary support for 3 years Principal Investigator: Rebecca Aslakson, MD Role: Co-investigator
9/8/2018-2019	NIH U01CA220477 Gamma-OHPdG as a prognostic biomarker of HCC recurrence and its prevention Goal: Determine a new prognostic marker for hepatocellular carcinoma. \$336,246 2% salary support Principal Investigator: Fung-Lung Chung Role: Co Investigator
9/21/20-present	Northwell Health Center for Liver Disease Industry sponsored Trial

	A creon study for patients with resected pancreatic cancer (also an arm for unresectable cancer too).
	0% salary support
1/1/2021-present	Role: Sub-Investigator Lustgarten Foundation Inflammation promotes metastatic relapse of pancreatic cancer. \$88,000
05/01-2022-present	Role: Principal Investigator Nikki Mitchell Seed Grant for Pancreatic Cancer Microdose devices for personalized care of pancreatic cancer patients \$20,000 Principal Investigator: Oliver Standring, MD Role-Research Mentor

Industry Grants

8/1/2016-08/1/2018	A randomized trial of Prevena Peel and Place Dressing versus standard closure for patients undergoing pancreaticoduodenectomy who have undergone neoadjuvant chemotherapy or biliary stent placement. Acelity \$71,644 Role, Principal Investigator
--------------------	--

CLINICAL ACTIVITIES

Clinical Focus

I am a surgical oncologist specializing in hepatopancreatobiliary diseases. My practice involves liver, pancreas, stomach, adrenal, colon and numerous other malignancies.

Certification

2003	Advanced Trauma and Life Support
2010	Fundamentals of Laparoscopic Surgery
2010	Advanced Cardiac Life Support

Medical, other state/government licensure

2010-2012	New York State Medical Licensure	License # 256179
2012-present	Maryland State Medical Licensure	License #D0073814
2019-present	New York State Medical Licensure	License # 256179

Boards, other specialty certification

2010	American Board of Surgery
2022	Recertification, American Board of Surgery

Membership in or examiner for specialty board

2024-present	American Board of Surgery, Examiner
--------------	-------------------------------------

Clinical Program Building / Leadership

2012-2019	Robotic Pancreatectomy Program; consultant to outside institutions, JHH
2012-2019	Pancreatic Irreversible Electroporation Program; consultant to outside institutions, JHH
2013-2019	Surgical Director; Pancreas Cancer Multidisciplinary Clinic; modeled after at outside institutions, JHH
2014-2019	Investigator; Robotic Hepatectomy Program
2016-2019	Surgical Director, Liver Cancer Multidisciplinary Clinic; modeled after at outside institutions, JHH

2019-present	Robotic Pancreatectomy Program, Northwell Health
2019-present	Pancreas Cancer System-wide Multidisciplinary Clinic, Northwell Health
2019-present	Pancreatic Cyst and High-Risk Surveillance Clinic, Northwell Health
2021-present	Liver Cancer System-wide Multidisciplinary Clinic, Northwell Health

Clinical Demonstration Activities to external audience, on or off campus

2012-present	Visiting national and international surgeons to observe robotic pancreatectomies
2012-present	Visiting national and international surgeons to observe irreversible electroporation procedures
2016	International HBP Forum Live Surgery Demonstration of Whipple, Hangzhou, China.

Development of nationally/internationally recognized clinical standard of care (may not be published in peer-reviewed journals)

EDUCATIONAL ACTIVITIES

Educational Focus

I am dedicated to the training of fellows, residents, and medical students. My goal is to educate tomorrow's leaders in academic surgery and surgical oncology. I was the director of the JHH ACGME approved complex general surgical oncology fellowship and am currently the associate program director at Northwell Health where we received ACGME accreditation in 2021.

Teaching

Classroom instruction

2011-2012	Resident Teaching Coordinator	MSKCC
2011-2012	Oncology Fellow Multidisciplinary Teaching Conference Organizer	JHH
2012-2019	JHH Resident Lecture: Cancer Genetics	JHH
2013-2019	Surgical Resident Lecture Series: Jaundice	JHH
2013-2019	Surgical Resident Lecture Series: Principles of Surgical Oncology	JHH
2013-2019	Surgical Frontiers: Center for Bioengineering Innovation and Design	JHH
2013-2019	Sidney Kimmel Comprehensive Cancer Center Education Committee	JHH
2013-2019	JHU Medical Student Lecture Series: GI Bleed	JHH
2013-2019	Director, Surgical Oncology Randomized Clinical Trials Course	JHH
2013-2019	Surgical Residents and Fellows: Liver Anatomy Lecture with Videos	JHH
2016-2019	JHH Intern Lecture, Cancer: Chemotherapy and Clinical Trials	JHH
2016-2019	JHH School of Public Health: Lecture on Surgical Oncology-Liver Cancer	JHH
2019-present	Surgical Resident Lecture: Esophageal Cancer	Northwell Health
2019-present	Hepatobiliary and Transplant Classroom Instruction Course	Northwell Health
2019-present	Gastroenterology HBP Lecture	Northwell Health

Clinical instruction

2012-present	Fellow, Resident, and student surgical instructor
2012-present	Weekly rounds with fellows, residents, medical students on wards
2012-2019	Gynecologic Oncology intraoperative teaching of fellows
2016-2019	Halsted Resident Cadaveric Laparoscopic Splenectomy Proctor
2019-present	Northwell Resident Cadaveric Hepatobiliary Operations Proctor

CME instruction

2014	Lecturer, Minimally invasive pancreatectomy, Capitol Region CME course
2016	Suburban Hospital Pancreas and Liver Symposium, Pancreas Surgery Innovations

Workshops /seminars

2016	JHH Pancreas Cancer Webinar
2017	JHH Liver Cancer: What You Need To Know Webinar

2022 Podcast, 20 Minute Health Talk on Pancreatic Cancer
 2020-present Northwell Pancreatic Cancer Symposium

Mentoring

Pre-doctoral Advisees /Mentees

2012-2013 Saami Khalifian, MD Candidate, Surgical Residency, Medical Student Research Advisor, 1 publication
 2013-2014 Ali Rabi , Surgery Residency at MGH, Medical Student Research Advisor
 2015-2016 Shin-Rong Lee, Medical Student Research Advisor, 1 publication
 2015-2016 Niek Peters, Current Research Fellow, Medical Student Research Advisor, 2 publications
 2021-2020 Lucas Sher, High School Student,
 2021-2022 Shamsher Pasha, MD, Research Fellow
 2022-present Abdullah Khalid MD, Research Fellow

Post-doctoral Advisees /Mentees

2012-2013 Aitua Salami, MD, BS, MPH, UT Southwestern Research Fellow, Capstone Advisor for MPH
 2012-2014 Ioannis Hatzaras, MD, Attending Surgeon at NYU, Fellow Research Advisor
 2012-2014 Teviah Sachs, MD, Attending Surgeon at UMass, Fellow Research Advisor
 2012-2019 Neda Rezaee, MD, Research Fellow at JHH, Fellow Research Advisor
 2013-2019 Michol Cooper, MD, Chief Resident at JHH, ABSITE Advisor
 2013-2019 Ammar Javed, MD, Research Fellow at JHH, Fellow Research Advisor
 2013-2015 Wenchuan Wu, MD, Attending Surgeon in China, Fellow Research Advisor
 2013-2015 Jin He, MD, PhD, Attending Surgeon at JHH, Fellow Research Advisor
 2013-2019 Vicente Valero III, MD, Surgery Resident at JHH, Resident Research Advisor
 2013-2019 Katherine Poruk, MD, Surgery Resident at JHH, Resident Research Advisor
 2013 Ashwin Soni, MD, Plastic Surgery Resident UT Southwestern, Resident Research Advisor
 2013-2015 Andrew Page, MD, Attending Surgeon in Atlanta, Fellow Research Advisor
 2014-2015 Fengchun Lu, MD, PhD, Attending Surgeon in China, Fellow Research Advisor
 2014-2019 Kevin Soares, MD, Surgery Resident, Research Advisor
 2014-2019 Megan Winner, MD, Senior Fellow at JHH, Fellowship Advisor
 2014-2019 Miral Grandhi, MD, Senior Fellow at JHH, Fellowship Advisor
 2014-2019 Mohammed Al Efshat, MD, Surgery Resident at JHH, Resident Research Advisor
 2014-2019 James Griffin, MD, Surgery Resident at JHH, Resident Research Advisor
 2015-2019 Richard Burkhart, MD, Fellow at JHH, Fellowship Advisor
 2015-2019 Sean Ronnekleiv-Kelly, MD, Fellow at JHH, Fellowship Advisor
 2015-2019 Victoria Kim, MD, Surgery Resident at JHH, Resident Research Advisor
 2015-2019 Wei Jing, MD, PhD, Research Fellow, Research Fellow Advisor
 2016-2019 Bradley Reames, MD, Fellow at JHH, Fellowship Advisor
 2016-2019 Aslam Ejaz, MD, Fellow at JHH, Fellowship Advisor
 2016-2019 Michele Gage, MD, Fellow at JHH, Fellowship Advisor
 2016-2019 Georgios Margonis MD, Research Fellow at JHH, Advisor
 2017-2019 Jonathon Sham, MD, Fellow at JHH, Fellowship Advisor
 2018-2020 Georgios Margonis MD, Kenneth Warren Award from IHPBA
 2020-present Lyudmyla Demyan, MD, Northwell Health Research Fellowship Advisor
 2019-present Samantha Ruff, MD, Northwell Health Resident, Research Advisor
 2021-present Oliver Standring, MD, Northwell Health Resident, Research Advisor
 2022-present Emma Gazzarra MD, Northwell Health Resident, Research Advisor
 2023-present Shruti Koti MD, Northwell Health Resident, Research Advisor
 2023-present Grace Wu MD, Northwell Health Resident, Research Advisor
 2024-present Julien Hohenleitner MD, Northwell Health Resident, Research Advisor

2023-present Amanda Woodworth MD, Society of Surgical Oncology, Career Catalyst Mentorship Program

Thesis committees

Educational Program Building / Leadership

2012-2019 Course Developer, Surgical oncology randomized clinical trials course, for JHH residents and fellows
2013-2016 Associate Director, JHH Complex Surgical Oncology Fellowship
2016-2019 Program Director, JHH Complex Surgical Oncology Fellowship
2017-2019 Johns Hopkins Halsted Residency Ombudsman
2019-present Course Developer, Surgical oncology randomized clinical trials course, Northwell residents
2021-present Associate Program Director CGSO Fellowship, Zucker School of Medicine at Hofstra

Educational Demonstration Activities to external audiences

RESEARCH ACTIVITIES

Research Focus

My primary research focus is studying the outcomes of surgery for hepatopancreatobiliary diseases with an emphasis on clinical trials.

Research Program Building / Leadership

2013-2019 Director, JHH HPB division weekly clinical research group
2019-present Director, Northwell Health surgical oncology weekly clinical research group

Research Demonstration Activities

2013-2019 Mentor, HPB division weekly meeting

Inventions, Patents, Copyrights

Technology Transfer Activities

SYSTEM INNOVATION AND QUALITY IMPROVEMENT ACTIVITIES

2012-2019 Development of pancreas surgery clinical pathway, JHH
2012-2019 Assisted in the development of liver enhanced recovery after surgery (ERAS) pathway
2013-2019 Developed JHH IRE Protocols
2014 Ambulatory Management Program, Johns Hopkins University
2015-2019 Currently developing best practice guidelines for pancreaticoduodenectomy
2016 Economics of Clinical Operations Course, John Hopkins University
2020-present Northwell Health Preoperative Surgical Testing Redevelopment
2019-present Development of Enhanced Recovery Protocols for pancreas and liver surgery, Northwell Health

ORGANIZATIONAL ACTIVITIES

Institutional Administrative Appointments

1999-2003 Member, Thomas Jefferson University Hospital Commons Board
2010 Alpha Omega Alpha JHH Chapter
2012-2019 Faculty Advisor, JHH Comprehensive Unit-based Safety Program
2012-2019 Core Faculty Member, JHH Centers for Surgical Trials and Outcomes Research
2013-2016 Associate Program Director of ACGME Approved Complex Surgical Oncology Fellowship
2013-2019 Member, Clinical Advisory Board of the JHH Bioengineering Innovation and Design
2013-2019 Member, Associate Director ACGME Approved Surgical Oncology Fellowship
2013-2019 Surgical Director Johns Hopkins Pancreas Cancer Multidisciplinary Clinic
2014-2019 Surgical Advisor, HPB Comprehensive Unit-based Safety Program
2014-2019 Co-Chair, MCIC Obstructive Sleep Apnea Collaborative
2015 Member, Johns Hopkins Radiation Oncology GI Search Committee
2016-2019 Enhanced Recovery After Surgery Steering Committee
2016-2019 Member, Johns Hopkins Surgery Department Compensation Committee

2016-2019	Member, Enhanced Recovery after Surgery Steering Committee
2015-2019	Gynecologic Oncology Fellowship Interviewer
2016-2019	Surgical Director of Johns Hopkins Liver Cancer Multidisciplinary Clinic
2016-2019	Director of ACGME Approved Complex Surgical Oncology Fellowship
2018-2019	Operating Room Efficiency Task Force, Johns Hopkins Perioperative Services
2019-present	Member, Northwell Health Robotic Steering Committee
2019-present	Member, Northwell Health Division of Surgical Innovation
2019-present	Member, Northwell Health ERAS Steering Committee
2019-present	Member, Northwell Health Cancer Institute, Data Safety Monitoring Plan (DSMP)
2020-present	Member, Northwell Health Surgical Emergency Operations Steering Committee
2020-present	Co-Chair, Northwell Health System Perioperative Steering Committee
2020-present	Member, Northwell Health Translational Advisory Group
2020-present	Member, NY Medical Society
2021-present	Member, Northwell Health Opioid Management Steering Committee (OMSC) Pain Management Workgroup
2021-present	Member, Northwell Health Procedural Product Committee
2022-present	Physician Executive Sponsor, Breast Disease Strategy Steering Committee, Northwell Health
2022-present	Member, Northwell Health Breast Disease Strategy Steering Committee, Program Development and Support
2022-present	Member, Northwell Health Breast Disease Strategy Steering Committee, Access and Navigation
2022-present	Lead, Northwell Health Breast Disease Strategy Steering Committee, Recruitment
2022-present	Member, Northwell Health Excellence in Research Committee
2022-present	Member, Northwell Health Diversion, Equity and Inclusion Committee
2023-present	Member, Northwell Health Propcedural Time Out Committee
2023-present	Member, Northwell Health Blood Product Committee

Editorial Activities

Editorial Board appointments

2012	Associate Editor, The Johns Hopkins ABSITE Review Manual. Lippincott Williams and Wilkins,
2012	
2014-present	Editorial Board Member, Medicine
2015	Associate Editor, Pancreatic Cancer. Zhao Y, editor. AME publishing company
2017	Associate Editor, Journal of Visualized Surgery

Journal peer review activities

2012-present	Journal of the American College of Surgeons
2012-present	Annals of Surgery
2012-present	Annals of Surgical Oncology
2012-present	JAMA Surgery
2012-present	Journal of Surgical Research
2012-present	HPB
2012-present	British Medical Journal
2012-present	World Journal of Surgery
2012-present	Journal of Gastrointestinal Surgery
2016-present	Journal of Surgical Oncology
2016-present	Pancreatology
2018-present	British Journal of Surgery

Other peer review activities

Advisory Committees, Review Groups/Study Sections

2012-2015	Member, AHPBA Committee for Emerging Technologies and Therapeutics
2014	Clinical Trials Reviewer, German Ministry of Education and Research
2014-present	Member, Association for Academic Surgery Finance Task Force
2014-present	Member, Maryland Committee on Applicants of the American College of Surgeons

2015-present	Member, AHPBA Locally Advanced Pancreas Cancer Steering Committee
2015-present	Member, AHPBA Membership Committee
2015-present	Member, Pancreas Club Program Committee
2016-present	Clinical Trials Reviewer, Swiss Cancer League
2018-present	Clinical Trials Reviewer, Dutch Cancer Society
2019-present	Publications Committee, Association for Academic Surgery

Professional Societies

1998-2005	College of the Holy Cross Admissions, Interviewer
1999-2003	American Medical Association, Member
2003-2010	Maryland Medical Society, Member
2006	International Society for Heart and Lung Transplantation, Member
2009-present	Pancreas Club, Member
2003-present	American College of Surgeons, Member/Fellow
2010-present	American Hepatopancreatobiliary Association, Member
2010-present	International Hepatopancreatobiliary Association, Member
2011-present	Society for Surgical Oncology, Member
2012-present	Association for Academic Surgery, Member
2017-present	American College of Surgeons, MD Chapter, Councilor
2017-present	Society for Surgery of the Alimentary Tract, Member
2018-present	Surgical Biology Club II
2019-present	Society of University Surgeons, Member
2019-present	Halsted Society, Member
2024-present	American Board of Surgery, Examiner

Conference Organizer

National

2012-2014	Association for Academic Surgery Program Organizer
2016	Pancreas Club Annual Meeting Organizer/Program Committee
2018	44 th Johns Hopkins Annual Topics in Gastroenterology and Hepato-Biliary, Co Chair
2019-present	Northwell Annual Pancreatic Cancer Symposium
2024	Inaugural New York Pancreatic Cancer Consortium Meeting

Session Chair

National

2014	ASC: Clinical Trials/Outcomes 4: Quality of Care II	Moderator
2015	ASC: Clinical Trials/Outcomes-Quality of Care	Moderator
2015	AHPBA Video Session: Pancreas/Biliary	Moderator
2015	AHPBA Long Abstract Session	Discussant
2016	ACS: Hepatobiliary and Pancreas Session I	Discussant
2016	ACS: Surgical Oncology II	Discussant
2016	ACS: Surgical Oncology III	Discussant
2017	AHPBA Long Abstract Session	Discussant
2018	DDW 2018 Plenary HPB Section	Moderator
2018	4 th Annual IHBP Conference, Hangzhou China	Moderator
2020	NYSS Winter Scientific Meeting	Discussant

Consultantships

RECOGNITION

Awards, Honors

1998	Pi Mu Epsilon National Mathematics Honor Society
2000	William Potter Medical Student Research Prize

2001	Hobart Amory Hare Honor Society of Thomas Jefferson University
2003	Clinical Surgery Prize of Jefferson Medical College
2005-2007	Ruth L. Kirkstein National Research Service Award
2006-2007	American College of Surgeons Resident Research Scholarship
2006-2007	Thoracic Surgery Foundations for Research and Education Research Award
2006-2007	Novartis International Society for Heart and Lung Transplantation Research Award
2007	Genzyme Advances in Organ Transplantation Conference Scholarship Award
2007	Genzyme Advances in Organ Transplantation Basic Science Award
2007	Massachusetts General Hospital Calderwood Research Prize
2008	Johns Hopkins Hospital Medicine Department Osler Resident Teaching Award
2010	Alpha Omega Alpha Medical Honor Society
2010	The John L. Cameron Best Technical Surgical Resident Award
2016-2019	Baltimore Magazine Top Doctors
2017	Miller Coulson Academy of Clinical Excellence
2017	John L. Cameron Clinical Excellence Award, Department of Surgery Director's Award
2018	Mentor for Kenneth Warren IHPBA Fellowship Awardee (Georgios Margonis, MD)
2018	Paul K. Neumann Professor of Pancreatic Surgery
2019	Makuuchi Teaching Award at Johns Hopkins
2019	Northwell Health 6 th Annual Clinical Symposium, Cutting Edge Innovations in Robotic Surgery
Award	
2019	Step-By-Step Foundation Healthcare Hero Award
2020	Senior Surgical Resident Faculty Teaching Award, Northwell Health
2022	American Cancer Society Doctors of Distinction Golf Invitational, Honoree
2024	Springside Chestnut Hill Academy Roll of Fame
2024	Senior Surgical Resident Faculty Teaching Award, Northwell Health
2024	Complex General Surgical Oncology Teaching Award, Northwell Health
2025	Lustgarten Foundation's Inaugural Hope Through Compassion Award

Invited Talks

Regional

2014	Johns Hopkins Medical Student Society for Oncology Guest Lecturer, Baltimore, MD.
2015	Johns Hopkins Hospital Grand Rounds. Invited Speaker, Contemporary Management of Pancreatic Cancer.
2016	Johns Hopkins Colorectal Department Resident Teaching Session: Treatment of Colorectal Cancer
Liver	Metastases.
2016	Johns Hopkins Hospital, Faculty Development Seminar: Managing a Surgical Practice
2017	Johns Hopkins Bloomberg School of Public Health. Invited Speaker. Liver Surgical Oncology, Hepatocellular Carcinoma
2017	Johns Hopkins Nutritional Department: Current concepts in the management of pancreatic cancer and nutritional considerations.
2017	Johns Hopkins Biennial Old Hands Meeting: John Cameron: A Historical Perspective
2017	43 rd Annual Topics in Gastroenterology and Hepato-biliary Update; Colorectal liver metastases in 2017: A surgeon's perspective
2018	Johns Hopkins Bloomberg School of Public Health. Invited Speaker. Liver Surgical Oncology, Cholangiocarcinoma
2018	44 th Annual Topics in Gastroenterology and Hepato-biliary Update; Precision Medicine for Colorectal Liver Metastases
2019	Northwell Health, Huntington Hospital Grand Rounds. Invited Speaker, Northwell Pancreatic Cancer Program
2019	Northwell Health, Southside Hospital Grand Rounds. Invited Speaker, Northwell Health Pancreatic Cancer Program
2019	Northwell Health, Huntington Hospital Grand Rounds. Invited Speaker, Northwell Health Colorectal Cancer with Liver Metastases
2019	Northwell Health 6 th Annual Clinical Symposium. Invited Speaker, Robotic Hepatobiliary Surgery – The Future is Now

2019 Northwell Health, Staten Island University Hospital Grand Rounds. Invited Speaker, Northwell Pancreatic Cancer Program

2019 Northwell Health, Plainview Hospital. Invited Speaker, Northwell Health Pancreatic Cancer Program

2019 Northwell Health, Monter Cancer Center, Invited Speaker, Oncology Grand Rounds. Surgical Aspects of Pancreatic Cancer

2020 Northwell Health, 11th Annual Estate Planning Committee Dinner Meeting. Invited Speaker, "Beating Pancreatic Cancer: The Northwell Approach"

2020 Northwell Health, Northern Westchester Hospital Surgical Grand Rounds. Invited Speaker, Northwell Health Pancreatic Cancer Program

2020 94th Annual Meeting of the Halsted Society, Invited Speaker. Optimizing Access to Surgical Care for Cancer Patients during the COVID-19 Pandemic: A Report from New York State's Largest Health System in the Epicenter of the Epicenter

2020 Northwell Health Virtual Seminar, Discover a Healthier You: Conquering Cancer Together. Invited Speaker, "Beating Pancreatic Cancer: The Northwell Approach"

2021 Northwell Health GI Fellow Conference Guest Lecturer. "Surgery on Benign and Malignant Hepatobiliary Disease"

2021 Northwell Health, Feinstein Faculty Forum Hot Science Invited Speaker, "The Evolving Prognostic Factors for Colorectal Liver Metastases: A Surgeon's Perspective" September 2021

2021 Long Island Cancer Registrars Association (LICRA), Winter Educational Conference. Invited Speaker, "Bile Duct Cancer/Cholangiocarcinoma and Pancreatic Cancer".

2022 South Shore University Hospital Grand Rounds Speaker, "Colorectal Liver Metastases; A Surgeon's View"

2023 Joint Cold Spring Harbor and Northwell Health Board Meeting Speaking, Carnegie Hall, NY

National

2007 Massachusetts General Hospital Grand Rounds, Mixed hematopoietic chimerism prevents lung allograft rejection in miniature swine. Boston, MA

2009 Pancreas Club, Is it safe to observe asymptomatic branch duct or mixed-type intraductal papillary mucinous neoplasms less than 3cm and without a solid component?: The pathological findings of 16 patients who underwent pancreatectomy for this condition. Chicago, IL

2013 8th Annual Academic Surgical Congress, 140 Portal/Superior mesenteric vein resections during pancreaticoduodenectomy: Evolution of technique and lessons learned. New Orleans, LA

2014 Annual American Hepatopancreatobiliary Association Meeting, Venous thromboembolic prophylaxis following hepatic resection: Patterns of care among liver surgeons. Long Oral Session. Miami, FL.

2014 Society of Surgical Oncology 67th Annual Cancer Symposium, The impact of post-operative complications on the administration of adjuvant therapy following pancreaticoduodenectomy for adenocarcinoma. Phoenix, AZ

2015 Annual American Hepatopancreatobiliary Association Invited Discussant. Miami, FL

2015 Harlem Hospital Grand Rounds. Invited Speaker, Pancreas Tumors.

2015 ACS Clinical Congress. Discussant, Multiple minor hepatectomies versus major or extended hepatectomies for colorectal liver metastases: A propensity score-matched dual-institution analysis.

2016 ACS Clinical Congress. Discussant, Non-steroidal anti-inflammatory drug (NSAID) use independently increases risk of post-operative pancreatic fistula following pancreaticoduodenectomy.

2017 AHPBA. Discussant, BRCA2 patients are underscreened for pancreatic cancer.

2017 American Surgical Association. Anatomical resections improve disease free survival in patients with KRAS-mutated colorectal liver metastases. Presenter

2017 Southern Surgical Association. A preoperative risk score can help predict long-term outcomes following hepatectomy for intrahepatic cholangiocarcinoma. Discussant

2018 Hopkins MedSurg GI Course, Vail Colorado. Robotic Pancreaticoduodenectomy

2018 Hopkins MedSurg GI Course, Vail Colorado. Whipple for T1N0 Ampullary Cancer

2018 Hopkins MedSurg GI Course, Vail Colorado. Case Presentations

2018 Memorial Sloan Kettering Cancer Center, HPB Malignancies: A surgeon's role beyond clinical volume

2018	Digestive Disease Week, How to best manage incidental pancreatic neuroendocrine tumors, Washington, DC
2018	Society of Surgical Oncology IRE Debate Webinar
2018	66 th Annual American Society of Cytopathologists Conference: Importance of cytology in the management of patients with pancreatic disease, Washington, DC.
2019	AHBPA. Discussant, RAMPS and Celiac Axis Resection.
2019	Pancreas Club, Metastatic PDAC – Is There Any Logic for Resection? San Diego, CA
2020	ASCO GI Cancers Symposium, Invited Speaker, Newer Modalities for Locally Advanced Pancreas Cancer, San Francisco, CA
2020	Northwell Health Seminar. Invited Speaker. Beating Pancreatic Cancer: The Northwell Approach.
Palm Beach, FL	
2020	AHPBA. Discussant, Debate: Resection Should Be Considered in Low Volume Metastatic Disease. Miami, FL
2020	Memorial Sloan Kettering Cancer Center, CGSO Virtual Alumni Lecture, Invited Speaker. Lessons learned from a high mileage academic surgeon
2021	ASCO Annual Meeting, Invited Speaker. The Now and Next in the Treatment of Pancreatic Cancer. “Oligometastatic Pancreas Cancer Management With Surgery or Radiation: We Can, But Should We?”
2022	SGO Annual Meeting, Invited Presenter. Faculty member for the hands-on cadaver session: SGO Master Class: Debulk & Deliver: A Cytoreductive Surgery Lab. Phoenix, AZ
2022	ASA 142 nd Annual Meeting. Invited Presenter. Pancreatic Cancer Patient-Derived Organoids Accurately Predict Response to Neoadjuvant Chemotherapy. Chicago, IL
2022	ACS Clinical Congress, Panel Session Co-Moderator. “Using Synoptic Operative Notes: Best Practice for Clinical Care, Research, and Billing for Common Cancer Operations” San Diego, CA
2022	Surgical Biology Club II Annual Meeting. Invited Presenter. Developing novel approaches for treating pancreatic ductal adenocarcinoma. San Diego, CA
2022	Mayo Clinic Hepato-Pancreatico-Biliary Cancer Symposium. Invited Presenter. “The Role of Surgery in Oligometastatic Pancreatico-biliary Cancers”. Las Vegas, NV
2022	MedStar Health Medical Group Grand Rounds, Baltimore, MD
2023	Robotic Complex GI Surgery Symposium, New York, NY
2024	Charting a Course for High-Quality Surgical Oncology in Expanding Healthcare Systems, Cedars Sinai Grand Rounds, California.
International	
2012	XIX Brazilian Congress of Cancer Invited International Speaker, Surgical Approach to Gallbladder Cancer, Fortaleza, Brazil.
2012	XIX Brazilian Congress of Cancer Invited International Speaker, Hepatic Resection Oncology: and Strategies of Extended Resection, Fortaleza, Brazil.
Principles	
2014	69th Annual Japan Society of Coloproctology Meeting Invited International Speaker, Management of colorectal liver metastasis. Yokohama, Japan.
2015	International College of Surgeons-United States Section Meeting. Invited Speaker, MIS Pancreas
Surgery-	
	Embrace Change Before You Become Outdated. Annapolis, MD.
2015	11th International Gastric Cancer Congress. Invited International Speaker, How to improve postoperative morbidity and mortality for pancreas cancer. Sao Paulo, Brazil.
2015	11th International Gastric Cancer Congress. Invited International Speaker, Locally Advanced
Pancreatic	
	Cancer-How to Improve Survival. Sao Paulo, Brazil.
2016	International HBP Forum. Invited Speaker, Surgical approaches to locally advanced and selected metastatic pancreas cancer. Hangzhou, China.
2016	2nd Annual GI and Hepatology Conference. Invited Speaker, Current surgical management strategies for hilar cholangiocarcinoma. Hangzhou, China.

2017 17th Annual Gastroenterology and Hepatology Viva la Vida. Invited Speaker, Outcomes following bariatric surgery. Puerto Rico.

2017 17th Annual Gastroenterology and Hepatology Viva la Vida. Invited Speaker, Surgical approaches to chronic abdominal pain. Puerto Rico.

2018 Pancreas 2018. If and when it's appropriate to operate on stage IV pancreas cancer

2018 HITEC 2018 Course. Great Debate: Surgical management of peri-pancreatic fluid collections

2018 4th Annual IHBP Conference, Preventing SSI's Following Pancreaticoduodenectomy. Hangzhou China

2018 4th Annual IHBP Conference, 2 Stage Hepatectomies with PVE. Hangzhou China

2018 4th Annual IHBP Conference, Precision Medicine for Colorectal Liver Metastases. Hangzhou China

2020 ALPS 2020, Invited Speaker, Standardising high quality pancreatic surgery across a large healthcare system. Madonna Di Campiglio, Italy

2020 ALPS 2020, Invited Speaker, Robotic Liver Surgery. Madonna Di Campiglio, Italy

2022 International Hepato-Pancreato-Biliary Association 15th World Congress, Invited Update session chair, Novel Biomarkers that Predict Outcomes in Patients Undergoing Surgery for Pancreatic Cancer. New York, NY

MATTHEW WEISS'S TESTIMONY HISTORY

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF NORTH CAROLINA
SOUTHERN DIVISION

IN RE:)	
)	
CAMP LEJEUNE WATER LITIGATION)	
)	
This Document Relates to:)	Case Nos.:
)	
ALL CASES)	7:23-CV-897
)	
DAVID DOWNS)	7:23-CV-01145-BO
)	
DAVID WILLIAM FANCHER)	7:23-CV-00275-BO-BM
)	
ALLAN WAYNE HOWARD)	7:23-CV-00490-BO
)	
FRANK W. MOUSSER)	7:23-CV-00667-BO-RN
)	
JACQUELINE JORDAN TUKES)	7:23-CV-01553-BO-BM

**PLAINTIFFS' DESIGNATION AND DISCLOSURE OF PHASE III EXPERT
WITNESSES WITH RESPECT TO KIDNEY CANCER**

MATTHEW J. WEISS, MD'S LIST OF TESTIMONY

Pursuant to Fed. R. Civ. P. 26(a)(2)(B)(v), Plaintiffs provide the following list of testimony:

During the previous 4 years, Matthew J. Weiss, MD, MBA, FACS has testified as an expert at trial or by deposition in only one matter, namely *Jacobs v. Shope*, Superior Court for the District of Columbia, docket number 2021 CA 000869 M. The deposition was taken on or about May 3, 2023.

**MATTHEW WEISS'S
STATEMENT OF
COMPENSATION**

IN THE UNITED STATES DISTRICT COURT
FOR THE EASTERN DISTRICT OF NORTH CAROLINA
SOUTHERN DIVISION

IN RE:)	
)	
CAMP LEJEUNE WATER LITIGATION)	
)	
This Document Relates to:)	Case Nos.:
)	
ALL CASES)	7:23-CV-897
)	
DAVID DOWNS)	7:23-CV-01145-BO
)	
DAVID WILLIAM FANCHER)	7:23-CV-00275-BO-BM
)	
ALLAN WAYNE HOWARD)	7:23-CV-00490-BO
)	
FRANK W. MOUSSER)	7:23-CV-00667-BO-RN
)	
JACQUELINE JORDAN TUKES)	7:23-CV-01553-BO-BM

**PLAINTIFFS' DESIGNATION AND DISCLOSURE OF PHASE III EXPERT
WITNESSES WITH RESPECT TO KIDNEY CANCER**

MATTHEW J. WEISS, MD'S STATEMENT OF COMPENSATION

Pursuant to Fed. R. Civ. P. 26(a)(2)(B)(vi), Plaintiffs provide the following statement of compensation: Matthew J. Weiss, MD, MBA, FACS charges \$750 per hour for work on the present matter.